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Abstract 
 
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that plays a 
pivotal role in protein homeostasis in responses to cellular stress. Hsp90 regulates the 
conformational maturation, activation, and integrity of a wide array of client proteins, 
including oncogenic proteins (Her2, Raf1, Akt, CDK4 etc.) associated with all six hallmarks 
of cancer. Consequently, Hsp90 inhibition offers a unique opportunity for the simultaneous 
degradation of multiple anti-cancer targets and hence, for the development of cancer 
chemotherapeutics. 
Hsp90 exists as a homodimer with each monomer consisting of a druggable domain; 
the N-terminal domain, the middle domain, and the C-terminus. The majority of research has 
focused on development of Hsp90 N-terminal inhibitors. In fact, all Hsp90 inhibitors in 
clinical trials belong to this class. One of the major drawbacks associated with N-terminal 
inhibitors is the concomitant induction of the pro-survival response, which results in an 
upregulation of Hsp’s and affects the dosing schedule. As a result, alternative strategies are 
sought for the development of future Hsp90 inhibitors. 
Over the last decade, Hsp90 C-terminal inhibitors have emerged an attractive 
alternative for Hsp90 modulation. These inhibitors exhibit similar inhibitory activity to N-
terminal inhibitors, but do not induce the pro-survival response and could potentially 
circumvent the clinical limitations imposed on N-terminal Inhibitors.   
Presented herein are the design, synthesis and biological evaluation of ring-
constrained novobiocin analogues that provide new insights into the Hsp90 C-terminal 
binding pocket and SAR’s that can be used for future analog development. In addition, 
identification of a novel class of Hsp90 inhibitors is discussed. These new agents provide a 
platform upon which future Hsp90 inhibitors can be built upon. 
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Chapter 1 
Hsp90 Structure, Function and Therapeutic Potential 
 
1. Introduction 
The 90 kDa heat shock proteins 90 (Hsp90) are molecular chaperones responsible for 
the conformational maturation, activation and stability of a wide-range of proteins, referred to 
as “client proteins”.
1, 2
 More than 200 clients have been identified that depend upon the 
Hsp90 protein folding machinery to produce active conformations.
3
 Hsp90 is one of the most 
abundant proteins in eukaryotic cells and is overexpressed under cellular stress, including 
elevated temperature, abnormal pH, or nutrient deprivation.
4
 In humans, Hsp90 exists in four 
isoforms: Hsp90α (inducible form) and Hsp90β (constitutive form) are primarily localized in 
the cytosol, whereas the 94kDa glucose-regulated protein (GRP94) and Hsp75/tumor necrosis 
factor receptor associated protein 1 (TRAP-1) reside in the endoplasmic reticulum and 
mitochondria, respectively.
5 
Hsp90 client proteins regulate a wide range of cellular functions, including signal 
transduction, chromatin remodeling, protein trafficking, cell proliferation and survival.
6 
A 
large number of these client proteins are often mutated and/or overexpressed in cancer and 
are actively pursued as individual therapeutic targets for the treatment of cancer.
7
 Therefore, 
Hsp90 inhibition offers a unique opportunity for the simultaneous degradation of multiple 
anti-cancer targets and hence, for the development of cancer chemotherapeutics. In addition 
to its potential for cancer treatment, Hsp90 inhibition has been found to induce a pro-survival 
response that results in increased level of molecular chaperones.
8
 Molecular chaperones 
protect cells by redirecting protein aggregation, a major attribute to the etiology of 
neurodegenerative diseases including Alzheimer’s and Parkinson disease.  Consequently, 
Hsp90 has emerged as a promising therapeutic target for the development of several diseases. 
3 
 
2. Hsp90 Structure 
The Hsp90 molecular chaperone belongs to the GHKL (Gyrase, Hsp90, Histidine 
Kinase and MutL) superfamily and shares structural homology with other ATPase members.
9
 
Like other members, eukaryotic Hsp90 exists as a homodimer with each monomer consisting 
of three highly conserved domains: A 25 kDa N-terminal ATP-binding domain (NTD), a 35 
kDa middle domain (MD), and a 12 kDa C-terminal dimerization domain (CTD) (Figure 
1.1).
4
 
              
Figure 1.1. The Crystal structure of yeast Hsp90; PDB 2CG9. 
 
The NTD contains an ATP-binding site wherein ATP binds in a unique, bent 
conformation, a characteristic feature shared by members of GHKL superfamily.
9
 Co-crystal 
structures of this domain revealed that the ATP-binding motif comprises four-interstranded β-
sheets and three α-helices with an ATP-binding pocket located in the middle.
10-12
 The NTD is 
responsible for Hsp90 ATPase activity and represents a major binding site for the 
development of Hsp90 inhibitors. 
The MD of Hsp90 is connected to the NTD by a flexible, highly charged linker (CL). 
This domain plays a key role in modulating Hsp90 ATPase activity by binding to the            
γ-phosphate of ATP when bound to the N-terminus.
13
 Structural and functional analyses 
4 
 
suggest that it is a major site for recognition and binding of several client proteins and co-
chaperones (e.g. Aha1).
14 
The CTD is responsible for Hsp90 homodimerization.
10
 This domain comprises of a 
dimer consisting of a mixed α/β domain and features a conserved MEEVD sequence that 
recognizes TPR (tetratricopeptide-containing repeats) domains that bind with co-chaperones, 
such as Hsp70-Hsp90 organizing protein (HOP), immunophilins etc. The CTD also contains 
a second ATP-binding site that modulates N-terminal ATPase activity in an allosteric 
manner.
15, 16 
Natural products such as novobiocin and EGCG have been found to bind this 
site and disrupt Hsp90 function.
17-19
   
 
3. Hsp90 Function 
Hsp90 is a versatile protein that is responsible for the maintenance of protein 
homeostasis as well as the stress response.
20
 Hsp90 comprises about 1-2% of total protein 
present in the cytoplasm of unstressed cells and can become significantly overexpressed (4-
6%) under hostile conditions to buffer proteotoxic stresses.
21
 Hsp90 performs a wide range of 
cellular functions, including conformational maturation of the nascent polypeptides, 
solubilizing and refolding of aggregated or denatured proteins, protein disposition and 
degradation.
22
 
Although the mechanism of the Hsp90-mediated protein folding cycle remains elusive, 
accumulating evidence suggests that a multi-protein complex containing a variety of co-
chaperones, immunophilins and partner proteins, is involved in the folding process.
23
 During 
the chaperone cycle, a nascent polypeptide is relayed through various multiprotein complexes 
before gaining conformational maturity (Figure 1.2). 
 
5 
 
  
Figure 1.2. The Hsp90-mediated protein folding mechanism. 
 
Proteins are synthesized as linear polypeptides by the ribosome. As nascent 
polypeptides exit the ribosome, they have the propensity to aggregate via hydrophobic 
interactions between amino acid side chains. Molecular chaperones stabilize these 
polypeptides from aggregation and facilitate their folding into biologically active structures.
24
 
The chaperone cycle begins by binding nascent polypeptides with the molecular chaperone, 
Hsp70, in conjunction with Hsp40 and ATP. Bound ATP is then hydrolyzed to ADP, which 
prevents the aggregation of polypeptides.
25
 Hsp70 interacting protein (HIP) then binds to and 
stabilizes this complex. Alternatively, Bcl2 associated athanogene (BAG) homologs can bind 
to this complex and exchange ATP for ADP, resulting in polypeptide release and dissociation 
of the complex.
26 
Hsp90-Hsp70 organizing protein (HOP), which contains a TPR domain 
recognized by both Hsp90 and Hsp70, coordinates association of the Hsp70-protein complex 
and Hs90, transferring the unfolded protein from Hsp70 to the Hsp90.
27
 Subsequently, 
6 
 
immunophilins (FKBP51, FKBP52), co-chaperones and partner proteins bind the Hsp90 
homodimer to form an activated multiprotein complex with concomitant release of Hsp70, 
Hip and HOP.
28
 ATP binds the Hsp90 multiprotein complex at the N-terminus and promotes 
the clamping of Hsp90 around the bound client protein, resulting in a closed clamp 
conformation.
29
 At this stage, Hsp90 inhibitors can compete with ATP at the N-terminal 
binding site and prevent formation of the closed clamp conformation, leading to the 
degradation of the client through the ubiquitin-proteasome pathway.
4
 In the absence of 
inhibition, the co-chaperone p23 is recruited to the complex and assists in the folding of 
client proteins into biologically active structures through an ATP-driven process.
30 
Finally, 
the mature protein is released from the complex along with the dissociation of immunophilins 
and co-chaperones from Hsp90. 
The folding process is regulated by a number of co-chaperones and post-translational 
modifications.
3
 Many co-chaperones and co-activators work in conjunction with Hsp90 by 
modulating the protein folding machinery (Table 1.1).
6, 23
 Numerous post-translational 
modifications including acetylation, phosphorylation, and S-nitrosylation control Hsp90 
chaperone activity by modulating its affinity for co-chaperones or client proteins.
3
   
 
Table 1.1. Co-chaperones and Co-activators that comprise the Hsp90 protein folding cycle.
6, 23
 
Co-chaperone or 
Co-activator 
Description 
Aha1 Stimulates ATPase activity 
Cdc37 Mediates activation of protein kinase substrates 
CHIP Involved in degradation of unfolded client proteins 
Cyclophilin-40 Peptidyl propyl isomerase 
FKBP51 and 52 Peptidyl propyl isomerase 
Hop Mediates interaction between Hsp90 and Hsp70 
Hsp40 Stabilizes and delivers client proteins to Hsp90 complex 
Hsp70 Stabilizes and delivers client proteins to Hsp90 complex 
7 
 
p23 Stabilizes closed, clamped substrate bound conformation 
HIP Inhibits ATPase activity of Hsp70 
PP5 Protein phosphatase 5 
Sgt1 Client adaptor, involved in client recruitment 
Tom70 Facilitates translocation of pre-proteins into mitochondrial matrix 
WISp39 Regulates p21 stability 
 
4. Therapeutic Potentials of Hsp90 
A. Therapeutic opportunities 
Hsp90 plays an integral role in the stability and function of a wide range of client 
proteins including signaling kinases, steroid hormones receptors, and telomerase.
31
 A large 
number of these client proteins contribute to the development, maintenance and progression 
of human diseases including cancer, neurodegenerative diseases, and infections.
32
 In cancer, 
malignant cells depend upon the Hsp90 chaperone machinery for the folding of mutated and 
over-activated oncoproteins. As a result, inhibition of Hsp90 by a small molecule provides an 
excellent opportunity for the treatment of cancer.
33
 In contrast to its role in oncoprotein 
degradation, Hsp90 inhibition can also induce the pro-survival heat shock response, which in 
turn, causes the upregulation of heat shock proteins (Hsps). Although detrimental for cancer 
treatment, upregulation of Hsps could be beneficial for neurodegenerative diseases, where 
Hsps protects cells from the accumulation of neurotoxic proteins.
34
 As a consequence, non-
toxic molecules manifesting such activities could be potential candidates for the treatment of 
neurodegenerative disorders. 
 
A.1. Cancer 
Cancer is a group of diseases involving uncontrolled cell growth and is one of the 
leading causes of disease-related deaths worldwide. Cancer results from the de-regulation of 
signaling pathways essential for cell proliferation and survival.
2
 Conventional therapeutic 
8 
 
strategies have focused on the inhibition of a specific enzyme and/or receptor associated with 
signaling pathways, but often become ineffective due to the development of resistance. As 
our understanding of cancer physiology advances, it has become apparent that malignant 
transformations result from multiple interconnected dysregulated pathways. Consequently, 
combinatorial therapy has evolved as a new paradigm for cancer treatment. As an alternative 
approach, Hsp90 inhibition has shown potential to simultaneously disrupt multiple signaling 
pathways through a single target.
35
 Figure 1.3 represents the proposed mechanism of Hsp90 
inhibition for cancer treatment. Hsp90 inhibitors bind to the Hsp90 multiprotein complex and 
halt the protein folding process. Consequently, the complex is directed to the ubiquitin-
proteasome pathway, which leads to the degradation of client proteins. 
 
 
Figure 1.3. Proposed mechanism of Hsp90 inhibition for the cancer treatment. 
 
Clientele of Hsp90 include several oncogenic proteins such as Her2, Raf1, Akt, and 
CDK4, which are distributed among all the six hallmarks of cancer (Table-1.2).
5, 33
 Hsp90 
client proteins protect cancer cells through regulation of various oncogenic cellular processes 
including signal transduction, anti-apoptosis, proliferation, angiogenesis and metastasis.
35
 
  
9 
 
Table-1.2. Hsp90 client proteins associated with the six hallmarks of cancer.
5
 
Hallmarks of Cancer Hsp90 Client Protein(s) 
1. Self-sufficiency in growth signals Raf-1, AKT, Her2, MEK, Bcr-Abl 
2. Insensitivity to anti-growth signals Plk, Wee1, Myc1, CDK4, CDK6, Myt1 
3. Evasion of apoptosis RIP, AKT, p53, c-MET, Apaf-1, Survivin 
4. Limitless replicative potential Telomerase (h-Tert) 
5. Sustained angiogenesis FAK, AKT, Hif-1α, VEGFR, flt-3 
6. Tissue invasion and Metastasis C-MET 
 
Since Hsp90 is abundantly expressed in both normal and cancer cells, there has been 
some apprehension about the therapeutic selectivity manifested by Hsp90 inhibitors. 
However, growing evidence suggests that Hsp90 inhibitors show significant differential 
selectivity towards cancer cells compared to normal cells and can therefore exhibit a large 
therapeutic window.
36-39
 Hsp90 inhibitors have been found to accumulate to a greater extent 
in tumors than in normal tissues.
36
 Kamal and co-workers demonstrated that the increased 
concentration of Hsp90 inhibitors in tumor cells originates from the altered conformation of 
Hsp90 in cancer vs normal cells.
37
 In cancer cells, Hsp90 exists in an activated multiprotein 
complex with enhanced ATPase activity and higher affinity for Hsp90 inhibitors, compared 
to latent complex found in normal cells. As a proof-of-concept for Hsp90 inhibition with 
therapeutic benefit, first Hsp90 inhibitor 17-AAG has shown encouraging results in phase I 
and II studies with HER2+ breast cancer patients.
40, 41 
Consequently, Hsp90 has become a 
promising target for the development of cancer chemotherapeutics. 
 
A.2. Neurodegenerative diseases 
Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson disease 
(PD), Hungtinton disease (HD), Polyglutamine disease (PGD) and Prion disease, are chronic 
and progressive diseases that arise from dysfunction or loss of neurons in the central nervous 
10 
 
system.
34, 42
 Although, there could be multiple causes for the development of 
neurodegenerative diseases, the most common characteristic shared is accumulation of 
misfolded/aberrant proteins, which eventually leads to neuronal toxicity.
43
 Therefore, the 
prevention of neurotoxic aggregates represents a therapeutic strategy for the treatment of 
neurodegenerative diseases.  It has been observed that inhibition of Hsp90 results in the 
release of a transcription factor, heat shock factor-1 (HSF-1).
8
 Upon release, HSF-1 is 
trimerized, phosphorylated and translocated to nucleus, wherein it causes overexpression of 
molecular chaperones, including Hsp27, Hsp40, Hsp70 and Hsp90 (Figure 1.4).
44
 These 
molecular chaperones provide neuroprotection by preventing protein aggregation, 
solubilizing aggregated proteins, and promoting the clearance of the misfolded and 
aggregated proteins that are difficult to degrade through other mechanisms. 
26, 45
  
 
 
Figure 1.4. Proposed mechanism of Hsp90 modulation for the treatment of neurodegenerative diseases. 
 
In addition to its indirect role via induction of the pro-survival response, Hsp90 
inhibition causes degradation of many aberrant proteins, including TauP301L and α-
synuclein that form neurotoxic aggregates.
46, 47
 This approach is important in the treatment of 
neurodegenerative diseases, such as AD and PD, where aberrant protein is responsible for 
progression and the maintenance of the diseased condition.  
AD is a protein misfolding disease (proteopathy), caused by formation of β-amyloid 
(Aβ) plaques and neurofibrillary tangles in the brain.
47 
In AD, hyperphosphorylation of the 
11 
 
Tau protein results in aggregation of filamentous structures that lead to neurofibrillary 
tangles.
48
 A study conducted by Chiosis and co-workers revealed that Hsp90 client proteins, 
including cyclin-dependent protein kinase 5 (Cdk5) and glycogen synthase kinase-3β 
(GSK3β) are dysregulated in AD and cause hyperphosphorylation of the Tau protein, leading 
to neuronal death.
46
 Furthermore, the study showed that suppression of Hsp90 client proteins 
p35 (activator of Cdk5) and TauP301L (most common mutant in AD) led to reduction in 
neuronal loss and functional improvement.  Another Hsp90 client protein α-synuclein has 
been found to be associated with the pathogenesis of PD and its suppression by the Hsp90 
inhibitor, GDA, was shown to alleviate PD-like symptoms in a transgenic mouse model.
49
 
Collectively, these findings highlight the role of Hsp90 in the pathogenesis of 
neurodegenerative diseases. Consequently, Hsp90 inhibitors are emerging as 
chemotherapeutics for the treatment of neurodegenerative diseases as they offer dual 
therapeutic advantages by inhibiting the maturation of client proteins implicated in disease 
and by induction of the protective heat shock response.    
 
A.3. Infectious diseases 
Hsp90 plays a central role in the pathogenesis of many infectious diseases such as viral 
replication, bacterial, and fungal infection.
32, 50
 Hsp90 folds clients that are essential for the 
replication of many viruses including hepatitis B, hepatitis C, polio, herpes simplex and 
influenza viruses.
20
 So, inhibition of Hsp90 can provide an alternative strategy for the 
treatment of viral diseases. Similar to viral infection, Hsp90 client proteins have been directly 
linked with virulence of various fungal pathogens including Candida albicans, Aspergillus 
fumigatus and teereus and hence could be targeted for development of antifungal agents.
51
 
Recently, Novartis developed a recombinant antibody Mycograb that binds Hsp90 and 
sensitizes fungal pathogens to antifungal agents.
52
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B.  Hsp90 Inhibitors and their implications  
Hsp90 inhibitors represent a unique class of therapeutic agents for the treatment of a 
variety of human diseases through a single target. Small molecules belonging to a wide range 
of chemical classes have been identified, that disrupt Hsp90 chaperone activity via various 
mechanisms. Hsp90 chaperone function can be inhibited by small molecules that either 
compete with ATP for the binding pocket or interfere with the C-terminal or middle region of 
Hsp90.
53
 Hsp90 inhibitors can be broadly divided into three main categories; (1) N-terminal 
inhibitors, (2) C-terminal inhibitors, or (3) other inhibitors, which will be discussed in detail 
below. 
 
B.1.  N-terminal Inhibitors 
B.1.1.  Geldanamycin and Related Analogues 
 Geldanamycin (GDA), a naturally occurring ansamycin, was originally isolated in cell 
culture screening for antimicrobial agents from the broth of Streptomyces hygroscopicus in 
1970s.
54
 Later, GDA was shown to manifest anti-proliferative activity against v-Src oncogene 
transformed cells.
55
 Further studies by Whitesell and Neckers revealed that GDA exerted its 
activity through inhibition of Hsp90.
56
 Finally, crystal structure analysis of the human and 
yeast Hsp90 N-terminus established that GDA competes with ATP for binding pocket to the 
N-terminus of Hsp90, resulting in the disruption of the chaperone cycle and degradation of 
client proteins.
11, 12
 Since the discovery of GDA as an Hsp90 inhibitor, it has been used a 
standard probe for the identification of additional Hsp90 client proteins and to explore the 
role of Hsp90 in malignant transformations. Although GDA showed promising antitumor 
activities against various cell lines, its clinical utility was limited by poor solubility, poor in 
vivo stability, and high hepatotoxicity.
38
 Subsequent structure-activity relationship studies 
resulted in the identification of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) and 
17-(2-dimethylaminoethylamino)-17-desmethoxygeldanamycin (17-DMAG), which 
13 
 
demonstrated an improved toxicity profile and are currently under investigation in clinical 
trials.
57, 58
 
 
 
Figure 1.5. Structures of geldanamycin and related analogues. 
 
B.1.2. Radicicol and Related Analogues 
Radicicol (RDC), a natural resorcyclic lactone, was originally isolated from 
Monosporium bonorden in 1953 as an antifungal agent.
59
 Like GDA, RDC was found to be a 
competitive inhibitor of the Hsp90 N-terminus (Kd= 14nM).
60, 61
 Although RDC exhibits 
promising in vitro affinity, it is inactive in vivo, likely due to the presence of an electrophilic 
α,β,γ,δ-unsaturated ketone and an epoxide, which make it prone to rapid metabolism.
62
 
Therefore, SAR studies have focused on the identification of analogues with better in vivo 
stability profile. Various oxime derivatives of RDC have been reported that manifest potent 
inhibitory activity both in whole cell assays and human tumor xenograft models.
63
 
Furthermore, it was observed that the labile allylic epoxide could be replaced with a 
cyclopropyl ring (cycloproparadicicol, c-RDC) without compromising inhibitory activity.
64
 
Currently, this class of compounds has been the subject of extensive research for the 
development of potent Hsp90 inhibitors.
65
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Figure 1.6. Structure of radicicol and related analogues. 
 
B.1.3. Synthetic small molecule inhibitors 
Limited synthetic accessibility and potential toxicity of natural products and their derivatives 
promoted a search for small molecule inhibitors of Hsp90 that exhibit improved drug-like 
features. Chiosis and co-workers used X-ray crystallographic analysis and molecular 
modeling to identify PU3, a purine analog, which showed low micromolar affinity (Kd = 15-
20 µM) for the N-terminus of Hsp90 and moderate anti-proliferative activity (IC50 = 50) 
against the MCF-7 breast cancer cell line.
66
 Further improvement of this class led to 
identification of PU24FC1, which manifested better antitumor activities both in in vitro and 
in vivo models of cancer.
67
 Finally, an optimized purine-based molecule BIIBB021 was 
identified in 2005 and is currently under investigation for the treatment of advanced solid 
tumors.
68
 
 
 
Figure 1.7. Structures of purine analogues. 
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In 2004, high throughput screening (HTS) of a library of 60,000 compounds led to 
identification of 3,4-diarylpyrazole CCT018159, which showed potent ATPase inhibition 
activity against yeast Hsp90 (IC50= 7.1 µM).
69
 Later, protein crystallographic studies revealed 
that CCT018159 binds deep into the ATP pocket of the Hsp90 N-terminal domain and that 
the resorcinol groups and pyrazole nitrogen form water-mediated hydrogen bonding 
interactions.
70
 In another HTS, the Novartis Research Foundation screened a library of 
1,000,000 compounds and identified two lead compounds G3129 and G3130. Co-crystal 
structures of G3129 and G3130 bound to Hsp90 suggested that both compounds bind the N-
terminus of human Hsp90α and the resorcinol ring bind Hsp90α similar to that of RDC.
71
 
Building on this information, Dymock and co-workers identified a highly potent analog of 
CCT018159, VER49009 (ATPase IC50 = 0.14 µM), which contains an amide group that 
formed an additional interaction with Gly97 of the Hsp90 N-domain.
72
 Subsequent structural 
optimization involved replacement of the pyrazole with an isoxazole and produced 
VER50589, which exhibits higher affinity and good cellular uptake (Kd = 4.5 nM).
73, 74
 
Finally, an optimized isoxazole analog, VER52296/NVP-AUY922, entered clinical trials in 
2008 and is currently being investigated in phase I/II for the treatment of solid 
malignancies.
75, 76
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Figure 1.8. Stuctures of pyrazole and isoxazole derivatives. 
 
 
B.2. C-terminal Inhibitors 
B.2.1. Novobiocin and Related Natural Products 
The coumarin antibiotics including Novobiocin (NB), chlorobiocin and coumermycin 
A1, are potent inhibitors of DNA gyrase and have been used extensively for the treatment of 
infections caused by multi-resistant gram-positive bacteria.
77
 In 2000, Neckers and co-
workers reported that NB bound weakly to a previously unrecognized Hsp90 C-terminal 
nucleotide binding site (IC50 = 700 µM in SKBr3 cells) and caused the degradation of Hsp90 
client proteins including v-src, Raf-1 and Erb2.
17, 78
 Interestingly, NB did not induce a pro-
survival heat shock response, which is a major drawback associated with N-terminal 
inhibition. 
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Figure 1.9. Novobiocin and other natural inhibitors of Hsp90 C-terminus. 
 
Encouraged by the initial findings, attempts were made to improve the inhibitory 
activity of NB. Initial SAR studies done by Blagg and co-workers revealed key structural 
features of NB required for the observed activities.
79
 Compound A4, lacking both the 4-
hydroxy substituent and the carbamoyl group, and containing an N-acyl side chain was found 
to induce Hsp90 client protein degradation at ~70 fold lower concentrations than NB (IC50 = 
10 µM). Surprisingly, compound A4 also induced Hsp90 levels at much lower concentrations 
(1000-1000 fold) than that required for client protein degradation and showed the potential of 
being a neuroprotective agent. KU32, a variant of compound A4 is currently under 
investigation for the treatment of neurodegenerative diseases.
80
 Further studies highlighted 
the role of the benzamide side chain in the paradoxical activities observed with Hsp90 C-
terminal inhibitors.
81
 Incorporation of a benzamide side chain was shown to restore the anti-
proliferative activity without induction of the heat shock response and subsequently resulted 
in identification of two potent compounds, DHN1 and DHN2.  The improved activities 
manifested by both compounds reiterated the detrimental effect of 4-hydroxy substituent and 
18 
 
carbamoyl group for Hsp90 inhibition and marked the first selective Hsp90 C-terminal 
inhibitors. Further SAR studies on this class of compounds resulted in highly potent 
compounds with mid nanomolar activities in anti-proliferative assays against various cancer 
cell lines.
82-84
   
 
 
Figure 1.10. Structures of A4, KU32, DHN1 and DHN2. 
 
B.2.2. Epigallocatechin-3-Gallate (EGCG) 
EGCG is a polyphenolic compound found in green tea. EGCG has been shown to 
inhibit the activity of a wide range of proteins including telomerase, aryl hydrocarbons 
receptor (AhR), several kinases and transcription factors, all of which are well known Hsp90 
client proteins.
18
 In 2005, Palermo and co-workers showed that EGCG exhibits its 
antiagonistic behavior against AhR through Hsp90 inhibition.
85
 Subsequent SAR studies 
revealed the essential role of phenols for anti-proliferative activity. Studies are currently 
underway to improve the inhibitory activity of EGCG analogues. 
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B.2.3. Cisplatin 
Cisplatin is a platinum-containing chemotherapeutic agent used to treat bladder, 
cervical, testicular, ovarian, and other solid tumors.
86
 Cisplatin binds DNA and induces 
intrastrand and/or interstrand adducts, which ultimately triggers apoptosis.
87
 Additionally, 
cisplatin has been found to bind Hsp90 and interfere with its chaperone activity.
88
 Subsequent 
studies suggested that cisplatin is a selective C-terminal inhibitor that binds near the C-
terminal ATP-binding site.
89
  
 
 
Figure 1.11. Structures of EGCG, cisplatin, celastrol and gedunin. 
 
B.3. Miscellaneous Inhibitors 
A third class of Hsp90 inhibitors includes compounds that disrupt protein-protein 
interactions between Hsp90 and its co-chaperones such as Cdc37 and p23.
90
 Natural products 
such as celastrol and gedunin, have been identified that disrupt these interactions.
91, 92
 
Celastrol is a natural product that disrupts the Hsp90-cdc37 complex formation, thus 
inhibiting Hsp90 chaperone activity.
91
 The co-chaperone Cdc37 is required for the 
recruitment and maturation of several oncoproteins kinases such as BRAF and EGFRvIII and 
hence, disruption of this interaction provides a potential opportunity against malignant cells.
93
 
Gedunin, a tetranortriterpenoid natural product, has traditionally been used for the treatment 
of malaria and other infectious diseases.
92
  In addition, gedunin exhibits potent anti-
proliferative activity against various cancer cell lines. Patwardhan and co-workers determined 
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that gedunin manifests its inhibitory activity via disruption of Hsp90-p23 interactions and 
causes cell death through the activation of caspase 7.
94
 In the light of these results, this class 
of compounds is now gaining importance as powerful pharmacological tools to selectively 
block one set of Hsp90 client proteins and to limit off-target effects. 
 
5. Conclusion and Future Directions 
The recognition of Hsp90 as a crucial mediator of oncogene addiction in the 
laboratory and the translation of these findings into clinically useful interventions have 
created a new dimension in cancer chemotherapeutics. Natural products and their derivatives 
have been developed as Hsp90 inhibitors that show encouraging results against a variety of 
cancers. As the potential use of Hsp90 inhibitors has extended beyond cancer, new 
opportunities for use in non-oncological diseases such as neurodegenerative, aberrant 
inflammation, viral, and bacterial infections are being pursued. 
Although initial success with Hsp90 inhibitors generated significant interest, clinical 
challenges are emerging from clinical trials. Currently, all administered agents are Hsp90 N-
terminal inhibitors. One of the major issues with N-terminal inhibitors is induction of the pro-
survival heat shock response, which increases Hsp90 levels and directly affects the dosing 
schedule. In addition, all Hsp90 inhibitors in clinical trials are pan-inhibitors and exhibit 
unanticipated side effects. Several toxicities such as cardiotoxicity and hepatotoxicity, have 
been observed during clinical evaluation of these agents. As a consequence, alternative 
strategies are desired for the future development of Hsp90 inhibitors. 
Recently, Hsp90 C-terminal inhibitors have emerged as an attractive alternative for 
Hsp90 modulation. These agents manifest similar, and in some cases, even superior 
inhibitory activity without induction of the pro-survival heat shock response and may 
potentially overcome the clinical limitations attributed to N-terminal inhibitors. Alternatively, 
isoform-selective agents that target a specific isoform of Hsp90, could provide a new avenue 
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for the development of future Hsp90 inhibitors. Another potential strategy includes the 
development of therapeutic agents that inhibit protein-protein interactions between Hsp90 
and co-chaperones, leading to degradation of a subset of client proteins with fewer side-
effects. In conclusion, as we gain a better insight into the biology of Hsp90 and its client 
proteins, it is likely that a more rational approach to drug design can be implemented and that 
drugs of superior therapeutic benefits will emerge. 
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Chapter 2 
Development of Ring-constrained Novobiocin Analogues as Hsp90 
Inhibitors 
 
1. Introduction 
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone responsible 
for the maintenance of protein homeostasis.
1-3
 It is the key component of a protein folding 
machinery that regulates the conformational maturation, activation and stability of a vast 
array of client proteins, including protein kinases, steroid receptors, telomerase, and 
transcription factors.
4
 These client proteins perform several housekeeping functions, such as 
signal transduction, protein trafficking, cell proliferation and survival.
3
 However, in cancer 
cells, many of these client proteins are frequently mutated and/or over-expressed and are 
believed to be critical for transformation and the maintenance of oncogenic phenotypes.
5
 
Approximately 50 Hsp90 client proteins (e.g., Her2, Raf1, Akt, MET, Src, CDK4 etc.) are 
known to be directly associated with all six hallmarks of cancer, which are actively pursued 
as individual therapeutic targets for cancer treatment.
6, 7
 Consequently, Hsp90 inhibition 
provides an attractive opportunity for the simultaneous disruption of multiple oncogenic 
pathways and hence, for the development of anti-cancer agents.  
The Hsp90 protein function can be inhibited by small molecules that competitively 
displace ATP from the Hsp90 nucleotide-binding site and halt the protein folding cycle.
8
 
Over past two decades, a large number of small molecules have been developed that 
competitively block ATP from binding to the Hsp90 N-terminus, leading to the degradation 
of client proteins.
9
 In fact, 17 such inhibitors of Hsp90 are currently in clinical trials for the 
treatment of cancer.
2
 Although there has been great interest in the development of this class 
of Hsp90 inhibitors, challenges such as concomitant induction of the pro-survival response, 
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hepatotoxicity and multidrug resistance, have raised serious concerns about their clinical 
utility.
5
 
In 2000, Neckers and co-workers demonstrated that the coumarin antibiotics, such as 
novobiocin (a DNA gyrase inhibitor), bound to a previously unrecognized ATP binding site 
at the Hsp90 C-terminus and induced a concentration-dependent degradation of Hsp90 client 
proteins.
10
 In addition, it was found that the Hsp90 C-terminal binding site allosterically 
modulates ligand binding to the N-terminus. Unlike N-terminal inhibitors, novobiocin and 
other C-terminal inhibitors do not induce Hsp levels and thus, present an attractive alternative 
to modulation of the Hsp90 folding machinery.11 However, novobiocin exhibits low affinity for 
Hsp90 (~700 μM aganist SKBr3) and therefore has limited therapeutic application.   
In an effort to improve its efficacy, Yu and co-workers developed a small library of 
novobiocin analogues and elucidated the first structure-activity relationships for this 
molecule.
12
 Their study revealed that the 4- hydroxy substituent and the carbamoyl group were 
detrimental towards Hsp90 inhibitory activity and removal of both substituents resulted in the 
identification of the compound A4 (Figure 1), which induced Hsp90 client protein degradation at 
~70 fold lower concentrations than novobiocin (IC50 = 10 μM). Additional SAR studies, aimed at 
elucidating functionality responsible for Hsp90 inhibition vs DNA gyrase, led to the development 
of two novobiocin analogues DHNI and DHN2 (Figure 1), which transformed this DNA gyrase 
inhibitor (novobiocin) into a selective Hsp90 inhibitor.13  
In 2008, Donnelly and co-workers explored the coumarin core and benzamide side 
chain of novobiocin and revealed structure-activity relationships for these moieties.
14
 Inspired 
by activity manifested by A4 and its dimer
15
, derivatives of A4 with variations to the 
coumarin core and the benzamide chain were designed and then evaluated for anti-
proliferative activity. Their studies demonstrated that substitutions at the 6- and 8-position of 
the coumarin core were tolerable and that incorporation of a hydrogen-bond acceptor (e.g. 
OMe) at these locations improved inhibitory activity (Figure 2.1). In addition, replacement of 
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the acetamide side chain with benzamide led to development of KU174, which manifests 
sub-micromolar to mid nanomolar activity in cell proliferation assay against various cancer 
cell lines. Unlike N-terminal inhibitors, KU174 exhibits potent cytotoxicity without induction 
of the heat shock response.
16
 Furthermore, it induces apoptosis within 24 hours, which is 
consistent with clinical administration protocols. 
 
 
Figure 2.1. Structures of Novobiocin, A4, DHN1 and DHN2. 
 
 Recently, the role of the novoise sugar was explored and SAR revealed.
17-19
 These 
SAR studies demonstrated that the sugar moiety, although important for enhancing solubility 
(and hence efficacy), could be replaced with other sugars or sugar surrogates without 
compromising inhibitory activity. These SAR studies led to development of several 
promising lead molecules such as KU135 and KU292 (Figure 2.2), which manifest anti-
proliferative activity against multiple cancer cell lines. 
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Figure 2.2. A1 SAR and structures of KU174, KU135 and KU292. 
 
2. Design, Synthesis and Biological Evaluation of Ring-constrained Novobiocin 
Analogues 
Since the discovery of novobiocin as the first Hsp90 C-terminal inhibitor, intense 
investigations for the development of more efficacious Hsp90 inhibitors have been pursued.
10, 
13, 14, 19
 Extensive structural modifications to novobiocin led to identification of several 
efficacious analogues (e.g., KU174, KU135) that manifest potent anti-proliferative activity 
against multiple cancer cell lines.
14, 16, 18, 19
 Recently, it was shown that replacement of the 
sugar with amines improve inhibitory activity and several analogues such as KU292 were 
identified.
19
 These SAR studies led to elucidation of the following structure-activity 
relationships: 1) The biaryl side chain appears optimal compared to other side chains; 2) the 
amide linker provides hydrogen bonding interactions with the binding pocket; 3) 
incorporation of a hydrogen-bond acceptor at the 8-position improves inhibitory activity; and 
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4) modification to the phenolic ether are tolerated and allows for replacement of the sugar 
with other moieties without compromising inhibitory activity.  
Based on these structure-activity relationships as well as molecular docking studies
20
, 
it was hypothesized that compounds containing lactams and substituents at the α-position in 
lieu of the sugar moiety would provide ring-constrained analogues containing all these 
features (Figure 2.3). Furthermore, as a consequence of ring constraint, the analogues would 
exhibit less entropic penalty compared to their freely rotating counterparts, and would 
therefore project the side chain into the region occupied by the novoise sugar. In addition, 
replacement of hydrolytically sensitive ether linkage with a lactam would result in analogues 
with improved metabolic stability. 
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Figure 2.3. Rationale for proposed ring-constrained novobiocin analogues. 
 
 To evaluate this hypothesis, the design of investigational molecules commenced that 
would contain a sugar surrogate at the α-position of the lactam and would project into the 
region usually occupied by the sugar moiety and establish interactions with the binding 
pocket. Earlier SAR studies revealed that the incorporation of solubilizing moieties such as 
amines, in sugar-binding region of Hsp90, improves both solubility and efficacy. 
19, 21
 In 
addition, recent QSAR studies by Huang and co-workers suggested that modification to these 
amines can produce more efficacious inhibitors.
20
 Therefore, the amines were selected as 
sugar surrogate for these investigational molecules. Using our earlier reported molecular 
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docking strategy,
 22
 compound 9 (Scheme 2.1), which contains the physiologically ionizable 
pyrrolidine moiety appended to the α-position of the lactam was designed and docked into 
our Hsp90 C-terminal docking model. As shown in Figure 2.4B, compound 9 showed a 
strong structural alignment with the lead compound, KU174. 
 
A.                
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. A. Docked structure of KU174 in the putative Hsp90 C-terminal binding site. B. 
Molecular overlay of KU174 (blue) and investigational molecule 9 (green). 
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Retrosynthetically, we envisioned construction of 9 from O-alkylation of phenol 6 
with α-bromo ester 7, followed by a tandem reduction/ring closing reaction catalyzed by Pd 
hydrogenolysis (Scheme 2.1). Phenol 6 was proposed to result from an Aldol condensation 
between aldehyde 4 and acid 3. Aldehyde 4 could be obtained by the formylation of 
commercially available nitro resorcinol.
23
 Synthesis of acid 3 could be achieved via an amide 
coupling reaction between the glycine ester and the previously reported biaryl acid,
24
 
followed by base-catalyzed hydrolysis. 
 
  
Scheme 2.1. Retrosynthetic analysis of lactamized novobiocin analogue 9. 
  
As shown in Scheme 2.2 the synthesis of compound 9 began via an amide coupling 
reaction between amine 1 and biaryl acid 2 to afford amide 3, which underwent an Aldol 
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condensation with benzaldehyde 4 to give acetylated-coumarin, 5. Subsequent deacetylation 
of 5 gave the coumarin intermediate, 6, in high yield. Phenol 6 was O-alkylated with the 
previously reported α-bromo ester, 7,
25
 to yield the coumarin ether, 8. Pd-catalyzed reduction 
of 8 resulted in generation of the amine, which subsequently underwent an acid-catalyzed 
cyclization to afford lactam 9.  
 
Scheme 2.2. Synthesis of pyrrolidine-containing lactam 9. 
 
 
 Upon completion of its synthesis, lactam 9 was evaluated for anti-proliferative 
activity against SKBr3 (estrogen receptor negative, Her2 over-expressing breast cancer cells) 
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and MCF-7 (estrogen receptor positive breast cancer cells) cell lines (Table 2.1). The anti-
proliferative data suggested that it manifested comparable activity to KU174. 
  
Table 2.1. Anti-proliferative activity of pyrrolidine-containing lactam 9. 
 
 
 
 
Entry SKBr3  (IC50, µM) MCF-7   (IC50, µM) 
9 14.97 ± 4.3
a
 22.90 ± 0.96 
KU174 13.9 ± 0.15 9.0 ± 0.33 
a
 Values represent mean ± standard deviation for at least two separate experiments performed 
in triplicate.  
 
 The anti-proliferative activity manifested by compound 9 promoted additional 
investigations into the optimal substitutions that could be appended to the lactam core to 
produce more potent inhibitors. Since no co-crystal structure of Hsp90 bound to C-terminal 
inhibitors has been solved, there is limited knowledge about the size and nature of this 
binding pocket. Therefore, lactams containing various substituents, such as hydrophobic, 
rigid, ionizable and non-ionizable were pursued to elucidate potential interactions with the 
binding pocket. 
 To elucidate these structure-activity relationships, a small library of aromatic- and 
amine-containing analogues was synthesized first. As shown in Scheme 2.3, the syntheses of 
aromatic analogues commenced  by O-alkylation of phenol 6 with α-bromo esters 10a-e
26-28
 
to afford coumarin ethers 12a-e in moderate yield. The resulting coumarin ethers 12a-e were 
then reduced with Pd/C under a hydrogen atmosphere to furnish the free amines, which 
underwent an acid-catalyzed cyclization to afford lactams 13a-e.  
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Scheme 2.3. Synthesis of aromatic-containing lactams. 
 
 In parallel, the syntheses of amine-containing lactams (Scheme 2.4) were pursued by 
nucleophilic substitution of α-bromo esters 11a-c
25
 by phenol 6 to yield coumarin ethers 12f-
h, which in turn were subjected to a tandem reduction/intramolecular cyclization reaction, 
enlisting a Pd/C catalyst under hydrogen atmosphere to afford cyclic compounds 14a, 14c-d. 
Compound 14b was obtained by deprotection of the boc on amine 14a using 40% 
trifluoroacetic acid in dichloromethane. 
 
Scheme 2.4. Synthesis of amine-containing lactams. 
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Upon their construction, the lactams were evaluated for anti-proliferative activity 
against SKBr3 and MCF-7 breast cancer cell lines (Table 2.2). In general, the aromatic-
containing lactams were less effective than their amino counterparts, suggesting rigid 
moieties are not favorable. However, direct attachment of the aromatic moiety to the lactam 
core was found detrimental, as compound 13a exhibited an IC50 value of ~50 µM. Although, 
the benzyl analogue (13b) manifested comparable activity to compound 9, compounds 13c 
and 13d were inactive up to 50 µM against both cell lines. Interestingly, inclusion of a polar 
group onto the aromatic ring resulted in improved activity, as analogue 13e exhibited 3~4 
fold greater inhibitory activity than 13b. These results suggest that a polar moiety attached to 
a more flexible linker may be beneficial. Consistent with the inhibitory data observed for 
aromatic-containing analogues, compound 14b manifested improved inhibitory activity over 
compound 9, while compound 14a was inactive, suggesting that the polar moiety is necessary 
for activity, but a bulky group is not tolerable. Interestingly, replacement of the amino 
substituent with an amide resulted in inactive analogues (9 vs 14c and 14d). This data suggest 
that the physiologically ionizable amine forms key interactions with the cognate protein and 
that these are critical for the manifestation of anti-proliferative activity. 
 
Table 2.2. Anti-proliferative activity of aromatic- and amine-containing lactams.  
 
Entry R  SKBr3  (IC50, 
µM) 
MCF-7   (IC50, 
µM) 
13a 
 
48.18 ± 2.28 >50 
13b 
 
21.49 ± 0.70 22.11 ± 0.64 
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13c 
 
>50 >50 
13d 
 
>50 >50 
13e 
 
8.37 ± 1.41 6.12 ± 0.26 
14a 
 
>50 >50 
14b 
 
5.78 ± 0.91 5.27 ± 0.29 
14c 
 
>50 >50 
14d 
 
>50 33.35 ± 0.97 
 
  
 As mentioned earlier, preliminary structure-activity relationships suggest an amine 
and a flexible linker are important for inhibitory activity. To gain further insight into this 
region of the binding site, amino analogue 17a (Figure 2.5B) that contains the pyrrolidine 
moiety tethered to the lactam core through a flexible linker was designed and docked into the 
Hsp90 C-terminal homology model. As shown in Figure 2.5A, the amine in pyrrolidine 
provides a hydrogen bonding interaction with Gln682 in the binding pocket. Interestingly, 
this pyrrolidine ring projects into a hydrophobic subpocket that allow for the inclusion of 
other substituents. Docking studies suggest there is ample space and further extension is 
possible. Therefore, it was hypothesized that incorporation of a two- or three-carbon tethered 
amine would project into the hydrophobic subpocket, while maintaining essential interactions 
between the ammonium group and complementary amino acids in the binding pocket. 
Towards this objective, several amines containing analogues with an ethylene or propylene 
linker were designed for elucidation of new structure-activity relationships. Amines were 
selected based on potential hydrogen bond interactions, ring size and sterics. 
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A.  
 
 
 
       
              
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
Figure 2.5. A. Docked structures of compound 17a in the putative Hsp90 C-terminal binding 
site; B. structure of compound 17a. 
 
 As shown in Scheme 2.5, the syntheses of ethylene-containing lactams was initiated 
by O-alkylation of phenol 6 with 2,4-dibromo ether 15 to give coumarin ether 16 in high 
yield. The resulting coumarin ether, 16, was then treated with primary or secondary amines to 
give the corresponding products, which were then subjected to a tandem 
reduction/intramolecular ring closing, using a Pd/C catalyst under hydrogen atmosphere to 
furnish compounds 17a-i. 
 
 
 
 
 
  
43 
 
Scheme 2.5. Synthesis of ethylene-containing lactams. 
 
 
 Upon completion of these ethylene-containing lactams, they were evaluated for anti-
proliferative activity against SKBr3 and MCF-7 cell lines (Table 2.3). Consistent with 
docking studies, ethylene-containing lactams exhibited better inhibitory activity compared to 
their methylene-containing counterparts (14 vs 17a). Introduction of acyclic amine (17b) 
resulted in decreased potency, emphasizing a constrained ring system (entropy penalty) is 
important for activity. Increasing the ring to six atoms (17c) maintained activity, indicating 
various ring structures could be accommodated within the binding pocket. It was found that 
inclusion of a second hydrogen bond donor/acceptor (17d, 17e and 17f) decreased activity, 
suggesting the subpocket is hydrophobic in nature. Interestingly, the secondary amino 
analogues manifested better inhibitory activity than tertiary amino derivatives (17g, 17h and 
17i). These data also suggest that bulky groups are tolerated in the binding pocket. 
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Table 2.3. Anti-proliferative activity of ethylene-containing lactams. 
 
Entry R  SKBr3  (IC50, 
µM) 
MCF-7   (IC50, 
µM) 
17a 
 
3.49 ± 0.20 5.2 ± 0.38 
17b 
 
8.06 ± 0.82 11.40 ± 0.16 
17c 
 
1.03 ± 0.07 1.04 ± 0.01 
17d 
 
5.44 ± 0.12 7.63 ± 0.10 
17e 
 
4.1 ± 0.07 5.68 ± 0.37 
17f 
 
6.66 ± 0.47 7.44 ± 0.86 
17g 
 
0.78 ± 0.07 1.16 ± 0.04 
17h 
 
0.68 ± 0.04 1.22 ± 0.14 
17i 
 
0.88 ± 0.02 1.09 ± 0.17 
 
  
 With the SAR data from ethylene-containing lactams in hand, we next decided to 
investigate whether a two-carbon spacer is better. As discussed previously, docking studies 
suggested that analogues containing a three-carbon linker may maintain interactions with the 
binding pocket, but project deeper into the subpocket and therefore, manifest better affinity. 
Thus, a series of three carbon tethers were synthesized for comparison to their ethylene-
containing counterparts. Following the scheme provided for the ethylene-containing lactams, 
the amino analogues containing a propylene linker were synthesized as shown in Scheme 2.6. 
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Scheme 2.6. Synthesis of propylene-containing lactams. 
 
After completion of their syntheses, the propyl-amine lactams were evaluated for anti-
proliferative activity against both cancer cell lines. As shown in Table 2.4, the analogues 
containing a propane linker exhibited better inhibitory activity than the corresponding 
ethylene-containing lactams, suggesting a three-carbon spacer is better at producing favorable 
interactions with the binding pocket. Similar to the trend observed with the ethylene-
containing analogues, the piperidine (20b) analogue manifested improved anti-proliferative 
activity, while the piperazine (20c) and N-methylpiperazine (20d) resulted in decreased 
inhibitory activity. Interestingly, cyclohexylamino analog (20e) manifested the most potent 
inhibitory activity, validating that the propane linker is best at maintaining interactions with 
the binding pocket. Bicycloalkyl and tricyclic amino analogues (20f, 20g) exhibited 
decreased activity, indicating a limited hydrophobic space within the binding pocket. 
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Table 2.4. Anti-proliferative activity of propylene-containing lactams. 
 
 
Entry R  SKBr3  (IC50, 
µM) 
MCF-7   (IC50, 
µM) 
20a 
 
1.02 ± 0.19 1.49 ± 0.02 
20b 
 
0.78 ± 0.14 0.85 ± 0.05 
20c 
 
9.08 ± 0.02 12.85 ± 0.13 
20d 
 
1.76 ± 0.39 2.43 ± 0.45 
20e 
 
0.20 ± 0.08 0.35 ± 0.01 
20f 
 
1.26 ± 0.01 1.34 ± 0.11 
20g 
 
0.62 ± 0.01 0.72 ± 0.01 
 
To confirm that the anti-proliferative activity observed exhibited by these lactams 
resulted from Hsp90 inhibition, Western blot analysis was performed on lysates treated with 
17i, 20b and 20g. Actin, an Hsp90-independent protein, was used as a negative control. As 
shown in Figure 2.6A, incubation with these compounds induced the degradation of Hsp90-
dependent client proteins Her2, Raf-1, CDK6 and Akt, confirming these analogues manifest 
their cellular activity through Hsp90 inhibition.  In addition, treatment of MCF-7 cells with 
20b induced the degradation of the Hsp90-dependent client proteins Her2, Raf-1, CDK6, and 
AKt in a concentration-dependent manner (Figure 2.6B). Actin levels remained unaffected, 
indicating selective degradation of Hsp90 client proteins. Additionally, Hsp90 levels were not 
changed, which is a hallmark manifested by Hsp90 C-terminal inhibitors. 
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Figure 2.6. Western blot analyses of lactams after incubation with MCF-7 breast cancer cells 
for 24 h. Concentrations (in µM) are indicated above each lane. L represents a concentration 
½ of the anti-proliferative activity. H represents a concentration equal to 5-fold of the anti-
proliferative activity. Geldanamycin (G, 0.5 µM) and dimethylsulfoxide (D, 100%) serve as 
positive and negative controls respectively. 
 
3. Conclusion and Future Directions 
In summary, a series of ring-constrained novobiocin analogs was designed, 
synthesized and evaluated against MCF-7 and SKBr3 breast cancer cell lines. Incorporation 
of ring-constrained analogs led to the development of molecules that manifest sub 
micromolar to mid nanomolar inhibitory activity. SAR studies revealed that amines attached 
to a flexible linker manifested superior activity. In addition, it was determined that a three-
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carbon spacer represents the optimal length for interactions with the binding pocket. 
Furthermore, studies showed that the inclusion of a bulky substituent is tolerated. The most 
active analogue 20e manifests ~70 fold greater potency than KU174 and can serve as a lead 
compound for future analogue development. 
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4. Experimental Section 
General procedure A: Amide coupling 
 
2-(3',6-Dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)acetic acid (3) A mixture of acid 1 
(1.0 g, 3.87 mmol), glycine ester hydrochloride 2 (1.05 g, 4.65 mmol) and DMAP (10 mg, 
cat.) was dissolved in  anhydrous THF (5ml) and treated with triethylamine (1.58 mL, 11.5 
mmol). The reaction mixture (RM) was then cooled to 0 
o
C and EDCI.HCl (1.12 g, 5.78 
mmol) was added to it. The resulting solution was allowed to stir at rt for 12 h. After 12 h, the 
RM was diluted with water (10 ml), pH adjusted to 7-8 with saturated sodium bicarbonate 
and extracted with EtOAc (3 X 15 ml). The organic layers were combined, dried (over 
Na2SO4) and concentrated under reduced pressure to residue. The residue was purified by 
column chromatography (SiO2, 1:10, Methanol:DCM) to afford an ester as a colorless liquid 
(960 mg, 75%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.86 (dd, J = 8.6, 2.4 Hz, 1H), 7.83 (d, 
J = 2.4 Hz, 1H), 7.39 – 7.33 (m, 1H), 7.15 – 7.09 (m, 2H), 7.02 (dd, J = 8.7, 1.8 Hz, 1H), 
6.93 (ddd, J = 8.3, 2.7, 1.1 Hz, 1H), 4.22 (s, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 3.79 (s, 1H), 2.76 
(s, 1H). 
13
C NMR (126 MHz, CDCl3) δ 170.82, 167.42, 159.25, 159.19, 138.86, 130.40, 
129.81, 129.05, 128.32, 125.74, 121.97, 115.21, 112.85, 110.83, 55.73, 55.26, 52.38, 41.56. 
HRMS (ESI
+
) m/z: [M + Na
+
] calcd for C18H19NO5Na 352.1161; found 352.1165. 
Lithium hydroxide (477.83 mg, 11.388 mmol) was added to the ester (750 mg, 2.28) 
in a solution of MeOH:THF:H2O (2:2:1, 5 ml) and the resulting suspension was stirred at rt 
for 12 h. After 12 h, the RM was concentrated under reduced pressured to remove solvents. 
The residue was diluted with water (10 ml), pH adjusted to 3-5 and extracted with EtOAc (3 
X 25 ml). The organic layers were combined, dried and concentrated to afford 3 as white 
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solid (675 mg, 94%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.84 – 7.80 (m, 1H), 7.76 (dd, J = 
2.5, 1.1 Hz, 1H), 7.34 – 7.28 (m, 1H), 7.09 – 7.02 (m, 2H), 6.99 (d, J = 8.6 Hz, 1H), 6.88 
(ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 4.16 (s, 2H), 3.84 (s, 3H), 3.82 (s, 3H), 2.63 (s, 3H). 
13
C NMR 
(126 MHz, CDCl3) δ 170.90, 167.45, 159.41, 159.30, 138.94, 130.60, 129.86, 129.16, 
128.42, 125.85, 122.08, 115.31, 112.99, 110.95, 55.86, 55.39, 52.56, 41.69. HRMS (ESI
+
) 
m/z: [M - H
+
] calcd for C17H16NO5 314.1028; found 314.1022. 
General procedure B: Aldol Condensation 
 
 
 
3-(3',6-Dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-2H-chromen-7-yl 
acetate (5) A mixture of acid (300 mg, 0.951 mmol), nitro resorcinol (209 mg, 1.142 mmol), 
sodium acetate (312.04 mg, 3.804 mmol) and acetic anhydride (0.179 ml, 1.902 mmol)  was 
heated at 110 
o
C for 3 h. After 3 h, the RM was allowed to cool to room temperature. The 
RM was diluted with water, pH adjusted to 5-6 with dilute HCl solution and extracted with 
EtOAc. The organic layer was collected, dried (over Na2SO4) and concentrated to residue. 
The residue was purified by column chromatography (SiO2, 1:99, Acetone:DCM) to afford 
desired product as a brownish amorphous solid (325 mg, 68 %). 
1
H NMR (500 MHz, 
Chloroform-d) δ 8.90 (s, 1H), 8.76 (s, 1H), 7.96 – 7.86 (m, 2H), 7.71 (d, J = 8.7 Hz, 1H), 
7.42 – 7.37 (m, 1H), 7.29 (d, J = 1.6 Hz, 1H), 7.16 – 7.08 (m, 3H), 6.96 (ddd, J = 8.3, 2.6, 1.0 
Hz, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 2.38 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 166.86, 
164.81, 159.32, 158.45, 155.65, 141.95, 140.60, 137.48, 130.31, 129.19, 128.81, 128.35, 
128.33, 127.41, 124.33, 124.13, 121.05, 120.16, 119.67, 118.17, 114.42, 112.23, 110.21, 
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55.05, 54.44, 19.74. HRMS (ESI
+
) m/z: [M - H
+
] calcd for C26H19N2O9 503.1091; found 
503.0685. 
 
N-(7-hydroxy-8-nitro-2-oxo-2H-chromen-3-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-
carboxamide (6) Potassium carbonate (0.267 g, 1.935 mmol) was added to a solution of 5 
(0.32 g, 0.645 mmol) in anhydrous THF (2 ml) and the suspension was stirred at room 
temperature for 1 h. After 1 h, the RM was concentrated under reduced pressure to dryness 
and the residue was purified by column chromatography (SiO2, 5:95 Acetone:DCM) to 
afford a yellow amorphous solid (280 mg, 96%). 
1
H NMR (500 MHz, Chloroform-d) δ 10.69 
(s, 1H), 8.85 (s, 1H), 8.68 (s, 1H), 7.95 – 7.88 (m, 2H), 7.70 (d, J = 8.9 Hz, 1H), 7.41 – 7.36 
(m, 1H), 7.16 – 7.07 (m, 4H), 6.95 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 3.92 (s, 3H), 3.87 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 165.91, 160.26, 159.49, 157.29, 156.42, 144.43, 138.56, 
134.75, 131.36, 130.20, 129.38, 128.39, 125.56, 123.21, 122.74, 122.10, 116.58, 115.45, 
113.73, 113.28, 111.22, 56.09, 55.48. HRMS (ESI
+
) m/z: [M - H
+
] calcd for C24H17N2O8 
461.0985; found 461.0980. 
General procedure C: O-Alkylation 
 
Ethyl 2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-2H-
chromen-7-yl)oxy)-3-(pyrrolidin-1-yl)propanoate (8) Sodium hydride (60%, 18.17 mg, 
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0.45 mmol) was added to a solution of 6 (100 mg, 0.2163 mmol) in anhydrous DMF (0.5 ml) 
and stirred at rt for 15 min. After 15 min, the solution was cooled to 0 
o
C and a solution of 7
25
 
(162.33 mg, 0.649 mmol) in DMF (0.2 ml) was added. The solution was then allowed to stir 
at rt for 16 h. After 16 h, the RM was concentrated under reduced pressure to dryness. The 
resultant solid was diluted with water and extracted with EtOAc. The organic layer was 
collected, dried (over Na2SO4) and concentrated to residue. The residue was purified by 
column chromatography (SiO2, 1:9, Methanol:DCM) to afford desired product as a brownish 
amorphous solid (65 mg, 48%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.81 (s, 1H), 8.67 (s, 
1H), 7.90 – 7.80 (m, 2H), 7.54 (d, J = 8.9 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 7.12 – 7.01 (m, 
4H), 6.92 (ddd, J = 8.4, 3.4, 2.3 Hz, 2H), 5.07 (dd, J = 6.5, 3.5 Hz, 1H), 4.22 (qt, J = 7.6, 3.8 
Hz, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 3.15 (dd, J = 9.2, 5.0 Hz, 2H), 2.75 – 2.64 (m, 4H), 1.83 – 
1.71 (m, 4H), 1.32 – 1.18 (t, 3H). 
13
C NMR (126 MHz, CDCl3) δ 168.41, 165.68, 160.11, 
159.38, 157.02, 150.19, 141.90, 138.50, 131.14, 130.09, 129.92, 129.54, 129.26, 128.28, 
125.50, 123.49, 122.06, 122.00, 115.34, 114.69, 113.15, 111.12, 110.92, 78.69, 62.02, 56.87, 
55.98, 55.38, 54.95, 23.81, 14.15. HRMS (ESI
+
) m/z: [M - H
+
] calcd for C33H32N3O10 
630.2088; found 630.2103. 
General procedure D: Tandem Reduction/Intramolecular Cyclization  
 
N-(2,9-dioxo-3-(pyrrolidin-1-ylmethyl)-1,2,3,9-tetrahydrochromeno[7,8-b][1,4]oxazin-8-
yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (9) Pd/C was added to a solution of 8 
(50 mg, 0.016 mmol) in MeOH/EtOAc (1:1, 0.5 ml) and stirred at room temperature under 
hydrogen atmosphere for 2 days. After 2 days, RM was filtered through celite and filtrate was 
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concentrated under reduced pressure to get residue. The residue was purified by column 
chromatography (SiO2, 5:95 MeOH:DCM) to afford a yellow amorphous solid (10 mg, 23%). 
1
H NMR (400 MHz, Chloroform-d) δ 8.85 (s, 1H), 8.68 (s, 1H), 7.98 – 7.85 (m, 2H), 7.38 (t, 
J = 7.9 Hz, 1H), 7.22 – 7.06 (m, 5H), 7.03 (d, J = 8.5 Hz, 1H), 6.94 (ddd, J = 8.3, 2.6, 0.9 Hz, 
1H), 4.90 (dd, J = 7.9, 2.9 Hz, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 3.20 (dd, J = 13.7, 2.9 Hz, 1H), 
3.07 (dd, J = 13.8, 7.9 Hz, 1H), 2.77 – 2.63 (m, 4H), 1.85 – 1.77 (m, 4H). 
13
C NMR (126 
MHz, CDCl3) δ 165.69, 164.43, 160.08, 159.46, 158.11, 144.03, 138.64, 136.95, 131.24, 
130.07, 129.35, 128.39, 125.86, 124.03, 122.68, 122.11, 115.46, 114.74, 114.54, 114.49, 
113.22, 111.20, 77.97, 56.07, 56.05, 55.47, 55.20, 23.82.  HRMS (ESI
+
) m/z: [M + H
+
] calcd 
for C31H30N3O7 556.2084; found 556.2103. 
 
Methyl 2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-2H-chromen-
7-yl)oxy)-2-phenylacetate (12a) Potassium carbonate (59.70 mg, 0.433 mmol) was added to a 
solution of 6 (100 mg, 0.2163 mmol) in anhydrous DMF (0.5 ml) and stirred at rt for 15 min. 
After 15 min, the solution was cooled to 0 
o
C and a solution of 10a
26
 (148.63 mg, 0.649 mmol) in 
DMF (0.2 ml) was added. The solution was then allowed to stir at rt for 16 h. After 16 h, the RM 
was concentrated under reduced pressure to dryness. The resultant solid was diluted with water, 
pH adjusted to 6-7 and extracted with EtOAc (3 X 15 ml). The organic layer was collected, dried 
(over Na2SO4) and concentrated to residue. The residue was purified by column chromatography 
(SiO2, 1:99, Acetone:DCM) to afford desired product as a brownish amorphous solid (280 mg, 
96%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.83 (s, 1H), 8.69 (s, 1H), 7.95 – 7.84 (m, 2H), 7.58 
– 7.51 (m, 3H), 7.45 – 7.41 (m, 3H), 7.41 – 7.35 (m, 1H), 7.15 – 7.06 (m, 3H), 6.98 – 6.89 (m, 
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2H), 5.80 (s, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 3.76 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 168.66, 
165.80, 160.24, 159.47, 157.01, 149.58, 142.11, 138.55, 133.48, 131.34, 130.31, 130.17, 129.82, 
129.66, 129.36, 129.21, 128.36, 127.11, 125.54, 123.76, 122.08, 121.91, 115.43, 115.15, 113.27, 
111.22, 111.20, 79.97, 56.07, 55.47, 53.26. HRMS (ESI
+
) m/z: [M - H
+
] calcd for C33H25N2O10 
609.1509; found 609.1432. 
 
Methyl 2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-2H-
chromen-7-yl)oxy)-3-phenylpropanoate (12b) Compound 12b was prepared from 6 using 
general procedure C and 10b
27
 to afford a brownish amorphous solid (15 mg, 28%). 
1
H NMR 
(500 MHz, Chloroform-d) δ 8.81 (s, 1H), 8.67 (s, 1H), 7.94 – 7.83 (m, 2H), 7.49 (d, J = 8.9 
Hz, 1H), 7.41 – 7.31 (m, 3H), 7.30 – 7.25 (m, 3H), 7.15 – 7.03 (m, 3H), 6.94 (ddd, J = 8.2, 
2.6, 0.9 Hz, 1H), 6.73 (d, J = 8.9 Hz, 1H), 4.94 (dd, J = 8.1, 4.4 Hz, 1H), 3.91 (s, 3H), 3.86 
(s, 3H), 3.76 (s, 3H), 3.38 – 3.22 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 169.66, 165.79, 
160.22, 159.47, 157.05, 150.20, 142.01, 138.55, 135.27, 131.33, 130.16, 129.99, 129.67, 
129.53, 129.36, 128.82, 128.35, 127.54, 125.57, 123.61, 122.08, 121.96, 115.42, 114.86, 
113.27, 111.20, 110.75, 79.50, 56.07, 55.47, 52.93, 38.87. HRMS (ESI
+
) m/z: [M - H
+
] calcd 
for C34H27N2O10 623.1741; found 623.1692. 
 
Methyl 3-(4-chlorophenyl)-2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-
nitro-2-oxo-2H-chromen-7-yl)oxy)propanoate (12c) Compound 12c was prepared from 6 
using general procedure C and 10c
28
 to afford a brownish amorphous solid (22 mg, 28%). 
1
H 
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NMR (500 MHz, Chloroform-d) δ 8.82 (s, 1H), 8.67 (s, 1H), 7.93 – 7.85 (m, 2H), 7.51 (d, J 
= 8.9 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.34 – 7.28 (m, 2H), 7.23 – 7.16 (m, 2H), 7.14 – 7.06 
(m, 3H), 6.94 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.74 (d, J = 8.9 Hz, 1H), 4.91 (dd, J = 7.9, 4.2 
Hz, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 3.76 (s, 3H), 3.29 – 3.24 (m, 2H). 
13
C NMR (126 MHz, 
CDCl3) δ 169.52, 165.93, 160.36, 159.59, 157.12, 150.12, 142.13, 138.66, 133.77, 133.68, 
131.46, 131.17, 130.28, 130.07, 129.69, 129.48, 129.09, 128.80, 128.47, 125.66, 123.81, 
122.20, 122.00, 115.54, 115.13, 113.39, 111.32, 110.73, 79.16, 56.19, 55.58, 53.12, 38.27. 
HRMS (ESI
+
) m/z: [M - H
+
] calcd for C34H26ClN2O10 657.1276; found 657.1305. 
 
 
Methyl 2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-2H-
chromen-7-yl)oxy)-3-(p-tolyl)propanoate (12d) Compound 12d was prepared from 6 using 
general procedure C and 10d
28
 to afford a brownish amorphous solid (35 mg, 38%). 
1
H NMR 
(500 MHz, Chloroform-d) δ 8.81 (s, 1H), 8.67 (s, 1H), 7.92 – 7.84 (m, 2H), 7.49 (d, J = 8.9 
Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.14 (s, 4H), 7.11 (ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 7.09 – 
7.06 (m, 2H), 6.94 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.74 (d, J = 8.9 Hz, 1H), 4.91 (dd, J = 7.9, 
4.5 Hz, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 3.76 (s, 3H), 3.29 – 3.21 (m, 2H), 2.33 (s, 3H). 
13
C 
NMR (126 MHz, CDCl3) δ 169.75, 165.82, 160.24, 159.48, 157.08, 150.28, 142.03, 138.57, 
137.17, 132.17, 131.34, 130.18, 129.98, 129.55, 129.51, 129.38, 128.37, 125.59, 123.60, 
122.10, 122.02, 115.44, 114.82, 113.29, 111.22, 110.77, 79.63, 56.08, 55.49, 52.92, 38.48, 
21.27. HRMS (ESI
+
) m/z: [M - H
+
] calcd for C35H29N2O10 637.1822; found 637.1802. 
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Methyl 2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-2H-
chromen-7-yl)oxy)-3-(4-methoxyphenyl)propanoate (12e) Compound 12e was prepared 
from 6 using general procedure C and 10e
28
 to afford a brownish yellow amorphous solid (26 
mg, 32%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.81 (s, 1H), 8.67 (s, 1H), 7.95 – 7.82 (m, 
2H), 7.49 (d, J = 8.9 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.18 (d, J = 2.1 Hz, 1H), 7.15 – 7.10 
(m, 2H), 7.09 – 7.06 (m, 2H), 6.94 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.87 (d, J = 8.7 Hz, 2H), 
6.74 (d, J = 9.0 Hz, 1H), 4.90 (dd, J = 7.8, 4.5 Hz, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 3.80 (s, 
4H), 3.75 (s, 3H), 3.27 – 3.21 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 169.59, 165.67, 
160.09, 159.33, 158.87, 156.93, 150.14, 141.88, 138.42, 131.20, 130.61, 130.47, 130.03, 
129.41, 129.23, 128.22, 127.06, 123.46, 121.95, 121.86, 115.29, 114.68, 114.05, 113.88, 
113.14, 111.07, 110.61, 79.51, 55.93, 55.33, 55.24, 52.76, 37.90. HRMS (ESI
+
) m/z: [M - H
+
] 
calcd for C35H29N2O11 653.1771; found 653.1692. 
 
 
tert-butyl 4-(2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-2H-
chromen-7-yl)oxy)-3-ethoxy-3-oxopropyl)piperazine-1-carboxylate (12f) Compound 12f 
was prepared from 6 using general procedure C and 11a
25
 to afford a brownish yellow 
amorphous solid (60 mg, 30%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.84 (s, 1H), 8.68 (s, 
1H), 7.95 – 7.79 (m, 2H), 7.56 (d, J = 8.9 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.16 – 7.05 (m, 
3H), 6.97 – 6.93 (m, 1H), 6.90 (d, J = 7.6 Hz, 1H), 4.34 – 4.15 (m, 1H), 3.91 (s, 3H), 3.86 (s, 
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3H), 3.49 – 3.28 (m, 3H), 3.13 – 2.97 (m, 2H), 2.71 – 2.42 (m, 4H), 1.27 (t, J = 7.1 Hz, 4H). 
13
C NMR (126 MHz, CDCl3) δ 168.50, 165.82, 160.24, 159.47, 157.06, 154.82, 150.23, 
142.00, 138.55, 131.33, 130.17, 130.09, 129.60, 129.36, 128.36, 125.55, 123.70, 122.08, 
121.99, 115.43, 114.98, 113.26, 111.21, 111.01, 79.90, 78.59, 59.30, 56.07, 55.47, 53.77, 
28.55, 14.33. HRMS (ESI
+
) m/z: [M - H
+
] calcd for C38H41N4O12 745.2721; found 745.2815. 
 
 
Ethyl 2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-2H-
chromen-7-yl)oxy)-3-oxo-3-(pyrrolidin-1-yl)propanoate (12g) Compound 12g was 
prepared from 6 using general procedure C and 11b to afford a brownish amorphous solid (60 
mg, 30%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.84 (s, 1H), 8.68 (s, 1H), 7.95 – 7.79 (m, 
2H), 7.56 (d, J = 8.9 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.16 – 7.05 (m, 3H), 6.97 – 6.93 (m, 
1H), 6.90 (d, J = 7.6 Hz, 1H), 4.34 – 4.15 (m, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 3.49 – 3.28 (m, 
3H), 3.13 – 2.97 (m, 2H), 2.71 – 2.42 (m, 4H), 1.27 (t, J = 7.1 Hz, 4H). 
13
C NMR (126 MHz, 
CDCl3) δ 168.50, 165.82, 160.24, 159.47, 157.06, 154.82, 150.23, 142.00, 138.55, 131.33, 
130.17, 130.09, 129.60, 129.36, 128.36, 125.55, 123.70, 122.08, 121.99, 115.43, 114.98, 
113.26, 111.21, 111.01, 79.90, 78.59, 59.30, 56.07, 55.47, 53.77, 28.55, 14.33. HRMS (ESI
+
) 
m/z: [M - H
+
] calcd for C38H41N4O12 745.2721; found 745.2815. 
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Ethyl 3-amino-2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-
2H-chromen-7-yl)oxy)-3-oxopropanoate (12f) Compound 12f was prepared from 6 using 
general procedure C and 11c to afford a brownish amorphous solid (75 mg, 59%). 
1
H NMR 
(500 MHz, Chloroform-d) δ 8.90 – 8.83 (m, 1H), 8.75 – 8.69 (m, 1H), 7.94 – 7.84 (m, 2H), 
7.69 – 7.63 (m, 1H), 7.42 – 7.35 (m, 1H), 7.16 – 7.04 (m, 3H), 7.01 – 6.89 (m, 2H), 6.69 (s, 
2H), 5.34 – 5.22 (m, 1H), 3.92 (s, 3H), 3.89 (s, 3H), 3.87 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 165.86, 165.20, 164.84, 160.35, 159.49, 156.76, 148.61, 142.39, 138.51, 131.41, 
130.58, 130.18, 129.39, 128.43, 125.40, 124.31, 122.08, 121.42, 116.35, 115.48, 113.26, 
111.25, 110.74, 78.14, 56.09, 55.48, 54.01. HRMS (ESI
+
) m/z: [M - H
+
] calcd for 
C29H24N3O11 590.1411; found 590.1437. 
 
 
N-(2,9-dioxo-3-phenyl-1,2,3,9-tetrahydrochromeno[7,8-b][1,4]oxazin-8-yl)-3',6-
dimethoxy-[1,1'-biphenyl]-3-carboxamide (13a) Compound 13a was prepared from 12a 
using general procedure D to afford a white amorphous solid (5 mg, 56%). 
1
H NMR (500 
MHz, Chloroform-d) δ 8.84 (s, 1H), 8.67 (s, 1H), 8.18 (s, 1H), 7.91 (dd, J = 8.6, 2.5 Hz, 1H), 
7.88 (d, J = 2.4 Hz, 1H), 7.49 – 7.42 (m, 2H), 7.40 – 7.34 (m, 4H), 7.18 (d, J = 8.6 Hz, 1H), 
7.14 – 7.02 (m, 4H), 6.94 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 5.81 (s, 1H), 3.90 (s, 3H), 3.86 (s, 
3H). 
13
C NMR (126 MHz, CDCl3) δ 165.68, 163.67, 160.11, 159.47, 158.02, 143.85, 138.64, 
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137.05, 134.50, 131.26, 130.07, 129.37, 129.36, 129.01, 128.40, 126.96, 125.83, 123.88, 
122.83, 122.33, 122.11, 115.46, 114.96, 114.68, 114.30, 113.23, 111.21, 79.11, 56.06, 55.48. 
HRMS (ESI
+
) m/z: [M + H
+
] calcd for C32H25N2O7 549.1662 ; found 549.1698. 
 
 
N-(3-benzyl-2,9-dioxo-1,2,3,9-tetrahydrochromeno[7,8-b][1,4]oxazin-8-yl)-3',6-
dimethoxy-[1,1'-biphenyl]-3-carboxamide (13b) Compound 13b was prepared from 12b 
using general procedure D to afford a white amorphous solid (5 mg, 36%).
1
H NMR (500 
MHz, Chloroform-d) δ 8.78 (d, J = 2.3 Hz, 1H), 7.87 (dd, J = 8.6, 2.5 Hz, 1H), 7.82 (d, J = 
2.4 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.26 – 7.15 (m, 5H), 7.12 (dd, J = 8.5, 3.6 Hz, 1H), 7.07 
(dt, J = 7.7, 1.2 Hz, 1H), 7.06 – 7.02 (m, 2H), 6.93 – 6.85 (m, 2H), 4.84 (ddd, J = 22.1, 8.8, 
3.6 Hz, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 3.25 (ddd, J = 14.7, 8.2, 3.6 Hz, 1H), 3.10 (dd, J = 
14.6, 8.7 Hz, 1H). 
13
C NMR (126 MHz, CDCl3) δ 164.51, 163.57, 158.92, 158.30, 156.88, 
142.57, 137.47, 135.72, 134.67, 130.08, 128.98, 128.88, 128.70, 128.61, 128.18, 127.42, 
127.21, 126.03, 124.68, 122.77, 121.53, 120.99, 120.93, 114.29, 113.53, 113.42, 113.15, 
112.05, 110.03, 77.34, 54.88, 54.30, 36.06. HRMS (ESI
+
) m/z: [M + H
+
] calcd for 
C33H27N2O7 563.1818; found 563.1901. 
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N-(3-(4-chlorobenzyl)-2,9-dioxo-1,2,3,9-tetrahydrochromeno[7,8-b][1,4]oxazin-8-yl)-
3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (13c) A suspension of 12c (25 mg, 0.037 
mmol) and iron metal (10.24 mg, 0.186 mmol) was heated at 80 oC for 12 h. After 12 h, the 
RM was concentrated, filtered through celite and extracted with EtOAC (3 X 5 ml).  The 
organic layers were combined, dried (over Na2SO4) and concentrated to residue. The residue 
was purified by column chromatography (SiO2, 2:98, Acetone:DCM) to afford desired 
product as a white amorphous solid (14 mg, 61%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.77 
(s, 1H), 7.90 – 7.84 (m, 1H), 7.81 (t, J = 2.4 Hz, 1H), 7.32 (dd, J = 9.0, 6.9 Hz, 1H), 7.24 – 
7.18 (m, 2H), 7.18 – 7.10 (m, 3H), 7.08 – 7.03 (m, 3H), 6.90 – 6.85 (m, 2H), 4.80 (ddd, J = 
8.7, 3.8, 2.2 Hz, 1H), 3.85 (s, 3H), 3.81 (s, 3H), 3.23 (dt, J = 14.8, 3.0 Hz, 1H), 3.15 – 3.04 
(m, 1H). 
13
C NMR (126 MHz, CDCl3) δ 165.86, 165.18, 160.05, 159.34, 158.30, 143.81, 
138.58, 137.20, 134.39, 132.97, 131.12, 131.06, 129.94, 129.27, 128.60, 128.37, 125.68, 
124.40, 122.39, 122.18, 122.03, 115.36, 114.75, 114.59, 114.49, 113.12, 111.18, 77.97, 
55.95, 55.38, 36.26. HRMS (ESI
+
) m/z: [M + H
+
] calcd for C33H26N2O7 597.1429; found 
597.3356. 
 
3',6-Dimethoxy-N-(3-(4-methylbenzyl)-2,9-dioxo-1,2,3,9-tetrahydrochromeno[7,8-
b][1,4]oxazin-8-yl)-[1,1'-biphenyl]-3-carboxamide (13d) Compound 13d was prepared 
from 12d using general procedure D to afford a white amorphous solid (12 mg, 55%). 
1
H 
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NMR (500 MHz, Chloroform-d) δ 8.84 (d, J = 2.9 Hz, 1H), 8.67 (d, J = 2.9 Hz, 1H), 8.05 (d, 
J = 4.2 Hz, 1H), 7.95 – 7.83 (m, 2H), 7.37 (td, J = 7.9, 2.8 Hz, 1H), 7.20 – 7.03 (m, 8H), 6.97 
– 6.89 (m, 2H), 4.90 (dt, J = 8.5, 3.2 Hz, 1H), 3.90 (d, J = 2.8 Hz, 3H), 3.86 (d, J = 2.9 Hz, 
3H), 3.28 (dt, J = 14.8, 3.2 Hz, 1H), 3.13 (ddd, J = 14.4, 8.8, 2.7 Hz, 1H), 2.31 (d, J = 2.7 Hz, 
3H). 
13
C NMR (126 MHz, CDCl3) δ 165.70, 164.85, 160.10, 159.48, 158.09, 143.75, 138.65, 
136.92, 136.83, 132.76, 131.26, 130.07, 129.63, 129.36, 129.32, 128.40, 125.86, 124.00, 
122.68, 122.16, 122.11, 115.47, 114.70, 114.66, 114.40, 113.23, 111.21, 78.67, 56.06, 55.48, 
36.77, 21.24. HRMS (ESI
+
) m/z: [M + Na
+
] calcd for C34H28N2O7Na 599.1794; found 
599.1805. 
 
 
3',6-Dimethoxy-N-(3-(4-methoxybenzyl)-2,9-dioxo-1,2,3,9-tetrahydrochromeno[7,8-
b][1,4]oxazin-8-yl)-[1,1'-biphenyl]-3-carboxamide (13e) Compound 13e was prepared 
from 12e using general procedure D to afford a white amorphous solid (20 mg, 80%). 
1
H 
NMR (500 MHz, Chloroform-d) δ 8.84 (s, 1H), 8.68 (s, 1H), 8.12 (s, 1H), 7.95 – 7.83 (m, 
2H), 7.36 (t, J = 7.9 Hz, 1H), 7.21 – 7.04 (m, 7H), 6.93 (dd, J = 8.0, 2.7 Hz, 2H), 6.85 – 6.80 
(m, 2H), 4.88 (dd, J = 8.5, 3.7 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.77 (s, 3H), 3.25 (dd, J = 
14.7, 3.7 Hz, 1H), 3.13 (dd, J = 14.7, 8.5 Hz, 1H). 
13
C NMR (126 MHz, CDCl3) δ 165.94, 
165.12, 160.34, 159.72, 159.04, 158.34, 144.03, 138.90, 137.17, 131.48, 131.08, 130.33, 
129.60, 128.65, 128.02, 126.10, 124.25, 122.92, 122.39, 122.36, 115.72, 114.93, 114.82, 
114.61, 114.24, 113.46, 111.45, 78.93, 56.30, 55.72, 55.63, 36.63. HRMS (ESI
+
) m/z: [M + 
H
+
] calcd for C34H29N2O8 593.1924; found 593.3711. 
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tert-butyl 4-((8-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-2,9-dioxo-1,2,3,9-
tetrahydrochromeno[7,8-b][1,4]oxazin-3-yl)methyl)piperazine-1-carboxylate (14a) 
Compound 14a was prepared from 12f using general procedure D to afford a white 
amorphous solid (22 mg, 31%). 
1
H NMR (500 MHz, Chloroform-d + CD3OD) δ 8.78 (s, 
1H), 8.62 (s, 1H), 7.91 – 7.81 (m, 2H), 7.34 (t, J = 7.9 Hz, 1H), 7.22 (d, J = 8.5 Hz, 1H), 7.14 
– 7.01 (m, 3H), 6.98 (d, J = 8.5 Hz, 1H), 6.91 (dd, J = 8.1, 2.6 Hz, 1H), 4.99 (dd, J = 7.0, 3.1 
Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.41 (q, J = 5.8 Hz, 4H), 3.21 (dd, J = 14.4, 3.1 Hz, 1H), 
2.92 (dd, J = 14.4, 7.1 Hz, 1H), 2.65 – 2.54 (m, 4H), 1.44 (s, 9H). 
13
C NMR (126 MHz, 
CDCl3) δ 165.86, 161.65, 160.07, 159.35, 158.54, 154.86, 146.81, 139.18, 138.57, 131.13, 
129.97, 129.28, 128.38, 125.65, 124.54, 124.45, 122.41, 122.04, 118.11, 116.17, 115.36, 
114.25, 113.13, 111.18, 80.13, 78.57, 57.34, 57.31, 55.96, 55.39, 53.47, 28.40. HRMS (ESI
+
) 
m/z: [M - Boc] calcd for C31H30N4O7 570.2114; found 570.3211. 
 
General procedure E: Boc-deprotection 
 
N-(2,9-dioxo-3-(piperazin-1-ylmethyl)-1,2,3,9-tetrahydrochromeno[7,8-b][1,4] oxazin-8-
yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (14b) A solution of  14e (15 mg, 0.022 
mmol) in 40% TFA:DCM was stirred at rt for 4 h. After 4 h, the RM was concentrated, pH 
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adjusted to 8, and extracted with EtOAC (3 X 5 ml).  The organic layers were combined, 
dried (over Na2SO4) and concentrated to residue. The residue was purified by column 
chromatography (SiO2, 1:9, Methanol:DCM) to afford desired product as a white amorphous 
solid (5 mg, 42%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.74 (s, 1H), 7.85 (dd, J = 8.6, 2.5 
Hz, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.30 (t, J = 8.0 Hz, 1H), 7.21 (d, J = 8.6 Hz, 1H), 7.06 – 
7.01 (m, 3H), 6.94 (d, J = 8.5 Hz, 1H), 6.87 (ddd, J = 8.2, 2.6, 0.9 Hz, 1H), 4.79 (dd, J = 6.6, 
3.3 Hz, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.09 – 2.92 (m, 6H), 2.83 – 2.69 (m, 4H). 
13
C NMR 
(126 MHz, CDCl3+CH3OH) δ 166.10, 161.68, 160.15, 159.39, 158.50, 146.67, 139.21, 
138.64, 131.17, 130.04, 129.32, 128.46, 125.66, 124.62, 124.56, 122.56, 122.09, 118.06, 
116.39, 115.40, 114.18, 113.17, 111.27, 78.63, 56.97, 55.99, 55.41, 51.06, 43.89, 29.78. 
HRMS (ESI
+
) m/z: [M + H
+
] calcd for C31H31N4O7 571.2193; found 571.3309. 
 
 
N-(2,9-dioxo-3-(pyrrolidine-1-carbonyl)-1,2,3,9-tetrahydrochromeno[7,8-b][1,4]oxazin-
8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (14c) Compound 14c was prepared 
from 12g using general procedure D to afford a white amorphous solid (8 mg, 47%). 
1
H 
NMR (500 MHz, Chloroform-d) δ 8.82 (s, 1H), 8.68 (s, 1H), 8.48 (s, 1H), 7.94 – 7.87 (m, 
2H), 7.36 (t, J = 7.9 Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 7.14 – 6.98 (m, 4H), 6.93 (ddd, J = 
8.3, 2.6, 0.9 Hz, 1H), 5.48 (s, 1H), 3.93 (dt, J = 10.4, 7.0 Hz, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 
3.64 (dt, J = 10.3, 7.0 Hz, 1H), 3.48 (qt, J = 12.4, 7.0 Hz, 2H), 2.01 (ddd, J = 13.2, 9.3, 6.6 
Hz, 2H), 1.89 (q, J = 6.9 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.65, 163.61, 161.02, 
160.00, 159.44, 158.09, 144.21, 138.67, 137.09, 131.14, 130.11, 129.31, 128.40, 125.91, 
124.04, 122.60, 122.37, 122.12, 115.43, 114.82, 113.94, 113.62, 113.20, 111.14, 75.60, 
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56.01, 55.46, 47.20, 46.65, 26.23, 24.15. HRMS (ESI
+
) m/z: [M + H
+
] calcd for C31H27N3O8 
569.1798; found 569.1801. 
 
 
8-(3',6-Dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-2,9-dioxo-1,2,3,9-tetrahydro 
chromeno[7,8-b][1,4]oxazine-3-carboxamide (14d) Compound 14c was prepared from 12h 
using general procedure D to afford a white amorphous solid (15 mg, 47%). 
1
H NMR (500 
MHz, DMSO-d6) δ 8.52 (p, J = 1.3 Hz, 1H), 8.33 – 8.21 (m, 1H), 8.03 – 7.95 (m, 1H), 7.95 – 
7.90 (m, 1H), 7.36 (td, J = 9.0, 1.9 Hz, 2H), 7.28 – 7.22 (m, 1H), 7.15 – 7.05 (m, 3H), 6.94 
(ddd, J = 8.3, 2.7, 1.5 Hz, 1H), 5.21 (q, J = 1.2 Hz, 1H), 3.87 (q, J = 1.2 Hz, 3H), 3.84 – 3.78 
(m, 3H). 
13
C NMR (126 MHz, DMSO) δ 164.79, 163.35, 159.75, 157.41, 157.20, 155.36, 
142.41, 136.92, 136.34, 128.22, 127.66, 127.36, 127.31, 126.72, 123.87, 120.32, 119.94, 
113.46, 112.65, 112.48, 111.81, 110.78, 109.74, 74.64, 54.09, 53.29. HRMS (ESI
+
) m/z: [M 
+ H
+
] calcd for C27H22N3O8 516.1407; found 516.1425. 
 
General procedure F: O-alkylation 
 
Methyl 4-bromo-2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-
2H-chromen-7-yl)oxy)butanoate (14d) Potassium carbonate (59.70 mg, 0.433 mmol) was 
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to a solution of 6 (100 mg, 0.2163 mmol) in anhydrous DMF (0.5 ml) and stirred at rt for 15 
min. After 15 min, the solution was cooled to 0 
o
C and a solution of 15 (0.036 ml, 0.260 
mmol) in DMF (0.1 ml) was added dropwise. The solution was then allowed to stir at rt for 
16 h. After 16 h, the RM was concentrated under reduced pressure to dryness. The resultant 
solid was diluted with water, pH adjusted to 6-7 and extracted with EtOAc (3 X 15 ml). The 
organic layer was collected, dried (over Na2SO4) and concentrated to residue. The residue 
was purified by column chromatography (SiO2, 1:99, Acetone:DCM) to afford desired 
product as a yellow amorphous solid (90 mg, 65%). 
1
H NMR (500 MHz, Chloroform-d) δ 
8.86 (s, 1H), 8.69 (s, 1H), 7.95 – 7.85 (m, 2H), 7.59 (d, J = 8.9 Hz, 1H), 7.38 (t, J = 7.9 Hz, 
1H), 7.16 – 7.04 (m, 3H), 7.01 – 6.93 (m, 2H), 5.11 (dd, J = 9.2, 3.8 Hz, 1H), 3.91 (s, 3H), 
3.87 (s, 3H), 3.81 (s, 3H), 3.66 – 3.58 (m, 2H), 2.62 – 2.44 (m, 2H). 
13
C NMR (126 MHz, 
CDCl3) δ 169.67, 165.80, 160.24, 159.47, 157.01, 150.07, 142.03, 138.55, 131.33, 130.17, 
130.08, 129.79, 129.36, 128.37, 125.54, 123.78, 122.08, 121.89, 115.43, 115.21, 113.26, 
111.21, 111.01, 76.01, 56.07, 55.47, 53.17, 35.08, 28.40.  HRMS (ESI
+
) m/z: [M - H
+
] calcd 
for C29H24BrN2O10 639.0614; found 639.2997. 
 
 
Methyl 5-bromo-2-((3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-nitro-2-oxo-
2H-chromen-7-yl)oxy)pentanoate (19) Compound 19 was prepared from 6 using general 
procedure F and 15 to afford a white amorphous solid (90 mg, 65%). 
1
H NMR (400 MHz, 
Chloroform-d) δ 8.85 (s, 1H), 8.69 (s, 1H), 7.95 – 7.84 (m, 2H), 7.57 (d, J = 8.9 Hz, 1H), 
7.38 (t, J = 7.9 Hz, 1H), 7.15 – 7.06 (m, 4H), 6.97 – 6.92 (m, 1H), 6.85 (d, J = 8.9 Hz, 1H), 
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4.85 (dd, J = 7.6, 4.4 Hz, 1H), 3.92 (s, 3H), 3.87 (s, 3H), 3.80 (s, 3H), 3.57 – 3.38 (m, 2H), 
2.30 – 2.00 (m, 2H), 1.36 – 1.16 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 169.72, 165.86, 
160.29, 159.52, 157.06, 150.12, 142.08, 138.59, 131.39, 130.21, 129.82, 129.41, 128.42, 
125.59, 123.83, 122.13, 121.93, 115.47, 115.25, 113.32, 111.25, 111.05, 76.05, 56.12, 55.52, 
53.21, 35.11, 32.46, 28.45. HRMS (ESI
+
) m/z: [M – H
+
] calcd for C30H26BrN2O10 653.0771; 
found 653.0794. 
 
General procedure G: Nucleophilic substitution and cyclization 
 
N-(2,9-dioxo-3-(2-(pyrrolidin-1-yl)ethyl)-1,2,3,9-tetrahydrochromeno[7,8-b][1,4]oxazin-
8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (17a) A solution of 16 (100 mg, 0.156 
mmol) in dry DMF (0.5 ml) was treated with pyrrolidine (0.064 ml, 0.780 mmol) and stirred 
at rt for 16 h. After 16h, the RM was concentrated under reduced pressure to dryness. The 
resultant solid was filtered through a pad of silica gel column and used without further 
purification in the next step (65 mg mixture).  
Pd/C was added to a solution of the coumarin ether (65 mg, obtained from previous 
step) in MeOH/EtOAc (1:1, 0.5 ml) and stirred at room temperature under hydrogen 
atmosphere for 2 days. After 2 days, RM was filtered through celite and concentrated under 
reduced pressure to residue. The residue was purified by column chromatography (SiO2, 5:95 
MeOH:DCM) to afford a white amorphous solid (12 mg, 10%). 
1
H NMR (500 MHz, 
Chloroform-d + CD3OD) δ 8.84 (d, J = 0.9 Hz, 1H), 7.96 – 7.83 (m, 2H), 7.36 (t, J = 7.9 Hz, 
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1H), 7.18 (d, J = 8.6 Hz, 1H), 7.15 – 7.04 (m, 3H), 7.00 (d, J = 8.5 Hz, 1H), 6.93 (ddd, J = 
8.3, 2.6, 0.9 Hz, 1H), 4.80 (dd, J = 6.3, 5.1 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.39 – 3.08 
(m, 4H), 2.57 (d, J = 63.0 Hz, 2H), 2.38 – 2.15 (m, 2H), 1.68 – 1.28 (m, 4H). 
13
C NMR (126 
MHz, CDCl3) δ 165.69, 164.97, 160.04, 159.37, 158.18, 144.21, 138.58, 137.19, 131.12, 
129.95, 129.28, 128.38, 125.70, 124.14, 122.59, 122.22, 122.03, 115.39, 115.05, 114.78, 
114.41, 113.12, 111.18, 75.00, 55.98, 55.40, 54.12, 51.37, 29.76, 23.47. HRMS (ESI
+
) m/z: 
[M
+
] calcd for C32H31N3O7 569.2162; found 569.2102. 
 
 
N-(3-(2-(dimethylamino)ethyl)-2,9-dioxo-1,2,3,9-tetrahydrochromeno[7,8-b][1,4]oxazin-
8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (17b) Compound 17b was prepared 
from 16 using general procedure G and dimethylamine hydrochloride and potassium 
carbonate to afford a white amorphous solid (22 mg, 18%). 
1
H NMR (500 MHz, Chloroform-
d) δ 8.80 (s, 1H), 7.89 (dd, J = 8.6, 2.5 Hz, 1H), 7.84 (d, J = 2.4 Hz, 1H), 7.34 (t, J = 7.9 Hz, 
1H), 7.17 (d, J = 8.6 Hz, 1H), 7.12 – 7.03 (m, 3H), 6.96 (d, J = 8.5 Hz, 1H), 6.91 (ddd, J = 
8.3, 2.6, 1.0 Hz, 1H), 4.72 (dd, J = 6.8, 4.7 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.21 – 3.07 
(m, 2H), 2.71 (s, 6H), 2.53 – 2.31 (m, 2H). 
13
C NMR (126 MHz, CDCl3+CH3OH) δ 165.78, 
165.07, 160.06, 159.36, 158.20, 144.16, 138.58, 137.33, 131.13, 129.95, 129.28, 128.38, 
125.67, 124.15, 122.66, 122.39, 122.04, 115.38, 115.19, 114.70, 114.35, 113.12, 111.19, 
74.76, 55.97, 55.39, 53.98, 43.56, 29.76. HRMS (ESI
+
) m/z: [M + Na
+
] calcd for 
C30H29N3O7Na 566.1903; found 566.2942. 
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N-(2,9-dioxo-3-(2-(piperidin-1-yl)ethyl)-1,2,3,9-tetrahydrochromeno[7,8-b][1,4] oxazin-
8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (17c) Compound 17c was prepared 
from 6 using general procedure B and piperidine to afford a white amorphous solid (25 mg, 
36%).  
1
H NMR (400 MHz, Chloroform-d) δ 8.84 (s, 1H), 8.68 (s, NH), 8.36 (s, NH), 7.94 – 
7.87 (m, 2H), 7.35 (t, J = 7.9 Hz, 1H), 7.18 – 7.04 (m, 4H), 7.00 – 6.88 (m, 2H), 4.83 (dd, J = 
6.9, 4.9 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 2.81 – 2.69 (m, 2H), 2.68 – 2.40 (m, 4H), 2.40 – 
2.20 2.30 (m, 2H), 1.76 – 1.52 (m, 4H), 1.50 – 1.33 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 
165.70, 164.71, 160.03, 159.34, 158.21, 144.23, 138.55, 137.21, 131.09, 129.93, 129.26, 
128.37, 125.64, 124.16, 122.61, 122.30, 122.01, 115.38, 115.15, 114.76, 114.44, 113.08, 
111.16, 74.80, 55.95, 55.38, 53.54, 53.23, 24.92, 22.96, 22.23. HRMS (ESI
+
) m/z [M + H
+
] 
calcd for C33H34N3O7 584.2397; found 584.4839. 
 
 
N-(2,9-dioxo-3-(2-(piperazin-1-yl)ethyl)-1,2,3,9-tetrahydrochromeno[7,8-b][1,4] oxazin-
8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (17d) Compound 17d was prepared 
from Boc-protected 17d using general procedure E to afford a white amorphous solid (20 mg, 
95%).  
1
H NMR (400 MHz, Chloroform-d) δ 8.84 (s, 1H), 8.68 (s, 1H), 8.36 (s, 1H), 7.94 – 
7.87 (m, 2H), 7.35 (t, J = 7.9 Hz, 1H), 7.18 – 7.04 (m, 4H), 7.00 – 6.88 (m, 2H), 4.83 (dd, J = 
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6.9, 4.9 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 2.81 – 2.69 (m, 2H), 2.68 – 2.40 (m, 4H), 2.40 – 
2.20 2.30 (m, 2H), 1.76 – 1.52 (m, 4H), 1.50 – 1.33 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 
165.70, 164.71, 160.03, 159.34, 158.21, 144.23, 138.55, 137.21, 131.09, 129.93, 129.26, 
128.37, 125.64, 124.16, 122.61, 122.30, 122.01, 115.38, 115.15, 114.76, 114.44, 113.08, 
111.16, 74.80, 55.95, 55.38, 53.54, 53.23, 24.92, 22.96, 22.23. HRMS (ESI
+
) m/z: [M + H
+
] 
calcd for C32H33N4O7 585.2349; found 585.4844. 
 
 
3',6-Dimethoxy-N-(3-(2-(4-methylpiperazin-1-yl)ethyl)-2,9-dioxo-1,2,3,9-tetrahydro 
chromeno[7,8-b][1,4]oxazin-8-yl)-[1,1'-biphenyl]-3-carboxamide (17e) Compound 17e 
was prepared from 16 using general procedure G and N-methyl piperazine to afford a white 
amorphous solid (14 mg, 36%).  
1
H NMR (500 MHz, Chloroform-d + CD3OD) δ 8.86 (s, 
1H), 8.68 (s, 1H), 8.01 (s, 1H), 7.96 – 7.87 (m, 2H), 7.41 – 7.34 (m, 1H), 7.19 – 7.06 (m, 
4H), 6.98 – 6.91 (m, 2H), 4.86 (dd, J = 6.8, 4.9 Hz, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 2.59 (dt, J 
= 11.1, 6.6 Hz, 2H), 2.52 – 2.36 (m, 4H), 2.35 – 2.25 (m, 4H), 2.24 – 2.10 (m, 2H). 
13
C NMR 
(126 MHz, CDCl3) δ 165.71, 165.70, 160.10, 159.47, 158.12, 144.14, 138.65, 136.89, 
131.26, 130.05, 129.36, 128.39, 125.86, 124.04, 122.61, 122.10, 122.00, 115.47, 114.60, 
114.52, 114.23, 113.22, 111.21, 75.84, 56.06, 56.04, 55.48, 55.05, 53.03, 45.94, 28.47. 
HRMS (ESI
+
) m/z: [M
+
] calcd for C33H34N4O7 598.2428; found 598.2501. 
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3',6-Dimethoxy-N-(3-(2-morpholinoethyl)-2,9-dioxo-1,2,3,9-tetrahydrochromeno[7,8-
b][1,4]oxazin-8-yl)-[1,1'-biphenyl]-3-carboxamide (17f) Compound 17f was prepared from 
16 using general procedure G and morpholine to afford a white amorphous solid (25 mg, 
36%).  
1
H NMR (400 MHz, Chloroform-d + CD3OD) δ 8.85 (s, 1H), 8.67 (s, NH), 8.05 (s, 
NH), 7.95 – 7.86 (m, 2H), 7.37 (t, J = 7.9 Hz, 1H), 7.18 – 7.05 (m, 4H), 7.00 – 6.90 (m, 2H), 
4.87 (dd, J = 7.0, 4.7 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.69 – 3.59 (m, 4H), 2.62 – 2.56 (s, 
2H), 2.54 – 2.32 (m, 4H), 2.22 – 2.14 (s, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.71, 160.10, 
159.47, 158.09, 144.11, 138.64, 136.92, 131.26, 130.07, 129.36, 128.38, 125.85, 123.98, 
122.66, 122.10, 122.03, 115.46, 114.66, 114.52, 114.22, 113.23, 111.21, 75.72, 67.00, 56.06, 
55.48, 53.60, 45.44, 27.81. HRMS (ESI
+
) m/z: [M
+
] calcd for C33H33N3O8 599.2268; found 
599.2290. 
 
N-(3-(2-(cyclohexylamino)ethyl)-2,9-dioxo-1,2,3,9-tetrahydrochromeno[7,8-b][1,4] 
oxazin-8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (17g) Compound 17g was 
prepared from 16 using general procedure G and cyclohexylamine to afford a white 
amorphous solid (6 mg, 9%). 
1
H NMR (500 MHz, Chloroform-d + CD3OD) δ 8.80 (s, 1H), 
7.90 – 7.83 (m, 2H), 7.35 (d, J = 7.9 Hz, 1H), 7.19 – 6.96 (m, 4H), 6.93 – 6.88 (m, 2H), 4.64 
(dd, J = 7.2, 3.9 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.31 – 3.11 (m, 1H), 2.99 (ddd, J = 14.4, 
8.1, 4.5 Hz, 2H), 2.18 – 2.05 (m, 2H), 1.95 – 1.77  (m, 4H), 1.75 – 1.62 (m,  4H), 1.54 – 1.41 
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(m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.69, 165.58, 159.97, 159.29, 158.22, 144.14, 
138.51, 137.16, 131.05, 129.89, 129.22, 128.31, 125.61, 124.24, 122.43, 122.25, 121.97, 
115.32, 114.90, 114.62, 114.45, 113.06, 111.10, 76.33, 57.27, 55.89, 55.33, 43.85, 29.70, 
29.08, 24.81, 24.45. HRMS (ESI
+
) m/z [M
+
] calcd for C34H35N3O7 597.2475; found 597.3386. 
 
 
N-(3-(2-(bicyclo[2.2.1]heptan-2-ylamino)ethyl)-2,9-dioxo-1,2,3,9-tetrahydro 
chromeno[7,8-b][1,4]oxazin-8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (17i)  
Compound 17h was prepared from 16 using general procedure G and bicyclo[2.2.1]heptan-2-
amine hydrochloride and potassium carbonate to afford a white amorphous solid (14 mg, 
13%). 
1
H NMR (400 MHz, Chloroform-d + CD3OD) δ 8.78 (d, J = 3.4 Hz, 1H), 7.92 – 7.80 
(m, 2H), 7.36 – 7.28 (m, 1H), 7.14 (dd, J = 8.6, 3.3 Hz, 1H), 7.11 – 7.02 (m, 3H), 6.93 (ddd, 
J = 21.7, 8.4, 3.1 Hz, 2H), 4.75 (d, J = 6.2 Hz, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 3.32 – 3.26 (m, 
1H), 3.12 – 3.03 (m, 2H), 2.50 (s, 2H), 2.26 (s, 1H), 2.04 – 1.93 (m, 2H), 1.69 – 1.47 (m, 
1H), 1.38 (s, 3H), 1.21 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 165.79, 160.03, 159.33, 
158.27, 144.35, 138.55, 137.32, 131.09, 129.93, 129.26, 128.36, 125.62, 124.28, 122.55, 
122.33, 122.02, 115.36, 115.11, 114.81, 114.79, 114.38, 113.09, 111.16, 75.08, 59.57, 55.93, 
55.37, 43.27, 38.56, 38.28, 36.39, 34.34, 30.95, 29.74, 29.20. HRMS (ESI
+
) m/z [M + H
+
] 
calcd for C35H36N3O7 610.2553; found 610.2540. 
72 
 
 
N-(3-(2-((3s,5s,7s)-adamantan-1-ylamino)ethyl)-2,9-dioxo-1,2,3,9-tetrahydro 
chromeno[7,8-b][1,4]oxazin-8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (17i) 
Compound 17i was prepared from 16 using general procedure G and adamantan-1-amine to 
afford a white amorphous solid (22 mg, 16%). 
1
H NMR (400 MHz, Chloroform-d) δ 8.77 (s, 
1H), 7.89 – 7.80 (m, 2H), 7.32 (t, J = 7.9 Hz, 1H), 7.14 (d, J = 8.5 Hz, 1H), 7.10 – 6.99 (m, 
3H), 6.96 (d, J = 8.5 Hz, 1H), 6.89 (dd, J = 8.3, 2.6 Hz, 1H), 4.74 (t, J = 5.9 Hz, 1H), 3.85 (s, 
3H), 3.81 (s, 3H), 3.19 – 3.12 (m, 2H), 2.65 – 2.54 (m, 1H), 2.50 (dt, J = 14.4, 6.9 Hz, 1H), 
2.17 (s, 3H), 1.97 – 1.93 (m, 6H), 1.67 (d, J = 8.5 Hz, 6H). 
13
C NMR (126 MHz, CDCl3) δ 
165.78, 165.36, 160.05, 159.34, 158.28, 144.45, 138.56, 137.34, 131.10, 129.95, 129.27, 
128.36, 125.63, 124.27, 122.58, 122.37, 122.03, 115.37, 115.14, 114.79, 114.42, 113.10, 
111.17, 75.12, 57.50, 55.95, 55.38, 38.72, 35.74, 35.59, 29.05, 27.51. HRMS (ESI
+
) m/z: [M
+
] 
calcd for C38H39N3O7 649.2788; found 649.2803. 
 
 
N-(2,9-dioxo-3-(3-(pyrrolidin-1-yl)propyl)-1,2,3,9-tetrahydrochromeno[7,8-b][1,4] 
oxazin-8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (20a) Compound 20a was 
prepared from 19 using general procedure G and pyrrolidine to afford a light yellowish 
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amorphous solid (28 mg, 42%).  
1
H NMR (400 MHz, Chloroform-d + CD3OD) δ 8.80 (s, 
1H), 7.93 – 7.80 (m, 2H), 7.34 (t, J = 7.9 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 7.11 – 7.03 (m, 
3H), 6.98 (d, J = 8.6 Hz, 1H), 6.90 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 4.62 (dd, J = 6.9, 3.6 Hz, 
1H), 3.87 (s, 3H), 3.83 (s, 3H), 2.75 – 2.45  (m, 6H), 2.02 (dt, J = 10.7, 5.9 Hz, 2H), 1.85 – 
1.72 (m, 4H), 1.62 – 1.48 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.72, 165.25, 160.02, 
159.35, 158.25, 144.15, 138.58, 137.18, 131.08, 129.97, 129.27, 128.37, 125.68, 124.25, 
122.53, 122.25, 122.03, 115.39, 114.99, 114.75, 114.50, 113.10, 111.17, 76.32, 55.96, 55.40, 
54.97, 53.83, 27.49, 23.39, 21.41. HRMS (ESI
+
) m/z [M + H
+
] calcd for C33H34N3O7 
584.2397, found 584.2417. 
 
N-(2,9-dioxo-3-(3-(piperidin-1-yl)propyl)-1,2,3,9-tetrahydrochromeno[7,8-b][1,4] 
oxazin-8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (20b) Compound 20b was 
prepared from 19 using general procedure G and piperdine to afford a light yellowish 
amorphous solid (15 mg, 21%). 
1
H NMR (500 MHz, Chloroform-d + CD3OD) δ 8.77 (d, J = 
2.0 Hz, 1H), 7.89 – 7.80 (m, 2H), 7.31 (t, J = 7.9 Hz, 1H), 7.16 – 7.09 (m, 1H), 7.10 – 7.01 
(m, 3H), 6.97 (d, J = 8.5 Hz, 1H), 6.88 (dd, J = 8.1, 2.5 Hz, 1H), 4.62 (dd, J = 7.2, 4.3 Hz, 
1H), 3.84 (s, 2H), 3.81 (s, 2H), 3.10 – 3.00 (m, 2H), 2.72 (dt, J = 15.2, 4.8 Hz, 4H), 2.25 – 
2.04 (m, 6H), 1.98 (dd, J = 14.2, 7.0 Hz, 1H), 1.41 (ddq, J = 13.7, 9.7, 5.6, 4.2 Hz, 1H). 
13
C 
NMR (126 MHz, CDCl3) δ 165.77, 165.36, 160.03, 159.34, 158.29, 144.18, 138.58, 137.23, 
131.06, 129.97, 129.28, 128.38, 125.66, 124.36, 122.49, 122.26, 122.04, 115.39, 114.98, 
114.79, 114.53, 113.09, 111.18, 76.37, 56.75, 55.96, 55.40, 27.50, 22.63, 21.96, 19.40. 
HRMS (ESI
+
) m/z [M + H
+
] calcd for C33H34N3O7 584.2397, found 584.2407. 
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tert-butyl 4-(3-(8-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-2,9-dioxo-1,2,3,9-
tetrahydrochromeno[7,8-b][1,4]oxazin-3-yl)propyl)piperazine-1-carboxylate Compound 
Boc-protected amine 20 was prepared from 19 using general procedure G and N-boc 
piperzine to afford a light yellowish amorphous solid (45 mg, 42%). 
1
H NMR (500 MHz, 
Chloroform-d) δ 8.84 (s, 1H), 8.68 (s, 1H), 8.33 (s, 1H), 7.94 – 7.86 (m, 2H), 7.35 (t, J = 7.9 
Hz, 1H), 7.16 – 7.03 (m, 4H), 6.97 – 6.90 (m, 2H), 4.71 (dd, J = 8.3, 4.4 Hz, 1H), 3.89 (s, 
3H), 3.85 (s, 3H), 3.41 (t, J = 5.0 Hz, 4H), 2.44 – 2.34 (m, 6H), 2.08 – 1.91 (m, 1H), 1.87 – 
1.67 (m, 1H), 1.45 (s, 10H). 
13
C NMR (126 MHz, CDCl3) δ 165.66, 165.45, 160.05, 159.44, 
158.11, 154.84, 144.00, 138.63, 136.98, 131.18, 130.08, 129.31, 128.38, 125.82, 123.99, 
122.70, 122.08, 122.07, 115.46, 114.77, 114.61, 114.38, 113.16, 111.16, 79.74, 77.55, 57.97, 
56.02, 55.44, 53.05, 28.75, 28.55, 22.03. HRMS (ESI
+
) m/z [M - Boc] calcd for C33H35N4O7 
599.2506, found 599.2578. 
 
 
N-(2,9-dioxo-3-(3-(piperazin-1-yl)propyl)-1,2,3,9-tetrahydrochromeno[7,8-
b][1,4]oxazin-8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (20c) Compound 20c 
was prepared from Boc-amine (obtained from previous step) using general procedure E to 
afford a light yellowish amorphous solid (13 mg, 76%).  
1
H NMR (500 MHz, Chloroform-d 
75 
 
+ CD3OD) δ 8.77 (s, 1H), 7.89 – 7.76 (m, 2H), 7.31 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 8.5 Hz, 
1H), 7.09 – 7.01 (m, 3H), 6.94 – 6.85 (m, 2H), 4.62 (dd, J = 7.9, 4.6 Hz, 1H), 3.85 (s, 3H), 
3.81 (d, J = 1.4 Hz, 3H), 3.12 (t, J = 5.1 Hz, 4H), 2.62 (d, J = 8.7 Hz, 4H), 2.48 – 2.41 (m, 
2H), 1.94 (dt, J = 7.6, 3.8 Hz, 2H), 1.69 (ddt, J = 22.9, 15.6, 7.3 Hz, 2H). 
13
C NMR (126 
MHz, CDCl3) δ 166.11, 165.88, 159.99, 159.26, 158.31, 144.13, 138.52, 137.24, 131.04, 
129.88, 129.20, 128.30, 125.58, 124.53, 122.30, 122.15, 121.96, 115.29, 114.72, 114.63, 
114.28, 113.03, 111.12, 76.96, 60.60, 57.15, 55.86, 55.29, 43.33, 28.06, 22.30. HRMS (ESI
+
) 
m/z [M + H
+
] calcd for C33H35N4O7 599.2506; found 599.2556. 
 
 
3',6-Dimethoxy-N-(3-(3-(4-methylpiperazin-1-yl)propyl)-2,9-dioxo-1,2,3,9-
tetrahydrochromeno[7,8-b][1,4]oxazin-8-yl)-[1,1'-biphenyl]-3-carboxamide (20d) 
Compound 20d was prepared from 19 using general procedure G and N-methyl piperazine to 
afford a light yellowish amorphous solid (18 mg, 25%).  
1
H NMR (400 MHz, Chloroform-d 
+ CD3OD) δ 8.81 (s, 1H), 7.93 – 7.82 (m, 2H), 7.34 (t, J = 8.0 Hz, 1H), 7.16 – 7.03 (m, 4H), 
6.97 – 6.87 (m, 2H), 4.65 (dd, J = 8.2, 4.4 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 2.70 – 2.25 (m, 
8H), 2.36 (s, 3H), 2.04 – 1.87 (m, 2H), 1.75 (dd, J = 15.2, 7.8 Hz, 2H), 1.32 – 1.12  (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.53, 165.54, 159.79, 159.11, 158.02, 143.85, 138.33, 
136.90, 130.89, 129.71, 129.03, 128.11, 125.46, 124.09, 122.14, 121.83, 121.79, 121.77, 
115.12, 114.48, 114.17, 112.88, 110.93, 77.02, 57.32, 55.72, 55.15, 54.27, 51.89, 28.27, 
21.61. HRMS (ESI
+
) m/z [M + H
+
] calcd for C34H37N3O7 613.2662; found 613.2672. 
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N-(3-(3-(cyclohexylamino)propyl)-2,9-dioxo-1,2,3,9-tetrahydrochromeno[7,8-
b][1,4]oxazin-8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (20e) Compound 20e 
was prepared from 19 using general procedure G and cyclohexylamine to afford a white 
amorphous solid (15 mg, 21%).  
1
H NMR (500 MHz, Chloroform-d + CD3OD) δ 8.78 (s, 
1H), 8.67 (s, 1H), 7.89 – 7.81 (m, 2H), 7.37 – 7.29 (m, 1H), 7.14 (dd, J = 8.6, 1.0 Hz, 1H), 
7.11 – 7.00 (m, 3H), 6.98 (dd, J = 8.5, 1.0 Hz, 1H), 6.90 (ddt, J = 8.3, 2.5, 1.0 Hz, 1H), 4.63 
(dd, J = 7.5, 3.4 Hz, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.01 (qd, J = 7.1, 4.6, 3.7 Hz, 3H), 2.14 – 
2.08 (m, 3H), 1.90 – 1.81 (m, 4H), 1.66 (dd, J = 11.8, 4.1 Hz, 2H), 1.52 (qd, J = 12.5, 8.1 Hz, 
4H),  1.33 – 1.24 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.82, 165.70, 159.92, 159.19, 
158.23, 144.15, 138.45, 137.24, 130.93, 129.81, 129.12, 128.26, 125.49, 124.46, 122.29, 
122.17, 121.90, 115.22, 114.81, 114.69, 114.35, 112.94, 111.06, 76.23, 57.21, 55.78, 55.21, 
43.84, 28.97, 27.23, 24.73, 24.33, 21.56. HRMS (ESI
+
) m/z [M + H
+
] calcd for C35H38N3O7 
612.2710, found 612.2710. 
 
N-(3-(3-(bicyclo[2.2.1]heptan-2-ylamino)propyl)-2,9-dioxo-1,2,3,9-tetrahydro 
chromeno[7,8-b][1,4]oxazin-8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (20f) 
Compound 20f was prepared from 19 using general procedure G and bicyclo[2.2.1]heptan-2-
amine hydrochloride and potassium carbonate to afford a white amorphous solid ( 11 mg, 
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16%).  
1
H NMR (400 MHz, Chloroform-d) δ 8.78 (d, J = 3.4 Hz, 1H), 7.91 – 7.80 (m, 2H), 
7.36 – 7.29 (m, 1H), 7.14 (dd, J = 8.6, 3.3 Hz, 1H), 7.11 – 7.01 (m, 3H), 6.93 (ddd, J = 21.7, 
8.4, 3.1 Hz, 2H), 4.75 (d, J = 6.2 Hz, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 2.50 (s, 2H), 2.26 (s, 
1H), 2.08 – 1.89 (m, 2H), 1.73 – 1.46 (m, 3H), 1.46 – 1.02 (m, 8H). 
13
C NMR (126 MHz, 
CDCl3) δ 165.79, 165.55, 160.04, 159.34, 158.28, 144.29, 144.27, 138.56, 137.28, 131.11, 
129.94, 129.27, 129.24, 128.36, 125.65, 124.30, 122.51, 122.25, 122.03, 115.36, 114.99, 
114.79, 114.38, 113.11, 111.17, 75.38, 59.44, 55.95, 55.38, 43.40, 43.28, 38.78, 38.25, 36.44, 
35.45, 29.74, 29.49, 28.41.  HRMS (ESI
+
) m/z [M + H
+
] calcd for C36H38N3O7 624.2710, 
found 624.2740. 
 
N-(3-(3-((1s,3s)-adamantan-1-ylamino)propyl)-2,9-dioxo-1,2,3,9-tetrahydro 
chromeno[7,8-b][1,4]oxazin-8-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (20g) 
Compound 20g was prepared from 19 using general procedure G and (1s,3s)-adamantan-1-
amine to afford a white amorphous solid (22 mg, 31%).  
1
H NMR (500 MHz, Chloroform-d) 
δ 8.77 (d, J = 1.0 Hz, 1H), 7.88 – 7.82 (m, 2H), 7.32 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 1.0 Hz, 
0H), 7.11 – 6.95 (m, 4H), 6.90 (ddd, J = 8.3, 2.5, 1.1 Hz, 1H), 4.63 (dd, J = 7.7, 4.5 Hz, 1H), 
3.84 (s, 3H), 3.82 (s, 3H), 3.03 – 2.90 (m, 2H), 2.20 – 2.16 (m, 5H), 2.02 – 2.00 (m, 6H), 1.75 
– 1.61 (m, 6H), 1.24 – 1.20 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.64, 165.64, 159.95, 
159.31, 158.22, 144.07, 138.53, 137.14, 131.01, 129.98, 129.22, 128.28, 125.62, 124.20, 
122.42, 122.24, 121.99, 115.36, 114.85, 114.62, 114.52, 113.04, 111.07, 76.55, 57.79, 55.93, 
55.29, 39.24, 38.47, 35.47, 29.02, 27.68, 22.16.  HRMS (ESI
+
) m/z [M + H
+
] calcd for 
C39H42N3O7 664.3023, found 664.3070. 
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Scaffold for Hsp90 Inhibition 
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Chapter 3 
Identification of Arylbiphenylamides as Hsp90 C-Terminal Inhibitors 
 
1.  Introduction 
Hsp90 is a molecular chaperone that plays a crucial role in normal homeostatic 
processes as well as adaptive responses to cellular stress.
1, 2
 Hsp90 regulates the 
conformational maturation, activation, and integrity of a wide range of client proteins, 
many of which are critical for cell signaling, proliferation and survival.
3, 4
 However, in 
cancer, several of these client proteins are often mutated and/or over-expressed and 
therefore become highly dependent upon the Hsp90 folding machinery for their 
maturation and stability.
5, 6
 In fact, oncogenic proteins (e.g. Her2, Raf1, Akt, CDK4 etc.) 
associated with all six hallmarks of cancer have been found to be dependent upon Hsp90 
for their function.
7
 Consequently, Hsp90 has emerged as an attractive therapeutic drug 
target for the development of cancer chemotherapeutics.  
Hsp90 exists as a homodimer with each monomer consisting of three domains: (1) 
N-terminal ATP-binding domain, (2) middle domain, and (3) C-terminal dimerization 
domain. However, the majority of research to date has been focused on the development 
of Hsp90 N-terminal inhibitors. In fact, all Hsp90 inhibitors in  clinical trials belong to 
this class.
4
 Although, significant progress has been made towards the identification of 
potent inhibitors, concomitant induction of the pro-survival response and poor toxicity 
profiles of N-terminal inhibitors have remained obstacles to their clinical success.  
In 2000, Neckers and co-workers identified a second druggable site at the C-
terminus of Hsp90.
8
 Using affinity chromatography, they demonstrated the coumarin 
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antibiotics, such as novobiocin (NB), bound to a previously unrecognized Hsp90 C-
terminal domain and induced Hsp90 client protein degradation in a concentration-
dependent manner. In addition, it was observed that inhibitors bound to the Hsp90 C-
terminus allosterically modulate the binding of ligands to the N-terminus. Interestingly, 
NB did not induce the pro-survival heat shock response, one of the major drawbacks 
associated with N-terminal inhibitors. However, NB manifests poor anti-proliferative 
activity against cancer cell lines (e.g. SKBr3, IC50 ~700 µM), thus exhibits a limit for use 
as a chemotherapeutic agent. 
Following this pioneering work by Neckers, attempts were made to improve the 
efficacy and selectivity of NB. In 2005, SAR studies by Blagg and co-workers led to the 
development of the first selective and potent Hsp90 C-terminal inhibitors (DHN1, 
DHN2).
9
 Subsequent structural modification led to identification of several analogues 
that manifest efficacy similar to N-terminal inhibitors.
10
 In addition, SAR studies 
revealed a unique class of C-terminal inhibitors (A4, KU32) that induce Hsp90 levels at 
much lower concentration (1000-10000 fold) than that required for client protein degradation. 
These compounds are currently under investigation for the treatment of neurodegenerative 
diseases.11, 12 In light of these findings, it is desired to further explore C-terminal 
inhibitors to obtain additional insight into the unique mechanism exhibited by such 
compounds and to produce more efficacious modulators of the Hsp90 protein folding 
machine.  
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Figure 3.1.  Structures of DHN1, DHN2, A4 and KU32. 
 
2. Design, Synthesis and Biological Evaluation of Arylbiphenylamides 
Since identification of the Hsp90 C-terminal binding site, the majority of research 
efforts have been focused on the coumarin-containing natural products (Figure 3.2) for 
elucidation of the Hsp90 C-terminal nucleotide-binding pocket and development of more 
potent inhibitors.
11, 13-15
 Although, significant progress has been made towards the 
development of more potent analogues,
10, 13
 access to diversified novobiocin analogues 
has remained a challenge. Therefore, the identification of new chemical scaffolds that can 
be modified in an expeditious manner and can produce compounds with enhanced 
activities are actively sought.  
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Figure 3.2.  Hsp90 C-terminus inhibitors-containing coumarin scaffold. 
 
A. Rationale for design of Arylbiphenylamides 
Earlier SAR studies, focused on the modification of NB, unveiled key structural 
features of NB required for anti-proliferative activity and several potent analogues such 
as compound 4 were identified (Figure 3.3).
11, 13, 14
 These studies led to elucidation of the 
following structure-activity-relationships: 1) the sugar (or its surrogate) and benzamide 
side chain are critical for activity and removal of either decreases activity, 2) the 
coumarin core serves as an anchor for orientation of the side chains within the binding 
pocket and can be replaced without compromising activity
13
, 3) the amide linker provides 
additional hydrogen bonding interactions with the binding pocket. Furthermore, recent 
SAR studies revealed that replacement of the amide linker with a urea further improved 
inhibitory activity and lead candidate 5 was identified (manuscript in preparation, Figure 
3.3). As a consequence of these observations, it was proposed that replacement of the 
coumarin core with other scaffolds that incorporated an optimized sugar surrogate and the 
benzamide side chain could produce new compounds that exhibit improved inhibitory 
activities.  
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In an effort to find a suitable replacement for the coumarin core, several scaffolds 
were screened (in silico) based on their ease of accessibility and inclusion of points for 
diversification. Initial screening suggested the biphenyl ring system could serve as a 
replacement for the coumarin core. The biphenyl moiety is a privileged structure that 
could be easily modified to produce diverse analogues for development of more potent 
inhibitors. Furthermore, the biphenyl ring system is a flexible structure compared to the 
rigid coumarin scaffold and could therefore adopt different conformations within the 
binding pocket and serve to provide additional interactions with the protein.  
Since there is no co-crystal of Hsp90 bound to a C-terminal inhibitor, prior SAR 
studies and computational models were used to design new inhibitors. Earlier SAR 
studies demonstrated that replacement of the novoise sugar with ionizable amines such as 
N-methylpiperidine, enhance anti-proliferative activity (Figure 3.3).
10, 16
 Therefore, N-
methylpiperidine was selected as a sugar surrogate for analog development. In addition, 
studies have shown that biaryl side chain containing inhibitors  manifest improved 
activity compared to other analogues, thus the biaryl side chain was chosen for initial 
SAR studies.
10
  Recently it was observed that the optimum distance between the nitrogen 
atoms on the piperidine ring and the amide/urea is critical for Hsp90 C-terminal 
inhibition.
17
 Consequently, it was proposed that the biphenyl ring system that contains 
different substitution patterns (e.g., para-meta, meta-meta and para-para) could provide 
an optimized ring system for replacement of the coumarin core. In addition, we 
hypothesized that incorporation of different substitutions on the biphenyl system could 
elucidate additional interactions with the protein. Lastly, different benzamide side chains 
were explored to identify the most potent analogues. 
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Figure 3.3. Rationale for proposed arylbiphenylamides 
 
To support our hypothesis, the proposed biphenyl derivatives were docked into 
our homology model as illustrated in Figure 3.4. Molecular docking studies suggested 
that compound 8a, which contains a para-meta substitution showed the best structural 
alignment with lead molecule 4, while compound 8c, which contains a para-para 
substitution overlayed with lead molecule 5.   
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Figure 3.4. Molecular overlay of arylbiphenylamides to coumarin derivatives in the putative 
Hsp90 C-terminal binding site. (A) Compound 4 (grey) overlayed with proposed para-meta 
substituted arylbiphenylamide 8a (blue); (B) Compound 5 (grey) overlayed with proposed para-
para substituted arylbiphenylamide 8c (blue). 
 
 
B. Synthesis and Evaluation of Arylbiphenylamides 
To elucidate initial SARs, a small library of biphenyl derivatives containing para-
meta, meta-meta and para-para substitution patterns was synthesized and evaluated. 
A.  
B.  
88 
 
Retrosynthetically, we envisioned the construction of arylbiphenylamides via an amide 
coupling between amine 5 and acid chloride 7 (Scheme 3.1). The intermediate 5 could be 
obtained either from a Suzuki coupling between arylhalide 3 and phenylboronic acid 10 
or a Mitsunobu etherification between 1-methyl-4-hydroxypeperidine (1) and phenol 6, 
followed by reduction via a Pd-catalyzed hydrogenation. Arylhalide 3 was proposed to 
come from a Mitsunobu etherification between 1-methyl-4-hydroxypeperidine (1) and 
phenol 2. Phenol 6 could be then prepared from a Suzuki coupling between arylhalide 3 
and phenylboronic acid 4. 
 
Scheme 3.1. Retrosynthetic analysis of arylbiphenylamides. 
 
. 
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As shown in Scheme 3.2, synthesis of the biphenyl analogues began with 
Mitsunobu etherification of 1-methyl-4-hydroxypeperidine (1) with iodophenols 2a-b to 
give aryl iodides 3a and 3b respectively. The resulting aryl iodides 3a-b were then 
coupled with aryl boronic acid 4 under standard Suzuki coupling conditions to afford the 
corresponding amines 5a and 5b. Amine 5c was obtained by Mitsunobu etherification of 
phenol 6 with 1-methyl-4-hydroxypeperidine 1, followed by reduction with Pd/C under a 
hydrogen atmosphere.  Finally, amines 5a-c were coupled with acid chloride 7 via an 
amide coupling procedure to afford the requisite amides 8a-c in moderate to high yields.  
 
Scheme 3.2. Synthesis of biphenyl analogues. 
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 After completion of the syntheses, the arylbiphenylamides 5a-c were evaluated 
for anti-proliferative activity against SKBr3 and MCF-7 breast cancer cell lines. As 
shown in Table 3.1, all the biphenyl analogues showed low micromolar activity in these 
anti-proliferative assays. Consistent with our docking studies, the para-para (8c) 
biphenyl analogue was found 2~3-fold more active than the para-meta and meta-meta 
derivatives, suggesting that it represents the optimal distance between the nitrogen atoms 
on piperidine and amide for activity. 
 
Table 3.1. Anti-proliferative activity of novobiocin mimics. 
 
 
 
 
Entry Biphenyl SKBr3 MCF-7 
8a para-meta 3.65 ± 0.14
a
 1.25 ± 0.02 
8b meta-meta 1.62 ± 0.07 2.00 ± 0.07 
8c para-para 0.47 ± 0.06 0.71 ± 0.02 
a
Values represent mean ± standard deviation for at least two separate experiments 
performed in triplicate. 
 
To verify that the anti-proliferative activity manifested by the biphenyl analogues 
was the result of Hsp90 inhibition, compounds 8a and 8c were evaluated for their ability 
to induce the degradation of Hsp90-dependent client proteins by Western blot analyses. 
MCF-7 breast cancer cells were treated with high-low concentrations of compounds 8a or 
8c for 24 h. Actin, an Hsp90-independent protein, was used as a negative control to 
confirm that all protein levels were not affected by these analogues. As shown in Figure 
3.5, administration of both compounds 8a and 8c resulted in the degradation of Hsp90-
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dependent client proteins Her2, Raf, and Akt. Since actin levels remained unaffected, the 
inhibition of cell growth was directly linked to the degradation of Hsp90-dependent client 
proteins. Additionally, Hsp90 levels were not changed, which is consistent with 
inhibition of the Hsp90 C-terminus.  
 
 
Figure 3.5. Western blot analyses of biphenyl analogues 8a and 8c after incubation with 
MCF-7 breast cancer cells for 24 h. Concentrations (in µM) are indicated above each lane. 
L represents a concentration ½ of the anti-proliferative activity. H represents a 
concentration equal to 5-fold of the anti-proliferative activity. Geldanamycin (G, 0.5 µM) 
and dimethylsulfoxide (D, 100%) serve as positive and negative controls respectively. 
 
 Preliminary anti-proliferative data suggested that the para-para substituted 
biphenyl system is a good replacement for the coumarin core, and was thus chosen for 
further development of structure-activity relationships. Prior SAR studies on the 
coumarin scaffold have demonstrated that introduction of substituents at appropriate 
positions could enhance activity.
13
 Consequently, we directed our efforts toward 
identification of substituent(s) on the biphenyl system to explore structural surrounding 
of this molecule. Towards this objective, substituents containing differing electronic 
properties, such as nitro, chloro, methyl, methoxy and amine were systemically 
92 
 
incorporated at all four positions of the biphenyl system. Following the scheme provided 
for the para-para biphenyl system, biphenyl derivatives containing chloro, methyl and 
methoxy were synthesized. As shown in Scheme 3.3, Suzuki coupling of compounds 9a-
g with 10a-g afforded nitrophenols 11a-l in moderate yields. Nitrophenols 11a-l were 
coupled with 1-methyl-4-hydroxypeperidine via a Mitsunobu etherification, followed by 
reduction with Pd/C under a hydrogen atmosphere to give the corresponding amines, 
14a-f and 15a-f. Amines 14a-f and 15a-f were then coupled with acid chloride 7 to afford 
amides 16a-l, respectively.  
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Scheme 3.3. Synthesis of substituted biphenyl analogues. 
 
 As shown in Scheme 3.4, biphenyl analogues 16m-n that contain nitro 
substituents were prepared by a slightly modified synthetic route. Arylhalides 9g-h were 
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coupled with boc-protected aminophenylboronic acid 17 via Suzuki coupling to afford 
phenols 18a-b. The resulting phenols (18a-b) underwent Mitsunobu etherification, 
followed by boc-deprotection in the presence of trifluoroacetic acid to furnish the free 
amines, 14g-h. Amines 14g-h were coupled with acid chloride 7 to give amides 16m-n. 
The reduction of 16m-n with a Raney-Nickel catalyzed hydrogenation afforded the 
corresponding amines 16q-r, respectively. 
 
Scheme 3.4. Synthesis of substituted biphenyl analogues. 
 
Biphenyl analogues 16o-p were proposed for assembly by the same synthetic 
route. However, attempts to couple the amines with an acid chloride failed, due to the low 
nucleophilicity exhibited by these anilines. Therefore, syntheses of 16o-p were 
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accomplished by the synthetic route depicted in Scheme 3.5. Anilines 19a-b were 
coupled with acid chloride 7 to give amides 20a-b, which were then subjected to Suzuki 
coupling conditions containing boronic acid 9 to afford the phenols, 21a-b. The resulting 
phenols (21a-b) were treated with 1-methyl-4-hydroxypeperidine under Mitsunobu 
conditions to furnish 16o-p, followed by reduction with Raney-Nickel catalyzed 
hydrogenation to give compounds 16s-t. 
 
Scheme 3.5. Synthesis of substituted biphenyl analogues. 
 
Upon construction of the biphenyl analogues, 16a-t, they were evaluated for anti-
proliferative activity against SKBr3 and MCF-7 breast cancer cells (Table 3.2). In general, 
the substituted biphenyl analogues were less active than unsubstituted analogue 8c, 
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suggesting that any substitution on this molecule is not tolerated and the flexible biphenyl 
ring system is necessary for optimal interactions with the binding pocket. However, 
substitution close in proximity to the amide linker was found highly detrimental to 
activity, as compounds 16d, 16h, 16l, 16p and 16t manifested 5~10 fold decreased 
activity compared to the unsubstituted analogue 8c. Overall, structural modifications to 
the biphenyl moiety exhibited a relatively flat SAR, suggesting that like the coumarin 
core, it acts as backbone for orientation of the sugar and benzamide side chain. 
  
Table 3.2. Anti-proliferative activity of substituted biphenyl analogues. 
 
Entry R
1
 R
2
 R
3
 R
4
 SKBr3   
(IC
50
, µM) 
MCF-7  
(IC
50
, µM) 
8c H H H H 0.47 ± 0.06 0.71 ± 0.02 
16a Cl H H H 1.84 ± 0.57 1.48 ± 0.12 
16b H Cl H H 1.28 ± 0.14 1.48 ± 0.33 
16c H H Cl H 2.21 ± 0.18 3.44 ± 0.21 
16d H H H Cl 4.29 ± 0.65 1.80 ± 0.19 
16e Me H H H 0.83 ± 0.03 1.69 ± 0.08 
16f H Me H H 1.18 ± 0.11 1.21 ± 0.03 
16g H H Me H 0.97 ± 0.01 1.57 ± 0.56 
16h H H H Me 2.47 ± 0.39 1.43 ± 0.35 
16i OMe H H H 0.68 ± 0.13 1.32 ± 0.08 
16j H OMe H H 1.41 ± 0.35 1.35 ± 0.16 
16k H H OMe H 0.90 ± 0.08 1.50 ± 0.08 
16l H H H OMe 3.92 ± 0.21 1.22 ± 0.04 
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16m NO2 H H H 2.07 ± 0.17 1.23 ± 0.25 
16n H NO2 H H 1.18 ± 0.15 1.30 ± 0.12 
16o H H NO2 H 2.48 ± 0.77 3.32 ± 0.25 
16p H H H NO2 3.40 ± 0.14 1.15 ± 0.01 
16q NH2 H H H 2.23 ± 0.49 5.95 ± 1.22 
16r H NH2 H H 2.13 ± 0.06 1.76 ± 0.37 
16s H H NH2 H 3.90 ± 0.18 2.07 ± 0.23 
16t H H H NH2 3.21 ± 0.45 2.25 ± 0.49 
 
Earlier studies suggested that modification of the benzamide side chain in 
novobiocin analogues could improve anti-proliferative activity. To investigate this effect 
on the biphenyl scaffold, aromatic rings bearing various functionalities were installed 
onto the biphenyl amide. As shown in Scheme 3.6, substituted biaryl acids 18a-i were 
prepared by Suzuki coupling of aryl iodide 10 with boronic acid 11, followed by ester 
hydrolysis. Biaryl acids 18a-k were then converted to acid chlorides 19a-k via thionyl 
chloride and subsequently coupled with amine 4c to generate the corresponding biphenyl 
analogues that contain substituted benzamide ring system. 
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Scheme 3.6. Synthesis of biphenyl analogues with a modified benzamide side chain. 
 
Anti-proliferative activity of biphenyl analogues 20a-n against SKBr3 and MCF-
7 cells lines are summarized in Table 3.3. The data suggest that 4-methoxy substitution in 
8c is necessary for activity, as 20a and 20b exhibited decreased activity. In addition, the 
data suggest that a hydrogen bond acceptor at the para-position is beneficial for activity, 
as replacement of the methoxy group with acetoxy or hydroxy groups resulted in 
decreased activity. Concerning the structural requirements of the B ring on the benzamide 
side chain, we found that electron withdrawing groups such as acetoxy, nitro and chloro 
substituents at the 3’-position, were more active than the electron donating groups such as 
hydroxy and amine, suggesting that lipophilic interactions may be important in this 
region of the binding pocket. Decreased activity manifested by 20k compared to 20j 
suggested that the 4’-substituent is either in close proximity to polar residues or solvent 
exposed. Consistent with this observation, installation of polar substituents at the 4’-
position as in 20l, 20m and 20n improved inhibitory activity. 
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Table 3.3. Anti-proliferative activity of biphenyl analogues with a modified benzamide 
side chain. 
 
 
Entry R
1
 R
2
 R
3
 SKBr3   
(IC
50
, µM) 
MCF-7  
(IC
50
, µM) 
8c OMe OMe H 0.47 ± 0.06 0.71 ± 0.02 
20a H H H 0.73 ± 0.07 1.15 ± 0.18 
20b H OMe H 0.81 ± 0.14 1.02 ± 0.08 
20c OMe H H 0.51 ± 0.11 0.84 ± 0.01 
20d OAc OMe H 1.90 ± 0.47 1.62 ± 0.04 
20e OH OMe H 2.78 ± 0.35 2.71 ± 0.45 
20f OMe OH H 1.56 ± 0.35 1.08 ± 0.34 
20g OMe OAc H 0.27 ± 0.05 0.62 ± 0.07 
20h OMe NO2 H 0.40 ± 0.07 1.09 ± 0.28 
20i OMe NH2 H 1.52 ± 0.55 1.67 ± 0.68 
20j OMe Cl H 0.33 ± 0.03 0.32 ± 0.09 
20k OMe H Cl 1.06 ± 0.05 0.82 ± 0.13 
20l OMe H OMe 0.63 ± 0.04 0.79 ± 0.13 
20m OMe H OAc 0.14 ± 0.01 0.64 ± 0.08 
20n OMe H OH 0.13 ± 0.02 0.50 ± 0.01 
 
To verify these biphenyl analogues exhibited their anti-proliferative activity via 
Hsp90 inhibition, Western blot analysis was performed for compounds 20c, 20j and 20m. 
As shown in Figure 3.6, incubation with these compounds resulted in the degradation of 
Hsp90 client proteins Her2, Raf-1, and Akt, suggesting these analogues manifest their 
activity through Hsp90 inhibition. Actin and Hsp90 levels remained unchanged, which is 
consistent with observations made for earlier Hsp90 C-terminal inhibitors. 
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Figure 3.6. Western blot analyses of biphenyl analogues 20c, 20j, and 20m after 
incubation with MCF-7 breast cancer cells for 24 h. Concentrations (in µM) are indicated 
above each lane. L represents a concentration ½ of the anti-proliferative activity. H 
represents a concentration equal to 5-fold of the anti-proliferative activity. Geldanamycin 
(G, 0.5 µM) and dimethylsulfoxide (D, 100%) serve as positive and negative controls 
respectively. 
 
3. Conclusion and Future Directions 
 In summary, our studies demonstrated that a flexible biphenyl ring system could 
serve as a replacement for the rigid coumarin core in novobiocin analogues. Based on 
prior SAR studies and molecular modeling, a small library of biphenyl derivatives was 
designed, synthesized, and evaluated for anti-proliferative activity. SAR studies revealed 
that the unsubstituted para-para biphenyl ring system provides for the optimal 
conformation for maximum interactions with the binding pocket. In addition, 
incorporation of an optimized benzamide side chain onto the biphenyl moiety led to 
identification of several analogues that manifest low nanomolar activity. Identification of 
the arylbiphenylamide represents a novel class of Hsp90 C-terminal inhibitors and has 
opened the doors for development of future Hsp90 inhibitors, which could be made in an 
expeditious manner and could concurrently unravel interesting biological consequences 
of Hsp90 C-terminal inhibition. 
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4. Experimental Section 
 
General procedure A: Mitsunobo etherification 
 
 
 
 
4-(4-Iodophenoxy)-1-methylpiperidine (3a) Diisopropylazodicarboxylate (1.89 g, 9.36 
mmol) was added to an ice-cooled solution of 4-iodophenol (0.92 g, 4.18 mmol), N-
methyl-4-hydroxy-piperidine (480 mg, 4.18 mmol) and triphenylphosphine (2.46 g, 9.36 
mmol) in anhydrous THF (50 mL). The reaction mixture (RM) was then allowed to stir at 
room temperature for 12h. After 12 h, the RM was concentrated under reduced pressure 
and the residue was purified by column chromatography (SiO2, 1:10, Methanol:DCM) to 
afford desired product as a colorless amorphous solid (1.02 g, 77 %). 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.54 (d, J = 8.9 Hz, 2H), 6.69 (d, J = 2.0 Hz, 2H), 4.27 (m, 1H), 2.73 – 
2.59 (m, 2H), 2.31 (s, 3H), 2.30 (m, 2H), 1.98 (m, 2H), 1.82 (m, 2H). 
13
C NMR (101 
MHz, CDCl3) δ 157.34, 138.34, 118.50, 82.91, 72.18, 52.61, 46.28, 30.71. HRMS (ESI
+
) 
m/z: [M + H
+
] calcd for C12H17INO 318.0355; found 318.0357. 
 
 
4-(3-Iodophenoxy)-1-methylpiperidine (3b) Compound 3b was prepared following the 
general procedure A with N-methyl-4-hydroxy-piperidine 1 (557.10 mg, 4.18 mmol) and 
4-iodophenol 2a (0.92 g, 4.18 mmol) and was purified by column chromatography (SiO2, 
5:95 Methanol:DCM) to afford a yellow amorphous solid (611.1 mg, 46%). 
1
H NMR 
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(500 MHz, Chloroform-d) δ 7.26 (m, 2H), 6.98 (t, J = 9.3 Hz, 1H), 6.87 (dd, J = 7.8, 2.3 
Hz, 1H), 4.39 – 4.20 (m, 1H), 2.75 – 2.58 (m, 2H), 2.35 – 2.30 (m, 2H), 2.32 (s, 3H), 1.99 
(m, 2H), 1.84 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 158.22, 131.03, 130.11, 125.39, 
115.72, 94.61, 72.37, 52.67, 46.36, 30.81. HRMS (ESI
+
) m/z: [M + H
+
] calcd for 
C12H17INO 318.0355; found 318.0356. 
 
General procedure B: Suzuki coupling 
 
 
4'-((1-Methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-3-amine  (5a) A mixture of iodide 3a 
(250 mg, 0.79 mmol) and boronic acid 4 (216 mg, 1.58 mmol) and potassium carbonate 
solution (2M, 100 µL) was suspended in dioxane (15 mL) and purged with argon for 15 
min. After 15 min, [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (57 mg, 
0.08 mmol) was added to the suspension and the RM was heated in a sealed tube at 110 
o
C for 12 hours. The RM was concentrated to dryness and the brown residue was purified 
by column chromatography (SiO2, 1:10, Methanol:DCM) to afford desired product as a 
brown amorphous solid (149 mg, 67 %). 
1
H NMR (500 MHz, Chloroform-d) δ 7.50 (d, J 
= 8.7 Hz, 2H), 7.22 (t, J = 7.8 Hz, 1H), 6.99 – 6.92 (m, 3H), 6.88 (s, 1H), 6.66 (dd, J = 
7.9, 2.3 Hz, 1H), 4.45 – 4.34 (m, 1H), 3.74 (s, 2H), 2.79 (ddd, J = 11.8, 7.8, 3.8 Hz, 2H), 
2.48 – 2.42 (m, 2H), 2.39 (s, 3H), 2.11 (ddt, J = 11.5, 7.3, 3.6 Hz, 2H), 1.94 (ddt, J = 14.0, 
7.9, 3.7 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 156.77, 146.69, 141.94, 134.13, 129.65, 
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128.16, 117.28, 116.15, 113.60, 113.49, 71.45, 52.37, 45.96, 30.42. HRMS (ESI
+
) m/z: 
[M + H
+
] calcd for C18H23N2O 283.1810; found, 283.1808. 
 
 
3'-((1-Methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-3-amine (5b) Compound 5b was 
prepared following the general procedure B with iodide 3b (250 mg, 0.79 mmol) and 
boronic acid 4 (216 mg, 1.58 mmol) and was purified by column chromatography (SiO2, 
5:95 MeOH:DCM) to afford a brownish amorphous solid (116 mg, 52%). 
1
H NMR (500 
MHz, Chloroform-d) δ 7.19 (t, J = 7.9 Hz, 1H), 7.09 (t, J = 7.8 Hz, 1H), 7.03 (m, 2H, 
NH2), 6.98 – 6.96 (m, 1H), 6.86 – 6.83 (m, 1H), 6.80 (t, J = 2.0 Hz, 1H), 6.77 – 6.73 (m, 
1H), 6.68 – 6.64 (m, 1H), 6.59 (dd, J = 8.1, 2.3 Hz, 1H), 4.36 (m, 1H), 2.66 (m, 2H), 2.37 
(m, 2H), 2.25 (s, 3H), 1.92 (s, 2H), 1.80 (m, 2H). 
13
C NMR (126 MHz, CDCl3+CH3OH) 
δ 157.29, 146.62, 143.06, 142.03, 129.70, 129.59, 119.98, 117.78, 115.03, 114.74, 114.64, 
114.14, 72.15, 54.63, 45.46, 29.85. HRMS (ESI
+
) m/z: [M + H
+
] calcd for C18H23N2O 
283.1810; found, 283.18108. 
 
4'-((1-Methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-amine (5c) Compound 5c was 
prepared using the general procedure A with N-methyl-4-hydroxy-piperidine 1 (535.17 
mg, 4.65 mmol) and nitrophenol 6 (1.0 g, 4.65 mmol) to give yellow amorphous solid 
(855.4 mg, 65%). The yellow solid (850 mg, 3.01 mmol) was dissolved in methanol 
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(10ml) and 10% w/w Pd/C (10 mg) was added. The resulting mixture was stirred at room 
temperature under hydrogen atmosphere for 4h. After 4h, RM was filtered through celite 
and filtrate was concentrated to dryness to afford a brownish amorphous solid (765 mg, 
100%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.89 (d, J = 4.3 Hz, 2H), 7.57 (d, J = 8.8 
Hz, 2H), 7.14 (d, J = 4.3 Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 4.42 (m, 1H), 2.79 – 2.61 (m, 
2H), 2.39 (m, 2H), 2.36 (s, 3H), 2.08 (m, 2H), 1.91 (m, 2H). 
13
C NMR (126 MHz, CDCl3) 
δ 159.13, 152.41, 149.27, 129.99, 127.82, 124.74, 121.22, 116.52, 72.02, 52.41, 46.08, 
30.53. HRMS (ESI
+
) m/z: [M + H
+
] calcd for C18H23N2O 283.1810; found, 283.1811. 
 
General procedure C: Amide coupling 
 
 
3',6-Dimethoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-3-yl)-[1,1'-
biphenyl]-3-carboxamide (8a) A solution of acid chloride 7 (75 mg, 0.27 mmol) in  
anhydrous THF (1ml) was cooled to 0 
o
C and treated with anhydrous pyridine (0.04 mL, 
0.54 mmol) and a solution of 4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-3-amine 5a 
(75 mg, 0.18 mmol) in anhydrous THF (2 mL). The resulting solution was allowed to stir 
at rt for 4 h. After 4 h, the solvent was removed and the residue was purified by column 
chromatography (SiO2, 1:10, Methanol:DCM) to afford product as a colorless amorphous 
solid (48 mg, 52%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.97 (s, 1H), 7.90 – 7.82 (m, 
2H), 7.78 (s, 1H), 7.52 – 7.44 (m, 3H), 7.36 – 7.21 (m, 3H), 7.09 – 6.92 (m, 3H), 6.90 – 
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6.79 (m, 3H), 4.47 (s, 1H), 2.93 (ddd, J = 13.3, 10.4, 3.4 Hz, 2H), 2.84 – 2.73 (m, 2H), 
2.26 (td, J = 10.5, 4.9 Hz, 2H), 2.04 – 1.91 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 
165.26, 159.37, 159.32, 156.30, 141.41, 138.81, 138.61, 133.98, 130.67, 129.62, 129.43, 
129.16, 128.47, 127.02, 122.66, 121.99, 118.63, 118.58, 116.15, 115.34, 112.93, 111.08, 
68.68, 55.87, 55.35, 51.03, 44.81, 28.52. HRMS (ESI
+
) m/z: [M + H
+
] calcd for 
C33H35N2O4 523.2597; found 523.2599. 
 
 
3',6-Dimethoxy-N-(3'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-3-yl)-[1,1'-
biphenyl]-3-carboxamide (8b) Compound 8b was prepared following the general 
procedure C with amine 5b (100 mg, 0.36 mmol) and acid chloride 7 (150 mg, 0.54 
mmol) and was purified by column chromatography (SiO2, 1:10 MeOH:DCM) to afford 
a white amorphous solid (114.7 mg, 62%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.54 (s, 
1H, NH), 7.98 (s, 1H), 7.89 – 7.81 (m, 2H), 7.77 (s, 1H), 7.65 – 7.53 (m, 1H), 7.34 (t, J = 
7.8 Hz, 1H), 7.30 – 7.22 (m, 2H), 7.13 (dd, J = 7.7, 1.7 Hz, 1H), 7.08 (d, J = 2.5 Hz, 1H), 
7.08 – 6.92 (m, 3H), 6.83 (m, 2H), 4.41 (m, 1H), 3.81 (s, 3H), 3.77 (s, 3H), 2.77 (m, 2H), 
2.57 – 2.47 (m, 2H), 2.37 (s, 3H), 2.08 (m, 2H), 1.90 (m, 2H). 
13
C NMR (126 MHz, 
CDCl3) δ 165.47, 159.57, 159.51, 157.58, 150.01, 142.61, 142.01, 138.99, 130.87, 130.08, 
129.79, 129.63, 129.36, 128.65, 127.21, 123.32, 122.16, 120.32, 119.43, 119.14, 115.52, 
115.42, 114.94, 113.13, 111.27, 70.53, 56.05, 55.53, 51.96, 45.72, 29.91. HRMS (ESI
+
) 
m/z: [M + H
+
] calcd for C33H35N2O4 523.2597; found 523.2593. 
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3',6-Dimethoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-[1,1'-
biphenyl]-3-carboxamide (8c) Compound 8c was prepared following the general 
procedure C with amine 5c (750 mg, 2.68 mmol) and acid chloride 7 (1.11 g, 4.02 mmol) 
and was purified by column chromatography (SiO2, 1:10 MeOH:DCM) to afford a white 
amorphous solid (1.10 g, 78%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.93 (dd, J = 8.6, 
2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.71 (d, J = 8.6 Hz, 2H), 7.51 (d, J = 7.2 Hz, 2H), 
7.49 (d, J = 7.2 Hz, 2H), 7.32 (t, J = 7.9 Hz, 1H), 7.12 (dt, J = 7.6, 1.3 Hz, 1H), 7.09 (dd, 
J = 2.6, 1.6 Hz, 1H), 7.04 (d, J = 8.7 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.89 (ddd, J = 8.3, 
2.6, 1.0 Hz, 1H), 4.57 (m, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 3.05 (m, 2H), 2.99 (m, 2H), 
2.63 (s, 3H), 2.20 (ddt, J = 14.3, 10.4, 3.4 Hz, 2H), 2.12 – 1.98 (m, 2H). 
13
C NMR (126 
MHz, CDCl3+CH3OH) δ 166.41, 159.27, 159.17, 155.86, 148.91, 138.93, 137.31, 136.39, 
134.01, 130.38, 130.07, 129.04, 128.58, 128.00, 126.91, 122.01, 121.08, 116.23, 115.26, 
112.75, 110.88, 68.10, 55.69, 55.21, 50.60, 44.10, 28.06. HRMS (ESI
+
) m/z: [M + H
+
] 
calcd for C33H35N2O4 523.2597; found 523.2561. 
 
 
3-Chloro-4'-nitro-[1,1'-biphenyl]-4-ol (10a) Compound 11a was prepared following the 
general procedure B with bromide 9a (300 mg, 1.45 mmol) and 4-nitrophenylboronic 
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acid 10 (255.5 mg, 1.52 mmol). The residue was purified by column chromatography 
(SiO2, 10:1, EtOAc:Hexane) to afford a yellow amorphous solid (200 mg, 56%). 
1
H 
NMR (500 MHz, CDCl3) δ 8.34 – 8.23 (m, 2H), 7.71 – 7.64 (m, 2H), 7.62 (d, J = 2.3 Hz, 
1H), 7.48 (dd, J = 8.5, 2.3 Hz, 1H), 7.15 (d, J = 8.5 Hz, 1H), 5.74 (s, 1H). 
13
C NMR (126 
MHz, CDCl3) δ 152.10, 146.93, 145.83, 132.28, 127.88, 127.50, 127.24 (2C), 124.24 
(2C), 120.75, 116.95. HRMS (ESI
-
) m/z [M-H
+
] calcd for C12H8ClNO3 248.0114, found 
248.0117. 
 
2-Chloro-4'-nitro-[1,1'-biphenyl]-4-ol (11b) Compound 11a was prepared following the 
general procedure B with bromide 9a (300 mg, 1.45 mmol) and 4-nitrophenylboronic 
acid 10 (290 mg, 1.74 mmol). The residue was purified by column chromatography 
(SiO2, 10:1, EtOAc:Hexane) to afford a yellow amorphous solid (160 mg, 44%). 
1
H 
NMR (500 MHz, Chloroform-d) δ 8.25 – 8.14 (m, 2H), 7.58 – 7.43 (m, 2H), 7.11 (dt, J = 
8.4, 1.8 Hz, 1H), 6.92 (t, J = 2.4 Hz, 1H), 6.80 – 6.71 (m, 1H). 13C NMR (126 MHz, 
CDCl3) δ 158.21, 146.82, 146.34, 132.64, 131.88, 130.64, 129.48, 123.32, 117.12, 
114.74. HRMS (ESI
-
) m/z [M+K]
+
 calcd for C12H8ClNO3 288.0214, found 288.2896. 
 
 
2'-Chloro-4'-nitro-[1,1'-biphenyl]-4-ol (11g) Compound 11g was prepared following 
the general procedure B with 4-hydroxyphenylboronic acid 9 (300 mg, 2.18 mmol) and 
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iodide 10a (616 mg, 2.18 mmol). The residue was purified by column chromatography 
(SiO2, 10:1, EtOAc:Hexane) to afford a yellow amorphous solid (300 mg, 59%). 
1
H 
NMR (500 MHz, CDCl3) δ 8.36 (d, J = 2.4 Hz, 1H), 8.16 (dd, J = 8.5, 2.3 Hz, 1H), 7.51 
(d, J = 8.5 Hz, 1H), 7.44 – 7.31 (m, 2H), 6.99 – 6.91 (m, 2H), 4.91 (s, 1H). 
13
C NMR 
(126 MHz, CDCl3) δ 156.08, 147.01, 146.55, 133.51, 131.81, 130.77 (2C), 129.87, 
125.33, 121.83, 115.35 (2C). HRMS (ESI
-
) m/z [M-H
+
] calcd for C12H8ClNO3 248.0114, 
found 248.0118. 
 
3'-Chloro-4'-nitro-[1,1'-biphenyl]-4-ol (11h) Compound 11h was prepared following 
the general procedure B with 4-hydroxyphenylboronic acid 9 (300 mg, 2.18 mmol) and 
iodide 10b (616 mg, 2.18 mmol). The residue was purified by column chromatography 
(SiO2, 10:1, EtOAc:Hexane) to afford a yellow amorphous solid (259 mg, 42%). 
1
H 
NMR (500 MHz, Chloroform-d) δ 7.95 (d, J = 8.5 Hz, 1H), 7.67 (d, J = 1.9 Hz, 1H), 7.52 
(dd, J = 8.5, 2.0 Hz, 1H), 7.47 – 7.41 (m, 2H), 6.95 – 6.86 (m, 2H). 
13
C NMR (126 MHz, 
CDCl3+CH3OH) δ 154.32, 142.77, 141.49, 125.48, 124.80, 124.64, 123.86, 122.46, 
121.13, 112.19. HRMS (ESI
-
) m/z [M-H
+
] calcd for C12H8ClNO3 248.0114, found 
248.0108. 
 
3-Methyl-4'-nitro-[1,1'-biphenyl]-4-ol (11c) Compound 11c was prepared following the 
general procedure B with bromide 9c (187 mg, 1.00 mmol) and 4-nitrophenylboronic 
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acid 10 (249 mg, 1.50 mmol) and was purified via column chromatography (SiO2, 10:1, 
EtOAc:Hexane) to afford desired product as a yellow amorphous solid (134 mg, 59%). 
1H NMR (400 MHz, Chloroform-d + CD3OD) δ 8.28 (d, J = 8.9 Hz, 2H), 7.70 (d, J = 8.9 
Hz, 2H), 7.44 (s, 1H), 7.42 – 7.36 (m, 1H), 6.91 (d, J = 8.3 Hz, 1H), 2.36 (s, 3H). 13C 
NMR (126 MHz, CDCl3) 154.94, 146.75, 145.29, 129.30, 129.07, 125.97, 125.05, 
123.15, 122.42, 114.36, 15.18. HRMS (ESI
+
) m/z: [M + H
+
] calcd for C13H12NO3: 
230.0817; found 230.0815. 
 
 
2-Methyl-4'-nitro-[1,1'-biphenyl]-4-ol (11d) Compound 11d was prepared following  
the general procedure B with bromide 9d (374 mg, 2.0 mmol) and 4-nitrophenylboronic 
acid 10 (688 mg, 4.0 mmol). The residue was purified by column chromatography (SiO2, 
10:1, EtOAc:Hexane) to afford desired product as a yellow amorphous solid (185 mg, 
40%). 
1
H NMR (400 MHz, Chloroform-d) δ 8.13 (d, J = 2.4 Hz, 1H), 8.06 (dd, J = 8.4, 
2.5 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.26 - 7.14 (m, 2H), 7.00 - 6.91 (m, 2H), 2.37 (s, 
3H). 
13
C NMR (126 MHz, CDCl3) δ 155.57, 148.36, 146.85, 137.40, 132.38, 130.81, 
130.34, 125.35, 121.08, 115.49, 20.90. HRMS (ESI
+
) m/z: [M + H
+
] calcd for C13H12NO3: 
230.0817; found 230.0822. 
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2'-Methyl-4'-nitro-[1,1'-biphenyl]-4-ol (11i) Compound 11i was prepared follwoing  
the general procedure B with 4-hydroxyphenylboronic acid 9 (326 mg, 2.36 mmol) and 
iodide 10c (621 mg, 2.36 mmol). The residue was purified by column chromatography 
(SiO2, 10:1, EtOAc:Hexane) to afford desired product as a yellow amorphous solid (120 
mg, 22%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.14 (s, 1H), 8.08 (dd, J = 8.4, 2.4 Hz, 
1H), 7.36 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 8.5 Hz, 2H), 6.94 (d, J = 8.6 Hz, 2H), 5.03 (s, 
1H, OH), 2.38 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 155.63, 148.42, 146.92, 137.46, 
132.45, 130.88, 130.41, 125.42, 121.14, 115.56, 20.97. HRMS (ESI
+
) m/z: [M + H
+
] 
calcd for C13H12NO3: 230.0817; found 230.0819. 
 
 
3'-Methyl-4'-nitro-[1,1'-biphenyl]-4-ol (11j) A mixture of boronic acid (300 mg, 2.175 
mmol), 4-chloro-2-methyl-1-nitrobenzene (373 mg, 2.175 mmol), Pd(OAc)2 (5 mg, 0.022 
mmol), TBAB (723 mg, 2.175 mmol) and 2M Na2CO3 was irridated by microwave at 
175
o
 C for 10 min. The reaction mixture was then extracted by ethyl acetate. The organic 
layer was collected, dried (over Na2SO4) and concentrated under reduced pressure. The 
brown residue was purified by flash column chromatography (SiO2, 10:1, EtOAc:Hexane) 
to afford desired product as a yellowish amorphous solid ( 80 mg, 17 %). 
1
H NMR (500 
MHz, Chloroform-d) δ 8.09 (d, J = 9.0 Hz, 1H), 7.62 – 7.40 (m, 4H), 7.03 – 6.85 (m, 2H), 
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4.89 (s, 1H), 2.69 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 155.97, 147.51, 145.34, 144.15, 
134.24, 133.92, 131.29, 130.48, 128.50, 125.32, 124.59, 115.74, 20.87. HRMS (ESI
+
) 
m/z [M+] calcd for C13H11NO3 229.0739, found 229.0742. 
 
 
3-Methoxy-4'-nitro-[1,1'-biphenyl]-4-ol (11e) Compound 11e was prepared following 
the  general procedure B with bromide 9e (200 mg, 0.98 mmol) and 4-nitrophenylboronic 
acid 10 (240 mg, 1.45 mmol). The residue was purified by column chromatography 
(SiO2, 10:1, EtOAc:Hexane) to afford desired product as a yellow amorphous solid 
(180mg 74% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.27 (d, J = 8.9 Hz, 2H), 7.68 
(d, J = 8.9 Hz, 2H), 7.17 (dd, J = 8.2, 2.1 Hz, 1H), 7.10 (d, J = 2.1 Hz, 1H), 7.03 (d, J = 
8.2 Hz, 1H), 5.78 (s, 1H, OH), 3.99 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 147.70, 
147.16, 146.86, 131.21, 127.37, 124.28, 120.99, 115.22, 109.76, 56.23. HRMS (ESI+) 
m/z: [M + H+] calcd for C13H12NO4: 246.0766; found 246.0762. 
 
 
2-Methoxy-4'-nitro-[1,1'-biphenyl]-4-ol (11f) Compound 11f was prepared following 
the  general procedure B with bromide 9f (200 mg, 0.98 mmol) and 4-nitrophenylboronic 
acid 10 (240 mg, 1.45 mmol). The crude product was purified by flash column 
112 
 
chromatography (SiO2, 10:1, EtOAc:Hexane) to afford desired product as a yellow 
amorphous solid (180mg 74% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.23 (d, J = 
8.8 Hz, 2H), 7.66 (d, J = 8.8 Hz, 2H), 7.21 (d, J = 8.2 Hz, 1H), 6.62 – 6.45 (m, 2H), 4.96 
(s, 1H, OH), 3.82 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 157.18, 156.88, 145.60, 144.69, 
130.92, 129.41, 122.65, 120.40, 107.07, 98.88, 55.01.  HRMS (ESI+) m/z: [M + H+] 
calcd for C13H12NO4: 246.0766; found 246.0769. 
 
 
2'-Methoxy-4'-nitro-[1,1'-biphenyl]-4-ol (11k) Compound 11k was prepared following 
the  general procedure B with bromide 10e (538mg, 2.32 mmol) and 4-
hydroxyphenylboronic acid 9 (320 mg, 2.32 mmol). The crude product was purified by 
flash column chromatography (SiO2, 10:1, EtOAc:Hexane) to afford desired product as a 
yellow amorphous solid (152 mg, 27%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.91 (dd, J 
= 8.4, 2.2 Hz, 1H), 7.82 (d, J = 2.2 Hz, 1H), 7.46 (d, J = 8.6 Hz, 1H), 7.45 (s, 1H), 6.93 
(d, J = 8.6 Hz, 2H), 3.93 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 156.87, 155.93, 147.77, 
137.21, 131.11, 130.84, 129.03, 116.38, 115.45, 106.37, 56.29. HRMS (ESI+) m/z: [M + 
H+] calcd for C13H12NO4: 246.0766; found 246.0763. 
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3'-Methoxy-4'-nitro-[1,1'-biphenyl]-4-ol (11l) A mixture of boronic acid (300 mg, 2.18 
mmol), 4-chloro-2-methoxy-1-nitrobenzene (408 mg, 2.18 mmol), Pd(OAc)2 (5 mg, 
0.022 mmol), TBAB (723 mg, 2.18 mmol) and 2M Na2CO3 (3.27 ml, 6.54 mmol) was 
irridated by microwave at 175
o
 C for 10 min. The reaction mixture was then extracted by 
ethyl acetate. The organic layer was collected, dried (over Na2SO4) and concentrated 
under reduced pressure. The brown residue was purified by column chromatography 
(SiO2, 10:1, EtOAc:Hexane) to afford desired product as a yellowish amorphous solid (95 
mg, 18 %). 
1
H NMR (400 MHz, Chloroform-d) δ 7.93 (d, J = 8.5 Hz, 1H), 7.48 – 7.42 (m, 
2H), 7.19 – 7.11 (m, 2H), 6.95 – 6.87 (m, 2H), 4.00 (s, 3H). 
13
C NMR (126 MHz, CDCl3) 
δ 156.80, 152.76, 146.98, 136.59, 129.71, 127.71, 125.69, 117.48, 115.07, 110.41, 55.59. 
HRMS (ESI+) m/z: [M + H+] calcd for C13H11NO4 (M-H): 244.0546; found (M-H): 
244.0542.  
 
 
tert-butyl (4'-hydroxy-3'-nitro-[1,1'-biphenyl]-4-yl)carbamate (18a) Compound 18a 
was prepared following the  general procedure B with bromide 9g (150 mg, 0.69 mmol) 
and boronic acid 17 (300 mg, 0.82 mmol). The residue was purified by column 
chromatography (SiO2, 10:1, EtOAc:Hexane) to afford desired product as a yellow 
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amorphous solid (136 mg, 60%). 
1
H NMR (500 MHz, Chloroform-d) δ 10.58 (s, 1H), 
8.29 (d, J = 2.3 Hz, 1H), 7.81 (dd, J = 8.7, 2.4 Hz, 1H), 7.61 – 7.37 (m, 4H), 7.25 – 7.21 
(m, 1H), 6.55 (s, 1H), 1.55 (s, 9H). 
13
C NMR (126 MHz, CDCl3) δ 154.11, 151.21, 
138.75, 138.34, 136.01, 135.15, 132.82, 127.25, 122.26, 120.39, 118.90, 81.15, 28.35. 
HRMS (ESI
-
) m/z [M-H
+
] calcd for C17H18N2O5 329.1137, found 329.1133. 
 
 
tert-butyl (4'-hydroxy-2'-nitro-[1,1'-biphenyl]-4-yl)carbamate (18b) ) Compound 18b 
was prepared following the  general procedure B with bromide 9h (500 mg, 2.29 mmol) 
and boronic acid 17 (781.6 mg, 2.75 mmol). The residue was purified by column 
chromatography (SiO2, 10:1, EtOAc:Hexane) to afford desired product as a yellow 
amorphous solid (210 mg, 72%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.40 (d, J = 8.3 
Hz, 2H), 7.32 (d, J = 2.6 Hz, 1H), 7.28 (d, J = 5.0 Hz, 1H), 7.23 – 7.17 (m, 2H), 7.07 (dd, 
J = 8.4, 2.6 Hz, 1H), 6.53 (s, 1H), 5.47 (s, 1H), 1.54 (s, 9H).
13
C NMR (126 MHz, CDCl3) 
δ 155.35, 153.00, 149.83, 138.39, 133.34, 132.05, 129.00, 128.64, 119.86, 118.99, 
111.40, 81.16, 28.64. HRMS (ESI
-
) m/z [M-H
+
] calcd for C17H18N2O5 329.1137, found 
329.1132. 
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4-((3-Chloro-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)-1-methylpiperidine (12a) Compound 
12a was prepared following the  general procedure A with phenol (175 mg, 0.70 mmol) 
and N-methyl-4-hydroxy-piperidine (96.9 mg, 0.84 mmol). The residue was purified by 
column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired product as a 
yellow amorphous solid (200 mg, 83%). 
1
H NMR (500 MHz, CDCl3) δ 8.22 (d, J = 8.8 
Hz, 2H), 7.77 – 7.52 (m, 3H), 7.46 (dd, J = 8.5, 2.4 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1H), 
4.81 (m, 1H), 3.49 – 3.37 (m, 2H), 3.23 (m, 2H), 2.87 (s, 3H), 2.32 (m, 2H), 2.24 – 2.10 
(m, 2H). 
13
C NMR (126 MHz, CDCl3+CH3OH) δ 147.99, 142.90, 141.28, 129.32, 125.35, 
123.24, 123.19, 122.97, 120.71, 120.08, 120.04, 111.82, 67.46, 54.11, 44.12, 26.76. 
HRMS (ESI
+
) m/z [M+H
+
] calcd for C18H19ClN2O3 347.1163, found 347.1159. 
 
 
4-((2-Chloro-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)-1-methylpiperidine (12b) Compound 
12b was prepared following the  general procedure A with phenol (150 mg, 0.60 mmol) 
and N-methyl-4-hydroxy-piperidine (83.12 mg, 0.72 mmol). The residue was purified by 
column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired product as a 
yellow amorphous solid (150 mg, 78%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.28 (d, J 
= 8.7 Hz, 2H), 7.60 (d, J = 8.7 Hz, 2H), 7.27 (d, J = 0.7 Hz, 1H), 7.07 (d, J = 2.5 Hz, 1H), 
116 
 
6.92 (dd, J = 8.5, 2.5 Hz, 1H), 4.42 (m, 1H), 2.76 (m, 2H), 2.42 (m, 2H), 2.39 (s, 3H), 
2.11 (m, 2H), 1.93 (m, 2H). 
13
C NMR (126 MHz, CDCl3+CH3OH) δ 158.30, 147.19, 
145.92, 133.15, 131.99, 130.72, 126.23, 123.55, 117.64, 115.13, 72.44, 52.65, 46.15, 
30.40. HRMS (ESI
+
) m/z [M+H
+
] calcd for C18H19ClN2O3 347.1163, found 347.1158. 
 
 
4-((2'-Chloro-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)-1-methylpiperidine (12g) Compound 
12g was prepared following the  general procedure A with phenol 11g (200 mg, 0.80 
mmol) and N-methyl-4-hydroxy-piperidine (110.72 mg, 0.96 mmol). The residue was 
purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired 
product as a yellow amorphous solid (225 mg, 81%). 
1
H NMR (500 MHz, Chloroform-d) 
δ 8.35 (d, J = 2.3 Hz, 1H), 8.15 (dt, J = 8.4, 2.2 Hz, 1H), 7.51 (d, J = 8.5 Hz, 1H), 7.43 – 
7.34 (m, 2H), 7.05 – 6.94 (m, 2H), 4.41 (dt, J = 7.2, 3.7 Hz, 1H), 2.83 – 2.65 (m, 2H), 
2.34 (s, 3H), 2.07 (ddd, J = 13.9, 7.1, 3.5 Hz, 2H), 1.92 (ddd, J = 13.2, 7.9, 3.7 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 158.01, 146.90, 146.62, 133.42, 131.78, 130.57, 129.47, 
125.32, 121.80, 115.58, 71.98, 52.60, 46.17, 30.74. HRMS (ESI
+
) m/z [M+H
+
] calcd for 
C18H19ClN2O3 347.1163, found 347.1136. 
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4-((3'-Chloro-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)-1-methylpiperidine (12h) Compound 
12h was prepared following the  general procedure A with phenol 11h (125 mg, 0.50 
mmol) and N-methyl-4-hydroxy-piperidine (69.10 mg, 0.60 mmol). The residue was 
purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired 
product as a yellow amorphous solid (110 mg, 63%). 
1
H NMR (500 MHz, Chloroform-d) 
δ 7.99 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 1.9 Hz, 1H), 7.62 – 7.47 (m, 3H), 7.02 (d, J = 8.7 
Hz, 2H), 4.44 (m, 1H), 2.76 (m, 2H), 2.42 (m, 2H), 2.38 (s, 3H), 2.10 (m, 2H), 1.93 (m, 
2H). 
13
C NMR (126 MHz, CDCl3) δ 158.71, 146.52, 145.96, 130.06, 129.83, 128.80, 
128.10, 126.65, 125.45, 116.72, 71.93, 52.54, 46.21, 30.62. HRMS (ESI
+
) m/z [M+H
+
] 
calcd for C18H19ClN2O3 347.1163, found 347.1159. 
 
 
1-Methyl-4-((3-methyl-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)piperidine (12c) Compound 
12c was prepared following the  general procedure A with phenol 11c (280 mg, 1.20 
mmol) and N-methyl-4-hydroxy-piperidine (280 mg, 2.40 mmol). The residue was 
purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired 
product as a yellow amorphous solid (180 mg, 46%). 
1
H NMR (500 MHz, Chloroform-d) 
 8.35-8.18 (m, 2H), 7.75-7.62 (m, 2H), 7.49-7.36 (m, 2H), 6.92 (d, J = 8.4 Hz, 1H), 4.45 
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(s, 1H), 2.66 (s, 2H), 2.44-2.34 (m, 2H), 2.33 (s, 3H), 2.31 (s, 3H), 2.11-1.86 (m, 4H). 
13
C 
NMR (126 MHz, CDCl3) 156.59, 147.57, 146.54, 130.70, 130.04, 128.86, 127.15, 
124.23, 113.06, 52.57, 46.47, 30.92, 29.85, 16.80. HRMS (ESI
+
) m/z [M+H
+
] calcd for 
C19H23N2O3 327.1709, found 327.1724.  
 
 
1-Methyl-4-((2-methyl-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)piperidine (12d) Compound 
12d was prepared following the  general procedure A with phenol 11d (230 mg, 1.50 
mmol) and N-methyl-4-hydroxy-piperidine (230 mg, 3.10 mmol). The residue was 
purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired 
product as a yellow amorphous solid (300 mg, 61%). 
1
H NMR (500 MHz, Chloroform-d) 
 8.26 (d, J = 8.9 Hz, 2H), 7.68 (d, J = 8.9 Hz, 2H), 7.47 - 7.37 (m, 2H), 6.92 (d, J = 8.5 
Hz, 1H), 4.49 (s, 1H), 2.77 - 2.68 (m, 2H), 2.50 (s, 2H), 2.39 (s, 3H), 2.31 (s, 3H), 2.15 - 
2.08 (m, 2H), 2.02 - 1.92 (m, 2H). 
13
C NMR (126 MHz, CDCl3)  156.51, 147.61, 146.68, 
130.96, 130.20, 127.28, 124.35, 113.11, 52.42, 46.27, 30.57, 16.90. IR 2954, 2923, 2852, 
2358, 2341, 1593, 1514, 1485, 1340, 1307, 1274, 1247, 1135, 1108, 1039 cm
-1
. HRMS 
(ESI
+
) m/z [M+Na
+
] calcd for C19H22N2O3 349.1528, found 349.1528.  
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1-Methyl-4-((2'-methyl-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)piperidine (12i) Compound 
12i was prepared following the  general procedure A with phenol 11i (116 mg, 0.50 
mmol) and N-methyl-4-hydroxy-piperidine (116 mg, 2.02 mmol). The residue was 
purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired 
product as a yellow amorphous solid (120 mg, 73%). 
1
H NMR (500 MHz, Methanol-d4) 
 8.14 (d, J = 2.4 Hz, 1H), 8.09 - 8.02 (m, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.31 - 7.24 (m, 
2H), 7.03 (d, J = 8.7 Hz, 2H), 4.49 (q, J = 5.1, 4.6 Hz, 1H), 2.76 (s, 2H), 2.50 - 2.40 (m, 
2H), 2.37 (s, 3H), 2.33 (s, 3H), 2.05 (ddd, J = 12.7, 6.5, 3.1 Hz, 2H), 1.91 - 1.81 (m, 2H). 
13
C NMR (126 MHz, MeOD)  158.59, 149.66, 148.08, 138.64, 133.53, 131.82, 131.22, 
126.00, 124.48, 121.80, 116.90, 112.62, 79.50, 53.25, 46.10, 31.30, 20.88, 16.60. HRMS 
(ESI
+
) m/z [M+Na
+
] calcd for C19H22N2O4 365.1477, found 365.1481.  
 
 
 
1-Methyl-4-((3'-methyl-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)piperidine (12j) Compound 
12j was prepared following the  general procedure A with phenol 11j (75 mg, 0.33 mmol) 
and N-methyl-4-hydroxy-piperidine (45.4 mg, 0.39 mmol). The residue was purified by 
column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired product as a 
yellow amorphous solid (80.3 mg, 75%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.08 (d, J 
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= 9.1 Hz, 1H), 7.55 (d, J = 8.7 Hz, 2H), 7.52 – 7.46 (m, 2H), 7.01 (d, J = 8.8 Hz, 2H), 
4.46 (s, 1H), 2.83 – 2.79 (m, 2H), 2.69 (s, 3H), 2.56 – 2.48 (m, 2H), 2.42 (s, 3H), 2.18 – 
2.14 (m, 2H), 1.98 – 1.94 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 158.10, 147.64, 
145.77, 134.69, 131.60, 130.90, 128.79, 125.78, 125.02, 116.59, 71.39, 52.31, 45.99, 
30.29, 21.34. (ESI
+
) m/z [M+H
+
] calcd for C19H22N2O4  327.1709; found 327.1721.  
 
 
4-((3-Methoxy-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)-1-methylpiperidine (12e) Compound 
12e was prepared following the  general procedure A with phenol 11e (180 mg, 0.73 
mmol) and N-methyl-4-hydroxy-piperidine (160 mg, 1.46 mmol). The residue was 
purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired 
product as a yellow amorphous solid (200 mg, 80%). 
1
H NMR (500 MHz, Chloroform-d: 
Acetone d6 (10:1))  8.25 (d, J = 8.9 Hz, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.18 - 7.08 (m, 
2H), 7.00 (d, J = 8.4 Hz, 1H), 4.44 (dp, J = 6.9, 3.4 Hz, 1H), 3.92 (s, 3H), 2.90 (ddd, J = 
11.9, 8.6, 3.4 Hz, 2H), 2.70 -2.60 (m, 1H), 2.43 (s, 3H), 2.11 (ddd, J = 12.5, 8.5, 3.8 Hz, 
2H), 1.99 (s, 3H). 
13
C NMR (126 MHz, CDCl3: Acetone d6 (10:1)) δ 176.70, 151.31, 
146.78, 132.86, 127.43, 124.20, 120.20, 117.41, 111.54, 56.26, 44.99, 22.83. (ESI+) m/z 
[M+Na
+
] calcd for C19H22N2O4 365.1477, found 365.1473.  
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4-((2-Methoxy-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)-1-methylpiperidine (12f) Compound 
12f was prepared following the  general procedure A with phenol 11f (175 mg, 0.72 
mmol) and N-methyl-4-hydroxy-piperidine (124.2 mg, 1.08 mmol). The residue was 
purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired 
product as a yellow amorphous solid (191 mg, 78%). 
1
H NMR (500 MHz, Chloroform-d) 
δ 8.23 (d, J = 8.9 Hz, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.25 (d, J = 8.8 Hz, 1H), 6.59 (m, 
2H), 4.41 (m, 1H), 3.82 (s, 3H), 2.75 (m, 2H), 2.38 (m, 2H), 2.36 (s, 3H), 2.06 (m, 2H), 
2.00 – 1.82 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 159.53, 157.90, 146.38, 145.52, 
131.49, 130.18, 123.45, 121.25, 106.92, 101.09, 70.09, 55.80, 52.72, 46.31, 30.88. (ESI+) 
m/z [M+Na
+
] calcd for C19H22N2O4  365.1477, found 365.1493. 
 
 
4-((2'-Methoxy-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)-1-methylpiperidine(12k) 
Compound 12k was prepared following the general procedure A with phenol 11k (125 
mg, 0.51 mmol) and N-methyl-4-hydroxy-piperidine (88 mg, 0.77 mmol). The residue 
was purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired 
product as a yellow amorphous solid (113.5 mg, 65%). 
1
H NMR (400 MHz, Chloroform-
d) δ 7.96 – 7.87 (m, 1H), 7.82 (d, J = 2.2 Hz, 1H), 7.49 (d, J = 8.8 Hz, 2H), 7.44 (d, J = 
8.4 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 4.41 (m, 1H), 3.93 (s, 3H), 2.82 – 2.63 (m, 2H), 
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2.39 (m, 2H), 2.36 (s, 3H), 2.09 (m, 2H), 1.92 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 
157.69, 156.87, 147.77, 137.20, 130.97, 130.83, 128.90, 116.39, 115.79, 106.37, 70.23, 
56.30, 52.29, 45.98, 30.45. (ESI+) m/z [M+Na+] calcd for C19H22N2O4 365.1477; found 
365.1483. 
 
 
4-((3'-Methoxy-4'-nitro-[1,1'-biphenyl]-4-yl)oxy)-1-methylpiperidine (12l) 
Compound 12l was prepared following the general procedure A with phenol 11l (100 mg, 
0.41 mmol) and N-methyl-4-hydroxy-piperidine (57 mg, 0.49 mmol). The residue was 
purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford desired 
product as a yellow amorphous semi-solid (85 mg, 60 %). 
1
H NMR (400 MHz, 
Chloroform-d) δ 7.96 (d, J = 8.3 Hz, 1H), 7.53 (d, J = 8.7 Hz, 2H), 7.22 – 7.14 (m, 2H), 
7.01 (d, J = 8.7 Hz, 2H), 4.45 (s, 1H), 4.03 (s, 3H), 2.89 – 2.69 (m, 2H), 2.52 – 2.42 (m, 
2H), 2.37 (s, 3H), 2.15 (d, J = 16.9 Hz, 2H), 1.94 (s, 2H). 
13
C NMR (126 MHz, CDCl3) δ 
158.23, 153.75, 147.55, 137.94, 131.76, 128.73, 126.72, 118.62, 116.53, 111.59, 56.67, 
52.30, 45.99, 30.34. IR 3392, 2945, 2358, 2331, 1276, 1263 cm
-1
. (ESI+) m/z [M+H+] 
calcd for C19H22N2O4 343.1658, found 343.1658.
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tert-butyl (4'-((1-methylpiperidin-4-yl)oxy)-3'-nitro-[1,1'-biphenyl]-4-yl)carbamate 
(13a) Compound 13a was prepared following the general procedure A with phenol 18a 
(75 mg, 0.23 mmol) and N-methyl-4-hydroxy-piperidine (31.5 mg, 0.27 mmol). The 
residue was purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford 
desired product as a yellow amorphous semi-solid (80 mg, 82%). 
1
H NMR (500 MHz, 
Chloroform-d) δ 8.01 (d, J = 2.4 Hz, 1H), 7.70 (dd, J = 8.7, 2.4 Hz, 1H), 7.51 – 7.41 (m, 
4H), 7.13 (d, J = 8.8 Hz, 1H), 6.57 (s, 1NH), 4.70 (s, 1H), 2.85 (s, 2H), 2.70 (s, 2H), 2.48 
(s, 3H), 2.24 (s, 2H), 2.06 (ddd, J = 15.0, 7.7, 3.9 Hz, 2H), 1.54 (s, 9H). 
13
C NMR (126 
MHz, CDCl3) δ 153.49, 150.08, 141.99, 139.23, 134.69, 133.72, 132.74, 128.15, 124.54, 
119.81, 117.21, 81.78, 51.83, 46.40, 30.62, 30.18, 29.24. (ESI
+
) m/z [M+H
+
] calcd for 
C23H29N3O5 428.2186, found 428.2177. 
 
 
tert-butyl (4'-((1-methylpiperidin-4-yl)oxy)-2'-nitro-[1,1'-biphenyl]-4-yl)carbamate 
(13b) Compound 13b was prepared following the general procedure A with phenol 18b 
(150 mg, 0.46 mmol) and N-methyl-4-hydroxy-piperidine (63 mg, 0.54 mmol). The 
residue was purified by column chromatography (SiO2, 5:95, Methanol:DCM) to afford 
desired product as a yellow amorphous semi-solid (175 mg, 89%). 
1
H NMR (500 MHz, 
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Chloroform-d) δ 7.41 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 2.6 Hz, 1H), 7.29 (d, J = 33.1 Hz, 
1H), 7.23 – 7.19 (m, 2H), 7.13 (dd, J = 8.6, 2.6 Hz, 1H), 6.53 (s, NH), 4.42 (s, 1H), 2.73 
(s, 2H), 2.36 (s, 3H), 2.15 – 2.01 (m, 2H), 1.91 (d, J = 11.4 Hz, 2H), 1.65 – 1.54 (m, 2H), 
1.54 (s, 9H). 
13
C NMR (126 MHz, CDCl3) δ 156.95, 152.90, 149.98, 138.48, 133.18, 
131.97, 128.97, 128.51, 120.36, 118.84, 111.29, 81.09, 52.25, 46.19, 30.42, 30.03, 28.63. 
HRMS (ESI
+
) m/z [M+H
+
] calcd for C23H29N3O5 428.2186, found 428.2182. 
 
 
General Procedure D: TFA mediated boc-deprotection 
 
 
4'-((1-Methylpiperidin-4-yl)oxy)-3'-nitro-[1,1'-biphenyl]-4-amine (14g) A solution of 
TFA (0.5 ml) in dry DCM (0.5 ml) was added to an ice-cooled solution of boc-protected 
aniline (65mg, 0.15 mmol) in dry DCM (0.5 ml) and allowed to stir at rt for 2h. After 2h, 
the RM was concentrated under high vacuum to afford a brownish amorphous semi-solid 
(48 mg, 98%), which was used as such without further purification in the next step. 
HRMS (ESI
+
) m/z [M+H
+
] calcd for C18H21N3O3 328.1662, found 328.1667. 
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4'-((1-Methylpiperidin-4-yl)oxy)-2'-nitro-[1,1'-biphenyl]-4-amine (14h) Compound 
14h was obtained following the general procedure D  as a brownish amorphous solid 
(160 mg, 90%), which was used as such without further purification in the next step. 
HRMS (ESI
+
) m/z [M+H
+
] calcd for C18H21N3O3 328.1662, found 328.1653. 
 
 
N-(4-bromo-3-nitrophenyl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (20a)  
Compound 20a was prepared following the general procedure C with amine 19a (150 mg, 
0.69 mmol) and acid chloride 7 (200 mg, 0.72 mmol). The residue was purified by 
column chromatography (SiO2, 1:100, Acetone:DCM) to afford desired product as a light 
brown solid (283 mg, 90%). 
1
H NMR (400 MHz, Chloroform-d) δ 8.28 (d, J = 2.5 Hz, 
1H), 7.97 (broad, 1H, NH), 7.90 (dd, J = 8.6, 2.4 Hz, 1H), 7.79 (d, J = 2.4 Hz, 1H), 7.76 
(d, J = 2.5 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.13 – 7.05 (m, 3H), 
6.94 (dd, J = 8.3, 2.7 Hz, 1H), 3.91 (s, 3H), 3.86 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 
165.35, 160.13, 159.57, 150.09, 138.71, 138.57, 135.53, 131.18, 129.76, 129.45, 128.81, 
125.97, 124.32, 122.10, 116.92, 115.61, 113.18, 111.45, 108.40, 56.14, 55.56. HRMS 
(ESI
+
) m/z [M+H
+
] calcd for C21H18BrN2O5 457.0399, found 457.0402. 
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N-(4-bromo-2-nitrophenyl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide (20b) 
Compound 20b was prepared following the general procedure C with amine 19b (200 mg, 
0.75 mmol) and acid chloride 7 (242.3 mg, 0.91 mmol). The residue was purified by 
column chromatography (SiO2, 1:10, EtOAc:Hexane) to afford desired product as a light 
yellowish amorphous solid (80 mg, 43%).  
1
H NMR (500 MHz, Chloroform-d) δ 11.30 
(s, NH), 8.97 (d, J = 9.1 Hz, 1H), 8.43 (d, J = 2.4 Hz, 1H), 8.05 – 7.93 (m, 2H), 7.80 (dd, 
J = 9.1, 2.4 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.20 – 7.06 (m, 3H), 6.94 (ddd, J = 8.3, 2.6, 
1.0 Hz, 1H), 3.93 (s, 3H), 3.87 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 165.81, 160.78, 
159.94, 139.61, 139.05, 137.11, 135.41, 131.81, 130.97, 129.82, 128.99, 126.57, 124.11, 
122.53, 115.78, 115.65, 113.81, 111.79, 56.54, 55.92. HRMS (ESI
+
) m/z [M+H
+
] calcd 
for C21H17BrN2O5 457.0399, found 457.0402. 
 
 
N-(4'-hydroxy-2-nitro-[1,1'-biphenyl]-4-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-
carboxamide (21a) Compound 21a was prepared following the general procedure B with 
4-hydroxyphenylboronic acid 9 (72 mg, 0.52 mmol) and bromide 20a (120 mg, 0.26 
mmol). The residue was purified by column chromatography (SiO2, 1:100, 
Acetone:DCM) to afford desired product as a brown amorphous solid (52 mg, 43 %). 
1
H 
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NMR (400 MHz, Chloroform-d) δ 9.83 (s, 1H, NH), 8.16 (t, J = 1.8 Hz, 1H), 7.91 – 7.83 
(m, 3H), 7.29 (d, J = 8.3 Hz, 1H), 7.25 – 7.22 (m, 1H), 7.05 (m, 3H), 7.03 – 6.97 (m, 2H), 
6.82 (dd, J = 8.3, 2.6 Hz, 1H), 6.79 – 6.72 (m, 2H), 3.80 (s, 3H), 3.76 (s, 3H). 
13
C NMR 
(126 MHz, CDCl3) δ 166.66, 159.52, 159.17, 156.95, 149.16, 138.84, 138.32, 131.98, 
131.09, 130.42, 130.24, 129.07, 129.02, 128.78, 128.18, 127.52, 126.35, 123.76, 121.98, 
115.52, 115.24, 112.74, 110.87, 55.67, 55.18. HRMS (ESI
+
) m/z [M+Na
+
] calcd for 
C27H22N2O6Na 493.1376, found 493.1371. 
 
 
N-(4'-hydroxy-3-nitro-[1,1'-biphenyl]-4-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-
carboxamide (21b) Compound 21b was prepared following the general procedure B 
with 4-hydroxyphenylboronic acid 9 (102.3 mg, 0.36 mmol) and bromide 20a (110 mg, 
0.24 mmol). The residue was purified by column chromatography (SiO2, 1:100, 
Acetone:DCM) to afford desired product as a light yellowish amorphous solid (110 mg, 
92%).  
1
H NMR (500 MHz, Chloroform-d) δ 11.35 (s, OH), 9.05 (d, J = 8.8 Hz, 1H), 
8.45 (d, J = 2.3 Hz, 1H), 8.09 – 7.95 (m, 2H), 7.90 (dd, J = 8.8, 2.3 Hz, 1H), 7.59 – 7.47 
(m, 2H), 7.38 (t, J = 7.9 Hz, 1H), 7.21 – 7.05 (m, 3H), 6.98 – 6.89 (m, 3H), 3.93 (s, 3H), 
3.88 (s, 3H).  
13
C NMR (126 MHz, CDCl3) δ 165.90, 160.62, 159.94, 156.48, 139.16, 
137.21, 136.56, 134.72, 134.65, 131.73, 131.41, 130.97, 129.81, 128.96, 128.75, 126.96, 
123.77, 123.11, 122.58, 116.65, 115.77, 113.82, 111.76, 56.53, 55.93. HRMS (ESI
+
) m/z 
[M+Na]
+
 calcd for C27H22N2O6 493.1376, found 493.3180. 
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N-(3'-chloro-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-3',6-dimethoxy-
[1,1'-biphenyl]-3-carboxamide (16a) Compound 16a was prepared following the 
general procedure C with amine 14a (25 mg, 0.08 mmol) and acid chloride 7 (21.37 mg, 
0.08 mmol) and was purified by column chromatography (SiO2, 1:10 MeOH:DCM) to 
afford a white amorphous solid (20 mg, 47%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.08 
(s, 1H), 7.94 (dd, J = 8.6, 2.4 Hz, 1H), 7.85 (d, J = 2.4 Hz, 1H), 7.76 – 7.69 (m, 2H), 7.61 
(d, J = 2.3 Hz, 1H), 7.51 (d, J = 8.6 Hz, 2H), 7.41 (dd, J = 8.5, 2.3 Hz, 1H), 7.36 (t, J = 
7.9 Hz, 1H), 7.13 (dt, J = 7.6, 1.2 Hz, 1H), 7.10 (dd, J = 2.6, 1.6 Hz, 1H), 7.05 (d, J = 8.7 
Hz, 1H), 7.00 (d, J = 8.6 Hz, 1H), 6.92 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 4.55 (s, 1H), 3.89 
(s, 3H), 3.85 (s, 3H), 3.05 – 2.87 (m, 2H), 2.78 (d, J = 16.2 Hz, 2H), 2.52 (s, 3H), 2.32 – 
2.18 (m, 2H), 2.05 (dq, J = 14.6, 4.6 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.19, 
159.35, 159.30, 151.60, 138.78, 137.59, 135.18, 134.98, 130.64, 129.63, 129.14, 128.77, 
128.46, 127.18, 126.97, 125.98, 124.76, 121.96, 120.57, 116.34, 115.32, 112.91, 111.03, 
55.84, 55.32, 51.08, 45.24, 29.69, 29.06. HRMS (ESI
+
) m/z [M+H
+
] calcd for 
C33H33ClN2O4 557.2207, found 557.2215. 
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N-(2'-chloro-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-3',6-dimethoxy-
[1,1'-biphenyl]-3-carboxamide (16b) Compound 16a was prepared following the 
general procedure C with amine 14b (50 mg, 0.16 mmol) and acid chloride 7 (42.3 mg, 
0.16 mmol) and was purified by column chromatography (SiO2, 1:10 MeOH:DCM) to 
afford a white amorphous solid (90 mg, 87%). 
1
H NMR (400 MHz, Chloroform-d) δ 8.56 
(s, 1H), 7.99 (dd, J = 8.6, 2.4 Hz, 1H), 7.91 (d, J = 2.3 Hz, 1H), 7.83 – 7.72 (m, 2H), 7.41 
– 7.30 (m, 3H), 7.22 (d, J = 8.4 Hz, 1H), 7.17 – 7.09 (m, 2H), 7.03 (d, J = 8.6 Hz, 1H), 
6.98 (d, J = 2.5 Hz, 1H), 6.94 – 6.87 (m, 1H), 6.81 (dd, J = 8.5, 2.5 Hz, 1H), 4.52 (s, 1H), 
3.85 (d, J = 11.2 Hz, 6H), 3.01 (d, J = 8.7 Hz, 4H), 2.62 (s, 3H), 2.36 (d, J = 7.4 Hz, 2H), 
2.12 – 1.98 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.20, 159.35, 159.31, 149.80, 
138.79, 137.31, 135.06, 133.06, 132.06, 131.96, 130.69, 130.22, 130.15, 129.60, 129.15, 
128.41, 127.04, 121.97, 119.69, 117.24, 115.29, 114.70, 112.97, 111.03, 67.62, 55.85, 
55.33, 50.82, 45.61, 29.86. HRMS (ESI
+
) m/z [M+] calcd for C33H33ClN2O4 557.2207, 
found 557.2209. 
 
 
N-(2-chloro-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-3',6-dimethoxy-
[1,1'-biphenyl]-3-carboxamide (16c) Compound 16a was prepared following the 
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general procedure C with amine 15a (50 mg, 0.16 mmol) and acid chloride 7 (42.3 mg, 
0.16 mmol) and was purified by column chromatography (SiO2, 1:10 MeOH:DCM) to 
afford a white amorphous solid (35 mg, 39%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.77 
(m, 3H), 7.32 – 7.20 (m, 1H), 7.11 (d, J = 8.6 Hz, 2H), 7.07 (t, J = 7.9 Hz, 1H), 7.00 (d, J 
= 8.5 Hz, 1H), 6.88 (d, J = 7.6 Hz, 1H), 6.86 (s, 1H), 6.84 (d, J = 9.2 Hz, 1H), 6.72 (d, J 
= 8.2 Hz, 2H), 6.62 (dd, J = 8.3, 2.7 Hz, 1H), 4.45 (m, 1H), 3.63 (s, 3H), 3.57 (s, 3H), 
3.11 – 2.90 (m, 4H), 2.54 (s, 3H), 2.02 (m, 2H), 1.89 (m, 2H). 
13
C NMR (126 MHz, 
CDCl3+CH3OH) δ 166.39, 160.09, 159.95, 140.43, 139.92, 135.32, 132.62, 131.98, 
131.70, 131.14, 130.57, 130.25, 129.89, 127.79, 127.40, 122.88, 122.30, 119.94, 117.34, 
116.36, 116.31, 113.42, 111.78, 69.59, 56.68, 56.10, 50.37, 44.39, 27.88. HRMS (ESI
+
) 
m/z [M+H
+
] calcd for C33H33ClN2O4 557.2207, found 557.2211. 
 
 
N-(3-chloro-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-3',6-dimethoxy-
[1,1'-biphenyl]-3-carboxamide (16d) Compound 16a was prepared following the 
general procedure C with amine 15b (60 mg, 0.19 mmol) and acid chloride 7 (60.43 mg, 
0.23 mmol) and was purified by column chromatography (SiO2, 1:10 MeOH:DCM) to 
afford a white amorphous solid (92 mg, 86%) 
1
H NMR (500 MHz, Chloroform-d) δ 8.61 
(d, J = 8.6 Hz, 1H), 8.43 (s, NH), 7.95 (dd, J = 8.5, 2.4 Hz, 1H), 7.91 (d, J = 2.4 Hz, 1H), 
7.60 (d, J = 2.1 Hz, 1H), 7.55 – 7.48 (m, 3H), 7.38 (t, J = 7.9 Hz, 1H), 7.17 – 7.08 (m, 
4H), 6.98 (d, J = 8.8 Hz, 2H), 4.72 (s, 1H), 3.92 (s, 3H), 3.87 (s, 3H),  3.35 – 3.25 (m, 
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2H), 3.24 – 3.10 (m, 2H), 2.78 (s, 3H), 2.65 – 2.55 (m, 2H), 2.26 – 2.15 (m, 2H).
13
C 
NMR (126 MHz, CDCl3) δ 164.78, 159.68, 159.34, 138.69, 136.88, 133.72, 131.00, 
129.84, 129.20, 128.26, 128.20, 127.27, 126.94, 126.79, 126.02, 123.38, 121.98, 121.69, 
120.48, 116.24, 115.31, 113.06, 111.12, 71.59, 55.91, 55.34, 50.01, 43.62, 29.95. HRMS 
(ESI
+
) m/z [M+] calcd for C33H33ClN2O4 557.2207, found 557.2189. 
 
 
 
3',6-Dimethoxy-N-(3'-methyl-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (16e) Compound 16e was prepared from 14c using 
general procedure C and acid chloride 7 to afford a white amorphous solid (55 mg, 78%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.20 (s, 1H), 7.98 (dd, J = 8.6, 2.4 Hz, 1H), 7.89 (d, 
J = 2.4 Hz, 1H), 7.75 (d, J = 8.6 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.42 – 7.40 (m, 1H), 
7.37 – 7.32 (m, 2H), 7.17 – 7.14 (m, 1H), 7.12 (dd, J = 2.6, 1.5 Hz, 1H), 7.07 (d, J = 8.7 
Hz, 1H), 6.93 (dd, J = 8.3, 2.6 Hz, 1H), 6.84 (d, J = 8.5 Hz, 1H), 4.58 (m, 1H), 3.90 (s, 
3H), 3.86 (s, 3H), 3.00 (m, 4H), 2.64 (s, 3H), 2.45 – 2.34 (m, 2H), 2.30 (s, 3H), 2.17 – 
2.06 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.23, 159.32, 154.02, 149.81, 138.84, 
137.10, 136.60, 133.49, 130.61, 129.75, 129.69, 129.15, 128.51, 127.79, 127.14, 127.08, 
125.22, 122.01, 120.66, 115.33, 112.94, 112.83, 111.03, 67.89, 55.85, 55.35, 50.88, 44.64, 
28.28, 16.63. HRMS (ESI
+
) m/z [M+H+] calcd for C34H37N2O4 537.2753; found 
537.2758. 
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3',6-Dimethoxy-N-(2'-methyl-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (16f) Compound 16f was prepared from 14d using 
general procedure C and acid chloride 7 to afford a white amorphous solid (45 mg, 81%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.89 (s, 1H), 7.87 (dd, J = 8.6, 2.4 Hz, 1H), 7.77 (d, 
J = 2.4 Hz, 1H), 7.63 (d, J = 8.6 Hz, 2H), 7.47 (d, J = 8.6 Hz, 2H), 7.34 – 7.33 (m, 1H), 
7.31 – 7.26 (m, 2H), 7.06 (dt, J = 7.6, 1.3 Hz, 1H), 7.03 (dd, J = 2.7, 1.6 Hz, 1H), 6.99 (d, 
J = 8.6 Hz, 1H), 6.86 (dd, J = 8.3, 2.7 Hz, 1H), 6.79 (d, J = 8.5 Hz, 1H), 4.50 (s, 1H), 
3.82 (s, 3H), 3.78 (s, 3H), 2.94 – 2.74 (m, 4H), 2.52 (s, 3H), 2.33 – 2.25 (m, 3H), 2.23 (m, 
2H), 2.06 – 1.98 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.12, 159.34, 154.16, 138.83, 
136.97, 136.71, 133.41, 130.69, 129.69, 129.60, 129.17, 128.45, 127.85, 127.61, 127.20, 
127.10, 125.20, 121.99, 120.50, 115.33, 112.96, 112.87, 111.07, 68.06, 55.87, 55.35, 
50.99, 44.88, 28.84, 16.64. HRMS (ESI
+
) m/z [M+H+] calcd for C34H37N2O4 537.2753; 
found 537.2758. 
 
 
3',6-Dimethoxy-N-(2-methyl-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (16g) Compound 16g was prepared from 15c using 
general procedure C and acid chloride 7 to afford a white amorphous solid (25 mg, 76%). 
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1
H NMR (500 MHz, Chloroform-d) δ 7.91 (s, 1H), 7.87 (dd, J = 8.6, 2.4 Hz, 1H), 7.77 (d, 
J = 2.3 Hz, 1H), 7.50 (d, J = 2.3 Hz, 1H), 7.44 (dd, J = 8.3, 2.3 Hz, 1H), 7.28 (t, J = 7.9 
Hz, 1H), 7.16 (d, J = 8.6 Hz, 2H), 7.12 (d, J = 8.3 Hz, 1H), 7.06 (dt, J = 7.8, 1.2 Hz, 1H), 
7.03 (dd, J = 2.7, 1.5 Hz, 1H), 6.99 (d, J = 8.6 Hz, 1H), 6.87 – 6.83 (m, 3H), 4.46 (m, 1H), 
3.81 (s, 3H), 3.78 (s, 3H), 2.92 (m, 2H), 2.82 – 2.67 (m, 2H), 2.51 (s, 3H), 2.30 – 2.22 (m, 
2H), 2.21 (s, 3H), 1.99 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.17, 159.33, 159.31, 
155.62, 149.82, 138.85, 137.48, 137.01, 136.26, 134.56, 130.64, 130.56, 130.41, 129.62, 
129.16, 128.44, 127.14, 122.00, 117.77, 115.46, 115.32, 112.95, 111.05, 69.02, 55.86, 
55.35, 51.35, 44.89, 28.70, 20.75. HRMS (ESI
+
) m/z [M+H+] calcd for C34H37N2O4 
537.2753; found 537.2762. 
 
 
3',6-Dimethoxy-N-(3-methyl-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (16h) Compound 16h was prepared from 15d using 
general procedure C and acid chloride 7 to afford a white amorphous solid (13 mg, 58%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.01 (s, NH), 7.90 (dd, J = 8.5, 2.4 Hz, 1H), 7.85 – 
7.78 (m, 2H), 7.48 (dd, J = 8.4, 1.4 Hz, 2H), 7.39 (d, J = 8.6 Hz, 2H), 7.35 – 7.30 (m, 
1H), 7.12 – 7.08 (m, 1H), 7.08 – 7.03 (m, 2H), 6.93 (dd, J = 8.5, 1.4 Hz, 2H), 6.91 – 6.87 
(m, 1H), 4.52 – 4.38 (m, 1H), 3.86 (d, J = 1.2 Hz, 3H), 3.82 (d, J = 1.3 Hz, 3H), 2.92 – 
2.54 (m, 4H), 2.44 (s, 3H), 2.34 (s, 3H), 2.11 (d, J = 10.8 Hz, 2H), 1.96 (s, 2H). 
13
C NMR 
(126 MHz, CDCl3) δ 165.91, 159.56, 159.44, 156.55, 139.02, 138.03, 134.74, 133.89, 
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130.88, 130.78, 129.94, 129.33, 128.98, 128.58, 128.29 (2C), 127.10, 125.16, 124.33, 
122.17, 116.44 (2C), 115.43, 113.08, 111.25, 69.95, 55.97, 55.37, 51.73, 45.43, 29.44, 
18.24. HRMS (ESI
+
) m/z [M+H
+
] calcd for C34H36N2O4 537.2753, found 537.2757. 
 
 
3',6-Dimethoxy-N-(3'-methoxy-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-
yl)-[1,1'-biphenyl]-3-carboxamide (16i) Compound 16i was prepared from 14e using 
general procedure C and acid chloride 7 to afford a white amorphous solid (33 mg, 68%). 
1
H NMR (500 MHz, DMSO-d6) δ 10.25 (s, 1H, NH), 8.03 (dd, J = 8.6, 2.4 Hz, 1H), 7.98 
(d, J = 2.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.4 Hz, 2H), 7.37 (t, J = 7.9 Hz, 
1H), 7.27 (s, 1H), 7.26 (d, J = 5.7 Hz, 1H), 7.18 (d, J = 9.0 Hz, 1H), 7.14 – 7.07 (m, 3H), 
6.95 (dd, J = 8.3, 2.6 Hz, 1H), 4.51 – 4.39 (m, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.80 (s, 
3H), 3.09 (m, 2H), 2.83 (m, 2H), 2.57 (s, 3H), 2.05 (m, 2H), 1.83 (m, 2H). 
13
C NMR (126 
MHz, DMSO) δ 164.74, 158.92, 158.71, 150.62, 149.53, 145.14, 138.77, 138.30, 134.92, 
134.04, 129.80, 129.20, 129.14, 129.10, 126.80, 126.44, 121.73, 120.62, 118.41, 115.14, 
112.54, 111.40, 110.68, 71.29, 55.84, 55.67, 55.07, 51.02, 43.45, 28.64. HRMS (ESI
+
) 
m/z [M+H
+
] calcd for C34H37N2O5 553.2702, found 553.2757. 
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3',6-Dimethoxy-N-(2'-methoxy-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-
yl)-[1,1'-biphenyl]-3-carboxamide (16j) Compound 16j was prepared from 14f using 
general procedure C and acid chloride 7 to afford a white amorphous solid (31 mg, 72%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.86 (m, 2H), 7.77 (d, J = 2.4 Hz, 1H), 7.60 (d, J = 
8.5 Hz, 2H), 7.42 (d, J = 8.6 Hz, 2H), 7.29 (t, J = 7.9 Hz, 1H), 7.15 (d, J = 9.0 Hz, 1H), 
7.06 (dd, J = 7.6, 1.2 Hz, 1H), 7.03 (dd, J = 2.7, 1.6 Hz, 1H), 6.99 (d, J = 8.7 Hz, 1H), 
6.85 (dd, J = 8.3, 2.7 Hz, 1H), 6.49 – 6.44 (m, 1H), 4.41 (m, 1H), 3.81 (s, 3H), 3.78 (s, 
3H), 3.71 (s, 3H), 2.90 – 2.67 (m, 2H), 2.64 (m, 2H), 2.44 (s, 3H), 2.23 – 2.10 (m, 2H), 
2.01 – 1.84 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.09, 159.33, 159.30, 157.64, 
138.85, 136.68, 134.22, 131.15, 130.67, 129.99, 129.61, 129.16, 128.40, 127.21, 123.46, 
122.00, 119.79, 115.29, 112.99, 111.05, 106.57, 102.55, 100.79, 69.99, 55.86, 55.60, 
55.35, 51.55, 45.22, 29.31. HRMS (ESI
+
) m/z [M+H
+
] calcd for C34H37N2O5 553.2702, 
found 553.2727. 
 
 
3',6-Dimethoxy-N-(2-methoxy-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (16k) Compound 16k was prepared from 15e using 
general procedure C and acid chloride 7 to afford a white amorphous solid (42 mg, 79%). 
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1
H NMR (500 MHz, Chloroform-d) δ 8.11 (s, 1H), 7.98 (dd, J = 8.6, 2.4 Hz, 1H), 7.88 (d, 
J = 2.4 Hz, 1H), 7.70 (d, J = 2.1 Hz, 1H), 7.48 (d, J = 8.6 Hz, 2H), 7.38 (t, J = 7.9 Hz, 
1H), 7.27 (d, J = 8.3 Hz, 1H), 7.17 – 7.13 (m, 2H), 7.12 (s, 1H), 7.09 (d, J = 8.6 Hz, 1H), 
6.96 – 6.91 (m, 3H), 4.55 (m, 1H), 3.91 (s, 3H), 3.87 (s, 6H), 3.01 (m, 2H), 2.90 (m, 2H), 
2.61 (s, 3H), 2.41 – 2.27 (m, 2H), 2.10 – 2.00 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 
165.22, 159.39, 159.33, 156.73, 155.57, 149.83, 138.81, 138.52, 130.73, 130.68, 130.58, 
129.61, 129.17, 128.48, 127.00, 125.88, 122.00, 115.44, 115.36, 112.93, 112.07, 111.09, 
103.77, 68.43, 55.87, 55.67, 55.36, 50.95, 44.75, 28.50. HRMS (ESI
+
) m/z [M+H
+
] calcd 
for C34H37N2O5 553.2702, found 553.2707. 
 
 
3',6-Dimethoxy-N-(3-methoxy-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (16l) Compound 16l was prepared from 15f using 
general procedure C and acid chloride 7 to afford a white amorphous solid (50 mg, 65%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.55 (d, J = 8.4 Hz, 1H), 8.51 (s, NH), 7.91 (dd, J = 
8.5, 2.4 Hz, 1H), 7.87 (d, J = 2.4 Hz, 1H), 7.56 – 7.46 (m, 2H), 7.36 (t, J = 7.9 Hz, 1H), 
7.27 (s, 1H), 7.19 (dd, J = 8.4, 1.9 Hz, 1H), 7.17 – 7.09 (m, 2H), 7.07 (dd, J = 5.3, 3.4 Hz, 
2H), 6.99 – 6.95 (m, 2H), 6.93 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 4.59 (s, 1H), 3.97 (s, 3H), 
3.87 (d, J = 15.2 Hz, 6H), 3.11 – 2.89 (m, 5H), 2.64 (s, 3H), 2.43 – 2.31 (m, 2H), 2.11 (dt, 
J = 14.3, 4.6 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 164.67, 159.22, 159.18, 155.89, 
148.34, 138.81, 136.12, 134.27, 130.58, 129.61, 129.05, 128.10, 127.43, 126.81, 121.92, 
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119.95, 119.32, 116.15, 115.21, 112.87, 110.92, 108.31, 68.19, 55.82, 55.76, 55.23, 
50.61, 44.45, 27.93. HRMS (ESI
+
) m/z [M+H
+
] calcd for C34H36N2O5 553.2702, found 
553.2713. 
 
 
3',6-Dimethoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-3'-nitro-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (16m) Compound 16m was prepared from 14g using 
general procedure C and acid chloride 7 to afford a yellow amorphous solid (30 mg, 
63%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.28 (s, 1H), 8.05 (d, J = 2.4 Hz, 1H), 7.97 
(dd, J = 8.6, 2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.81 (d, J = 8.3 Hz, 2H), 7.75 (dd, J = 
8.7, 2.4 Hz, 1H), 7.53 (d, J = 8.4 Hz, 2H), 7.36 (t, J = 7.9 Hz, 1H), 7.17 – 7.09 (m, 3H), 
7.06 (d, J = 8.7 Hz, 1H), 6.92 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 4.84 (s, 1H), 3.87 (d, J = 
19.2 Hz, 6H), 3.30 – 2.89 (m, 4H), 2.67 (s, 3H), 2.54 – 2.37 (m, 2H), 2.16 – 2.09 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.28, 159.41, 159.29, 148.60, 140.80, 138.72, 138.34, 
134.09, 133.66, 132.21, 130.59, 129.71, 129.13, 128.58, 127.17, 126.81, 123.85, 121.95, 
120.77, 116.04, 115.35, 112.86, 111.03, 69.03, 55.84, 55.32, 49.78, 44.39, 27.82. HRMS 
(ESI
+
) m/z [M+H
+
] calcd for C33H33N3O6 568.2448, found 568.2445. 
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3',6-Dimethoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-2'-nitro-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (16n) Compound 16n was prepared from 14h using 
general procedure C and acid chloride 7 to afford a yellow amorphous solid (125 mg, 
63%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.95 (s, 1H), 7.87 (dd, J = 8.5, 2.4 Hz, 1H), 
7.78 (d, J = 2.4 Hz, 1H), 7.66 – 7.61 (m, 2H), 7.32 – 7.26 (m, 3H), 7.20 (d, J = 2.0 Hz, 
1H), 7.06 (ddd, J = 9.0, 5.3, 1.9 Hz, 2H), 7.04 – 6.97 (m, 2H), 6.86 (ddd, J = 8.3, 2.7, 1.0 
Hz, 1H), 4.50 (s, 1H), 3.80 (d, J = 18.6 Hz, 6H), 2.86 (t, J = 10.5 Hz, 2H), 2.48 (s, 3H), 
2.23 (s, 3H), 2.04 – 1.88 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.20, 159.43, 159.33, 
156.29, 149.67, 138.77, 138.05, 133.07, 132.82, 130.74, 129.68, 129.17, 128.71, 128.56, 
128.43, 126.92, 121.98, 120.33, 119.86, 115.29, 113.01, 111.24, 111.08, 70.27, 55.87, 
55.35, 51.14, 44.96, 29.71. HRMS (ESI+) m/z [M+H+] calcd for C33H33N3O6 568.2448, 
found 568.2446. 
 
 
3',6-Dimethoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-2-nitro-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (16o) Compound 16o was prepared from 21a using 
general procedure A and 1 to afford a yellow amorphous solid (85 mg, 65%).
1
H NMR 
(500 MHz, Chloroform-d) δ 8.15 (s, 1H), 7.93 (dd, J = 8.5, 2.5 Hz, 2H), 7.90 (d, J = 8.7 
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Hz, 1H), 7.85 (s, 1H), 7.31 (dd, J = 8.4, 2.5 Hz, 2H), 7.30 – 7.27 (m, 1H), 7.17 – 7.13 (m, 
1H), 7.07 (d, J = 7.7 Hz, 1H), 7.03 (d, J = 2.1 Hz, 1H), 7.01 (dd, J = 8.7, 2.4 Hz, 1H), 
6.85 (m, 3H), 4.35 (s, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 2.70 (m, 2H), 2.52 – 2.40 (m, 2H), 
2.30 (s, 3H), 1.99 (m, 2H), 1.85 (m, 2H). 
13
C NMR (126 MHz, CDCl3+CH3OH) δ 166.45, 
159.66, 159.30, 157.16, 149.24, 138.93, 138.60, 132.22, 130.87, 130.58, 130.21, 129.71, 
129.33, 129.18, 128.93, 126.43, 123.83, 122.11, 116.10, 115.66, 115.44, 112.86, 111.06, 
70.57, 55.87, 55.39, 51.93, 45.64, 29.74. HRMS (ESI
+
) m/z [M+K
+
] calcd for 
C33H33N3O6K 606.2006, found 606.2007. 
 
 
3',6-Dimethoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-3-nitro-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (16p) Compound 16p was prepared from 21b using 
general procedure A and 1 to afford a yellow amorphous solid (25 mg, 39%). 
1
H NMR 
(500 MHz, Chloroform-d) δ 11.34 (s, 1H), 9.05 (d, J = 8.8 Hz, 1H), 8.45 (d, J = 2.3 Hz, 
1H), 8.00 (d, J = 8.1 Hz, 2H), 7.90 (dd, J = 8.8, 2.3 Hz, 1H), 7.58 – 7.52 (m, 2H), 7.37 (t, 
J = 7.9 Hz, 1H), 7.18 – 7.10 (m, 3H), 7.04 – 6.99 (m, 2H), 6.96 – 6.92 (m, 1H), 4.43 (s, 
1H), 3.92 (s, 3H), 3.87 (s, 3H), 2.83 – 2.72 (m, 2H), 2.51 – 2.41 (m, 2H), 2.39 (s, 3H), 
2.11 (ddd, J = 11.3, 8.1, 3.7 Hz, 2H), 1.93 (tdd, J = 10.9, 7.2, 3.5 Hz, 2H). 
13
C NMR (126 
MHz, CDCl3) δ 165.23, 159.99, 159.32, 157.55, 138.55, 136.58, 135.90, 134.07, 134.03, 
131.09, 130.67, 130.34, 129.19, 128.33, 127.95, 126.34, 123.12, 122.47, 121.95, 116.52, 
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115.15, 113.19, 111.14, 71.62, 55.81, 55.36, 52.44, 45.84, 29.73. HRMS (ESI
+
) m/z [M
+
] 
calcd for C33H33N3O6 567.2348, found 567.2339. 
 
General procedure E: Raney-Nickel-catalyzed reduction 
 
 
N-(3'-amino-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-3',6-dimethoxy-
[1,1'-biphenyl]-3-carboxamide (16q) Raney-Nickel was added to a solution of 16m (25 
mg, 0.044 mmol) in MeOH (1 ml) and stirred at room temperature under hydrogen 
atmosphere for 12 h. After 12 h, RM was filtered through celite and filtrate was 
concentrated under reduced pressure to residue. The residue was purified by column 
chromatography (SiO2, 5:95 MeOH:DCM) to afford a white amorphous solid (10 mg, 
44%).
1
H NMR (400 MHz, Chloroform-d) δ 7.94 (d, J = 8.7 Hz, 1H), 7.84 (d, J = 2.3 Hz, 
1H), 7.69 (d, J = 8.2 Hz, 2H), 7.53 (d, J = 8.3 Hz, 2H), 7.37 (t, J = 7.9 Hz, 1H), 7.14 (d, J 
= 7.6 Hz, 1H), 7.10 (t, J = 2.1 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 7.00 (s, 1H), 6.97 – 6.91 
(m, 2H), 6.85 – 6.81 (m, 1H), 4.63 (m, 1H), 3.90 (s, 3H), 3.87 (s, 3H), 3.16 (m, 4H), 2.72 
(s, 3H), 2.42 (m, 2H), 2.20 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.31, 159.57, 
159.54, 143.58, 139.02, 137.56, 137.24, 137.04, 135.04, 130.92, 129.77, 129.38, 128.63, 
127.48, 127.28, 122.19, 120.62, 117.47, 115.54, 114.63, 114.31, 113.16, 111.29, 69.10, 
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56.08, 55.56, 50.61, 44.37, 28.10. HRMS (ESI
+
) m/z [M+H
+
] calcd for C33H36N3O4 
538.2706, found 538.2707. 
 
 
N-(2'-amino-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-3',6-dimethoxy-
[1,1'-biphenyl]-3-carboxamide (16r) Compound 16r was prepared from 16n using 
general procedure E to afford a white amorphous solid (28 mg, 39%). 
1
H NMR (500 
MHz, Chloroform-d) δ 8.03 (d, J = 2.9 Hz, 1H), 7.94 (dd, J = 8.5, 2.4 Hz, 1H), 7.86 (d, J 
= 2.5 Hz, 1H), 7.71 (dd, J = 8.5, 2.7 Hz, 2H), 7.42 (dd, J = 8.7, 2.6 Hz, 2H), 7.36 (td, J = 
7.9, 2.8 Hz, 1H), 7.17 – 7.09 (m, 2H), 7.05 (ddd, J = 18.4, 8.5, 2.7 Hz, 2H), 6.93 (dd, J = 
8.2, 2.6 Hz, 1H), 6.38 (dt, J = 8.5, 2.6 Hz, 1H), 6.33 (d, J = 2.5 Hz, 1H), 4.42 (s, 1H), 
3.89 (s, 3H), 3.86 (s, 3H), 3.80 (s, NH2), 2.95 – 2.81 (m, 2H), 2.67 (s, 2H), 2.49 (s, 3H), 
2.29 – 2.14 (m, 2H), 1.99 (d, J = 14.2 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.25, 
159.34, 159.30, 157.35, 144.89, 138.79, 136.90, 135.13, 131.38, 130.65, 129.70, 129.63, 
129.14, 128.45, 127.00, 121.96, 120.69, 120.60, 115.32, 112.91, 111.04, 106.02, 103.05, 
69.81, 55.84, 55.32, 51.86, 45.30, 29.69. HRMS (ESI
+
) m/z [M+H
+
] calcd for 
C33H35N3O4 538.2706, found 538.2704. 
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N-(2-amino-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-3',6-dimethoxy-
[1,1'-biphenyl]-3-carboxamide (16s) Compound 16s was prepared from 16o using 
general procedure E to afford a white amorphous solid (21 mg, 36%). 
1
H NMR (400 
MHz, Chloroform-d) δ 7.92 (dd, J = 8.5, 2.3 Hz, 1H), 7.82 (d, J = 2.4 Hz, 1H), 7.77 (s, 
1H), 7.39 (d, J = 8.7 Hz, 3H), 7.14 (d, J = 7.9 Hz, 1H), 7.10 (d, J = 2.3 Hz, 1H), 7.07 (dd, 
J = 8.5, 2.2 Hz, 2H), 6.97 (d, J = 8.5 Hz, 2H), 6.94 (dd, J = 8.3, 2.7 Hz, 1H), 6.86 (dd, J = 
8.2, 2.1 Hz, 1H), 4.58 (m, 1H), 3.90 (s, 3H), 3.87 (s, 3H), 3.02 (m, 4H), 2.63 (s, 3H), 2.37 
(m, 2H), 2.10 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 165.05, 159.33, 159.30, 155.73, 
144.29, 138.82, 138.19, 132.21, 130.79, 130.69, 130.45, 129.51, 129.16, 128.34, 127.24, 
123.26, 121.97, 116.17, 115.30, 112.96, 111.05, 110.21, 107.01, 69.03, 55.86, 55.34, 
50.67, 44.57, 28.34. HRMS (ESI
+
) m/z [M+H
+
] calcd for C33H36N3O4 538.2706, found 
538.2709. 
 
 
N-(3-amino-4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-3',6-dimethoxy-
[1,1'-biphenyl]-3-carboxamide (16t) Compound 16s was prepared from 16o using 
general procedure E to afford a white amorphous solid (12 mg, 34%). 
1
H NMR (400 
MHz, Chloroform-d) δ 7.91 (dd, J = 9.0, 2.4 Hz, 1H), 7.87 (s, 1H), 7.43 (d, J = 8.7 Hz, 
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2H), 7.29 (t, J = 7.9 Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 7.09 – 6.94 (m, 5H), 6.89 (d, J = 
8.8 Hz, 2H), 6.85 (dd, J = 8.3, 2.6 Hz, 1H), 4.51 (m, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 2.99 
– 2.74 (m, 4H), 2.54 (s, 3H), 2.15 (m, 2H), 2.06 – 1.94 (m, 2H). 
13
C NMR (126 MHz, 
CDCl3) δ 159.52, 159.32, 156.19, 141.22, 139.75, 138.96, 134.13, 130.65, 130.31, 129.19, 
128.84, 128.42, 128.27, 126.33, 126.25, 123.71, 122.11, 118.33, 116.42, 116.23, 115.37, 
112.96, 111.03, 68.80, 55.88, 55.39, 50.92, 44.54, 28.39. HRMS (ESI
+
) m/z [M+K
+
] 
calcd for C33H35N3O4K 576.2265, found 576.2264. 
 
 
N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-[1,1'-biphenyl]-3-
carboxamide (20a) Compound 20a was prepared from 19a using general procedure C 
and acid chloride 7 to afford a white amorphous solid (20 mg, 65%). 
1
H NMR (500 MHz, 
DMSO-d6) δ 10.24 (s, 1H, NH), 8.03 (dd, J = 8.6, 2.4 Hz, 1H), 7.97 (d, J = 2.3 Hz, 1H), 
7.85 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.4 Hz, 4H), 7.56 (d, J = 7.4 Hz, 2H), 7.46 (t, J = 
7.6 Hz, 2H), 7.38 (t, J = 7.4 Hz, 1H), 7.27 (d, J = 8.7 Hz, 1H), 7.08 (d, J = 8.5 Hz, 2H), 
4.63 (m, 1H), 3.15 (m, 2H), 2.96 (m, 2H), 2.64 (s, 3H), 2.11 (m, 2H), 1.96 – 1.78 (m, 2H). 
13
C NMR (126 MHz, DMSO) δ 164.73, 158.69, 155.89, 138.17, 137.46, 134.70, 132.63, 
129.87, 129.37, 129.34, 129.08, 128.08, 127.44, 127.19, 126.88, 126.18, 120.69, 116.38, 
111.38, 68.81, 50.55, 43.04, 28.02. HRMS (ESI
+
) m/z [M+H
+
] calcd for C31H31N2O2 
463.2386, found 463.2387. 
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3'-Methoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-[1,1'-biphenyl]-
3-carboxamide (20b) Compound 20b was prepared from 19b using general procedure C 
and acid chloride 7 to afford a white amorphous solid (52 mg, 72%). 
1
H NMR (500 MHz, 
DMSO-d6) δ 10.44 (s, 1H, NH), 8.24 (s, 1H), 7.96 (dt, J = 7.7, 1.4 Hz, 1H), 7.93 – 7.84 
(m, 3H), 7.68 – 7.57 (m, 4H), 7.44 (dd, J = 8.6, 7.1 Hz, 1H), 7.35 (dt, J = 7.8, 1.2 Hz, 1H), 
7.33 (t, J = 2.1 Hz, 1H), 7.10 – 7.05 (m, 2H), 7.03 – 6.98 (m, 1H), 4.61 (m, 1H), 3.86 (s, 
3H), 3.11 – 3.02 (m, 2H), 2.88 (s, 2H), 2.60 (s, 3H), 2.20 – 2.01 (m, 2H), 1.93 – 1.76 (m, 
2H). 
13
C NMR (126 MHz, DMSO) δ 165.34, 159.78, 156.00, 140.99, 140.15, 138.02, 
135.52, 134.95, 132.54, 130.08, 129.88, 129.06, 127.46, 126.97, 126.24, 125.86, 120.72, 
119.23, 116.36, 113.34, 112.49, 69.66, 55.20, 50.77, 43.33, 28.33. HRMS (ESI
+
) m/z 
[M+H
+
] calcd for C32H33N2O3 493.2491, found 493.2494. 
 
 
6-Methoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-[1,1'-biphenyl]-
3-carboxamide(20c) Compound 20c was prepared from 19c using general procedure C 
and acid chloride 7 to afford a white amorphous solid (33 mg, 78%). 
1
H NMR (500 MHz, 
DMSO-d6) δ 10.25 (s, 1H, NH), 8.04 (dd, J = 8.6, 2.4 Hz, 1H), 7.98 (d, J = 2.3 Hz, 1H), 
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7.86 (d, J = 8.6 Hz, 2H), 7.60 (dd, J = 8.6, 3.5 Hz, 4H), 7.56 (d, J = 7.3 Hz, 2H), 7.45 (t, J 
= 7.6 Hz, 2H), 7.37 (t, J = 7.4 Hz, 1H), 7.26 (d, J = 8.7 Hz, 1H), 7.06 (d, J = 8.5 Hz, 2H), 
4.58 (m, 1H), 3.86 (s, 3H), 3.11 – 2.93 (m, 2H), 2.78 (m, 2H), 2.52 (s, 3H), 2.08 (m, 2H), 
1.85 (m, 2H). 
13
C NMR (126 MHz, DMSO) δ 164.68, 158.68, 156.01, 138.20, 137.49, 
134.70, 132.52, 129.90, 129.36, 129.09, 128.06, 127.41, 127.17, 126.93, 126.16, 120.66, 
116.33, 111.36, 69.61, 55.85, 50.89, 43.61, 28.55. HRMS (ESI
+
) m/z [M+H
+
] calcd for 
C32H33N2O3 493.2491, found 493.2495. 
 
 
3'-Methoxy-5-((4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)carbamoyl)-
[1,1'-biphenyl]-2-yl acetate (20d) Compound 20d was prepared from 19d using general 
procedure C and acid chloride 7 to afford a white amorphous solid (35 mg, 76%). 
1
H 
NMR (500 MHz, Chloroform-d) δ 8.13 (s, 1H), 7.87 (s, 1H), 7.83 (dd, J = 8.3, 2.3 Hz, 
1H), 7.64 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 7.26 (t, J 
= 7.9 Hz, 1H), 7.16 (d, J = 8.3 Hz, 1H), 7.00 – 6.77 (m, 5H), 4.40 (m, 1H), 3.76 (s, 3H), 
2.82 (m, 2H), 2.63 (m, 2H), 2.41 (s, 3H), 2.12 (m, 2H), 2.06 (s, 3H), 1.97 – 1.86 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 169.13, 164.90, 159.60, 156.36, 150.41, 137.88, 136.89, 
136.80, 135.26, 133.58, 133.16, 129.94, 129.51, 128.05, 127.53, 127.20, 123.50, 121.19, 
120.67, 116.27, 114.39, 113.66, 69.70, 55.35, 51.31, 45.08, 29.17, 20.91. 
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General procedure F: Base-catalyzed deacetylation  
 
 
2'-Hydroxy-5'-((4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)carbamoyl)-
[1,1'-biphenyl]-3-yl acetate (20e) A solution of 20d (30 mg, 0.052 mmol) in MeOH (0.5 
ml) was treated with triethylamine (0.020 ml, 0.156 mmol) and stirred for 4 h. After 4h, 
the RM was concentrated and residue was purified by column chromatography (SiO2, 
5:95 MeOH:DCM) to afford a white amorphous solid (14 mg, 49%). 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.86 (d, J = 2.4 Hz, 1H), 7.77 (dd, J = 8.5, 2.4 Hz, 1H), 7.69 (d, J = 8.6 
Hz, 2H), 7.54 – 7.46 (m, 4H), 7.35 – 7.31 (m, 1H), 7.17 (d, J = 7.5 Hz, 1H), 7.14 (d, J = 
2.6 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.95 (d, J = 8.7 Hz, 2H), 6.88 (dd, J = 8.4, 2.6 Hz, 
1H), 4.52 (m, 1H), 3.83 (s, 3H), 3.03 – 2.86 (m, 2H), 2.81 (m, 2H), 2.53 (s, 3H), 2.26 – 
2.09 (m, 2H), 2.09 – 1.92 (m, 2H). 
13
C NMR (126 MHz, CDCl3+CH3OH) δ 166.63, 
159.37, 157.41, 156.02, 139.03, 137.26, 136.42, 133.88, 130.14, 129.26, 128.35, 128.34, 
127.96, 126.93, 126.05, 121.74, 120.97, 116.26, 115.87, 114.92, 112.85, 68.65, 55.20, 
51.11, 44.67, 28.69. 
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3'-Hydroxy-6-methoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide Compound 20f was prepared from 120g using general 
procedure F to afford a white amorphous solid (25 mg, 76%). 
1
H NMR (500 MHz, 
Methanol-d4) δ 7.95 (dd, J = 8.6, 2.5 Hz, 1H), 7.91 (d, J = 2.4 Hz, 1H), 7.74 (d, J = 8.5 
Hz, 2H), 7.56 (d, J = 8.6 Hz, 2H), 7.53 (d, J = 8.7 Hz, 2H), 7.27 (t, J = 7.9 Hz, 1H), 7.08 
(d, J = 8.6 Hz, 2H), 7.05 – 7.03 (m, 1H), 6.99 (d, J = 8.7 Hz, 2H), 6.84 (dd, J = 8.0, 2.5 
Hz, 1H), 4.49 (m, 1H), 3.90 (s, 3H), 2.86 (m, 2H), 2.63 (m, 2H), 2.46 (s, 3H), 2.12 (m, 
2H), 2.02 – 1.93 (m, 2H). 
13
C NMR (126 MHz, CDCl3+CH3OH) δ 166.57, 159.32, 
156.47, 156.29, 138.87, 137.19, 136.60, 133.67, 130.54, 130.01, 129.01, 128.41, 127.90, 
126.91, 126.88, 121.04, 120.98, 116.35, 116.31, 114.33, 110.87, 69.62, 55.62, 51.63, 
45.18, 29.42. HRMS (ESI
+
) m/z [M+H
+
] calcd for C32H33N2O4 509.2440, found 
509.2442. 
 
 
2'-Methoxy-5'-((4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)carbamoyl)-
[1,1'-biphenyl]-3-yl acetate (20g) Compound 20g was prepared from 19e using general 
procedure C and acid chloride 7 to afford a white amorphous solid (32 mg, 76%).  
1
H 
NMR (500 MHz, Chloroform-d) δ 7.93 (s, 1H), 7.86 (dd, J = 8.7, 2.4 Hz, 1H), 7.73 (d, J 
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= 2.4 Hz, 1H), 7.63 (d, J = 8.5 Hz, 2H), 7.47 (d, J = 8.7 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 
7.35 – 7.30 (m, 1H), 7.01 (d, J = 7.4 Hz, 1H), 6.98 (d, J = 8.7 Hz, 1H), 6.89 (d, J = 8.7 
Hz, 2H), 4.43 (m, 1H), 3.81 (s, 3H), 2.90 – 2.79 (m, 2H), 2.66 (m, 2H), 2.45 (s, 3H), 2.25 
(s, 3H), 2.19 (m, 2H), 1.95 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 169.64, 165.09, 
159.23, 156.27, 150.37, 138.92, 137.04, 136.58, 133.73, 129.62, 129.55, 129.12, 128.82, 
128.05, 127.22, 127.18, 127.03, 122.77, 120.64, 120.51, 116.27, 111.11, 69.73, 55.86, 
51.43, 45.19, 29.15, 21.21. HRMS (ESI
+
) m/z [M+H
+
] calcd for C34H35N2O5 551.2546, 
found 551.2543. 
 
 
6-Methoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-3'-nitro-[1,1'-
biphenyl]-3-carboxamide (20h) Compound 20h was prepared from 19f using general 
procedure C and acid chloride 7 to afford a yellow amorphous solid (23 mg, 72%).  
1
H 
NMR (500 MHz, DMSO-d6) δ 10.27 (s, 1H, NH), 8.42 (t, J = 2.0 Hz, 1H), 8.26 (dd, J = 
8.2, 2.4 Hz, 1H), 8.11 (dd, J = 8.6, 2.3 Hz, 1H), 8.08 – 8.03 (m, 2H), 7.86 – 7.83 (m, 2H), 
7.78 (t, J = 8.0 Hz, 1H), 7.65 – 7.57 (m, 4H), 7.34 (d, J = 8.8 Hz, 1H), 7.05 (d, J = 8.7 Hz, 
2H), 4.52 (m, 1H), 3.91 (s, 3H), 2.91 (m, 2H), 2.66 – 2.56 (m, 2H), 2.44 (s, 3H), 2.09 – 
1.96 (m, 2H), 1.85 – 1.66 (m, 2H). 
13
C NMR (126 MHz, DMSO) δ 164.46, 158.58, 
156.14, 147.68, 138.93, 138.06, 136.08, 134.82, 132.37, 130.15, 129.96, 129.71, 127.40, 
127.21, 126.80, 126.18, 123.79, 122.14, 120.68, 116.27, 111.69, 69.71, 56.10, 51.67, 
44.44, 29.14. HRMS (ESI
+
) m/z [M+H
+
] calcd for C32H32N3O5 538.2342, found 
538.2346. 
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3'-Amino-6-methoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-[1,1'-
biphenyl]-3-carboxamide Compound 20i was prepared from 20h using general 
procedure D to afford a white amorphous solid (10 mg, 76%). 
1
H NMR (400 MHz, 
Chloroform-d) δ 7.85 – 7.81 (m, 1H), 7.78 (s, 1H), 7.64 (d, J = 8.5 Hz, 2H), 7.43 (m, 4H), 
7.11 (t, J = 7.8 Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H), 6.87 (m, 3H), 6.81 (s, 1H), 6.64 – 6.62 
(m, 1H), 4.54 (m, 1H), 3.77 (s, 3H), 3.13 – 2.99 (m, 4H), 2.63 (s, 3H), 2.25 – 2.15 (m, 
2H), 2.08 – 2.00 (m, 2H). 
13
C NMR (126 MHz, CDCl3+CH3OH) δ 159.41, 156.00, 
146.03, 138.68, 137.32, 136.51, 134.07, 130.83, 129.93, 128.98, 128.53, 128.09, 127.04, 
126.93, 121.02, 120.98, 120.31, 116.69, 116.31, 114.71, 110.97, 68.71, 55.76, 50.83, 
44.44, 28.31. HRMS (ESI
+
) m/z [M+H
+
] calcd for C32H34N3O3 508.2600, found 
508.2598. 
 
 
3'-Chloro-6-methoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-[1,1'-
biphenyl]-3-carboxamide (20j) Compound 20j was prepared from 19g using general 
procedure C and acid chloride 7 to afford a white amorphous solid (32 mg, 80%).  
1
H 
NMR (500 MHz, DMSO-d6) δ 10.21 (s, 1H), 8.06 (dd, J = 8.6, 2.4 Hz, 1H), 8.00 (d, J = 
2.4 Hz, 1H), 7.84 (d, J = 8.6 Hz, 2H), 7.63 – 7.57 (m, 54H), 7.55 – 7.44 (m, 3H), 7.30 (d, 
J = 8.7 Hz, 1H), 7.02 (d, J = 8.7 Hz, 2H), 4.41 (m, 1H), 3.88 (s, 3H), 2.71 – 2.57 (m, 2H), 
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2.20 (m, 5H), 2.12 – 1.90 (m, 2H), 1.66 (m, 2H). 
13
C NMR (126 MHz, DMSO) δ 164.50, 
158.58, 156.38, 139.55, 138.04, 134.86, 132.73, 132.09, 129.95, 129.81, 129.71, 128.97, 
128.13, 127.70, 127.35, 127.12, 127.01, 126.13, 120.67, 116.17, 111.55, 71.85, 55.98, 
52.32, 45.74, 30.51. HRMS (ESI
+
) m/z [M+H
+
] calcd for C32H32ClN2O3 527.2101, found 
527.2100. 
 
 
4'-Chloro-6-methoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-[1,1'-
biphenyl]-3-carboxamide (20k) Compound 20k was prepared from 19i using general 
procedure C and acid chloride 7 to afford a white amorphous solid (23 mg, 70%).  
1
H 
NMR (500 MHz, DMSO-d6) δ 10.23 (s, 1H, NH), 8.04 (dd, J = 8.6, 2.3 Hz, 1H), 7.97 (d, 
J = 2.3 Hz, 1H), 7.84 (d, J = 8.7 Hz, 2H), 7.60 (m, 5H), 7.52 (d, J = 8.5 Hz, 2H), 7.28 (d, 
J = 8.7 Hz, 1H), 7.06 (d, J = 8.7 Hz, 2H), 4.55 (m, 1H), 3.87 (s, 3H), 3.33 (s, 3H), 2.98 
(m, 2H), 2.70 (m, 2H), 2.06 (m, 2H), 1.80 (m, 2H). 
13
C NMR (126 MHz, DMSO) δ 
164.60, 158.61, 156.07, 138.16, 136.26, 134.76, 132.48, 132.02, 131.18, 129.78, 129.44, 
128.10, 127.98, 127.43, 127.04, 126.19, 120.66, 116.33, 111.51, 69.88, 55.96, 51.10, 
43.86, 28.74. HRMS (ESI
+
) m/z [M+H
+
] calcd for C32H32ClN2O3 527.2101, found 
527.2105. 
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4',6-Dimethoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-[1,1'-
biphenyl]-3-carboxamide (20l) Compound 20l was prepared from 19j using general 
procedure C and acid chloride 7 to afford a white amorphous solid (23 mg, 56%).  
1
H 
NMR (500 MHz, DMSO-d6) δ 10.22 (s, 1H, NH), 7.99 (dd, J = 8.6, 2.4 Hz, 1H), 7.95 (d, 
J = 2.4 Hz, 1H), 7.85 (d, J = 8.7 Hz, 1H), 7.64 – 7.60 (m, 3H), 7.51 (d, J = 8.7 Hz, 1H), 
7.24 (d, J = 8.7 Hz, 1H), 7.09 (d, J = 8.6 Hz, 2H), 7.02 (d, J = 8.8 Hz, 1H), 4.65 (m, 1H), 
3.86 (s, 3H), 3.81 (s, 3H), 3.25 – 2.96 (m, 4H), 2.68 (s, 3H), 2.11 (m, 2H), 1.91 (m, 2H). 
13
C NMR (126 MHz, DMSO) δ 164.78, 158.67, 158.50, 155.86, 138.25, 134.63, 132.70, 
130.48, 129.63, 129.04, 128.52, 127.44, 126.91, 126.18, 120.63, 116.40, 113.56, 113.52, 
111.29, 66.97, 55.82, 55.12, 51.23, 42.74, 28.33. HRMS (ESI
+
) m/z [M+H
+
] calcd for 
C33H35N2O4 523.2597, found 523.2602. 
 
 
2'-Methoxy-5'-((4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)carbamoyl)-
[1,1'-biphenyl]-4-yl acetate (20m) Compound 20m was prepared from 19k using 
general procedure C and acid chloride 7 to afford a white amorphous solid (55 mg, 66%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.98 (s, 1H), 7.86 (dd, J = 8.6, 2.4 Hz, 1H), 7.74 (d, 
J = 2.4 Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 7.46 (m, 5H), 7.06 (d, J = 8.6 Hz, 1H), 6.98 (d, 
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J = 8.6 Hz, 1H), 6.89 (d, J = 8.7 Hz, 2H), 4.43 (m, 1H), 3.81 (s, 3H), 2.93 – 2.78 (m, 2H), 
2.66 (s, 2H), 2.45 (s, 3H), 2.26 (s, 3H), 2.26 – 2.10 (m, 2H), 1.95 (m, 2H). 
13
C NMR (126 
MHz, CDCl3) δ 169.68, 165.08, 159.28, 156.27, 149.97, 137.10, 136.56, 135.14, 133.71, 
130.58, 129.83, 129.63, 128.59, 128.04, 127.18, 127.15, 121.29, 120.51, 116.27, 111.06, 
69.72, 55.81, 51.41, 45.17, 29.16, 21.21. HRMS (ESI
+
) m/z [M+H
+
] calcd for 
C34H35N2O5 551.2546, found 551.2545. 
 
 
4'-Hydroxy-6-methoxy-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-
[1,1'-biphenyl]-3-carboxamide (20n) Compound 20n was prepared from 19m using 
general procedure F to afford a white amorphous solid (30 mg, 72%). 
1
H NMR (500 
MHz, Methanol-d4) δ 7.90 (dd, J = 8.5, 2.4 Hz, 1H), 7.87 (d, J = 2.4 Hz, 1H), 7.73 (d, J = 
8.6 Hz, 2H), 7.56 – 7.50 (m, 4H), 7.43 (d, J = 8.6 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1H), 6.98 
(d, J = 8.7 Hz, 2H), 6.90 (d, J = 8.6 Hz, 1H), 4.55 (m, 1H), 3.89 (s, 3H), 3.00 (m, 2H), 
2.84 (m, 2H), 2.57 (s, 3H), 2.20 (m, 2H), 2.06 (m, 2H). 
13
C NMR (126 MHz, 
CDCl3+CH3OH) δ 166.53, 159.30, 156.25, 156.03, 137.23, 136.47, 133.88, 130.59, 
130.56, 129.76, 128.81, 127.96, 127.80, 126.93, 126.91, 121.00, 116.26, 114.96, 110.79, 
68.82, 55.63, 51.12, 44.67, 28.69. HRMS (ESI
+
) m/z [M+H
+
] calcd for C32H33N2O4 
509.2440, found 509.2441. 
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